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Even though the first reports on venous thromboembolism date back to the 13th century and 
the mechanism of acute pulmonary embolism (PE) was unraveled almost 150 years ago by 
Rudolf Virchow, PE still keeps medical researchers occupied around the globe.1,2 PE is a disease 
characterized by obstruction of the pulmonary arteries with thrombotic emboli originating 
predominantly from pathological thrombi in the deep venous system of the lower extremities.2 
This obstruction of the pulmonary arteries causes an increase in right ventricular afterload that, 
in combination with the release of several neurohumoral factors, might induce right ventricle 
enlargement and decreased stroke volume.3 When the compensatory mechanisms to maintain 
right ventricular systolic function, i.e. catecholamine-driven tachycardia and the Frank-Starling 
preload reserve, are utilized, right ventricular cardiac output decreases resulting in decreased 
left ventricular filling. In turn, this causes left ventricular systolic function impairment and thus 
decreased coronary perfusion pressure.3 In the right ventricle, when exposed to increased 
oxygen demand, decreased coronary perfusion pressure contributes to the relative oxygen 
deficit and might therefore cause myocardial ischemia and further loss of systolic performance.3 
Depending on comorbid conditions as well as the extent of the embolus load, this vicious circle 
may have fatal outcome within minutes, or after several hours or days, especially when the 
patient is left untreated. Hence, accurate and rapid identification and treatment of patients 
with acute PE is of great clinical importance.
The diagnostic process of acute PE however, represents several challenges. In essence, the 
physician has to distinguish patients with this disease - and treat them - from patients that 
are suspected of PE but do not have the disease. Because the signs and symptoms of PE are 
largely non-specific, many patients presenting with respiratory or chest symptoms are further 
investigated but do not have PE. As a result of limitations of individual diagnostic tests, mis-
management of PE on the basis of the results of single diagnostic tools has been a frequent 
problem. In addition, invasive diagnostic procedures and exposure to ionizing radiation or 
nephrotoxic contrast dye should be prevented when possible. The use of well validated diag-
nostic algorithms combining different non-invasive tests, i.e. clinical decision rules, D-dimer 
blood tests and radiological imaging, are the solution for these issues.4 Clinical decision rules 
predict the probability of having PE for individual patients and aid the clinician in determining 
the preferred diagnostic approach. D-dimer blood tests should be performed in patients with 
an unlikely probability since a normal test result safely excludes PE under this condition.4,5 
Because this is not true for patients with a likely probability, D-dimer tests are not useful for 
these patients and radiological imaging should follow.4,6 Chapter 2 and 3 of this thesis focus on 
the clinical validation, simplification and performance of a recently developed clinical decision 
rule, the revised Geneva score.7
Currently, the radiological imaging test of choice for suspected PE is computed tomography 
pulmonary angiography (CTPA). It has been shown that this test has excellent sensitivity and 
specificity for diagnosing acute PE.8 Nonetheless, experts have raised concern for false negative 






studied the safety of withholding anticoagulant treatment in patients with suspected PE and 
a strict indication for CTPA, in whom the CT scan revealed no pulmonary emboli. Furthermore, 
we have evaluated the additional clinical value of performing compression ultrasonography of 
the legs subsequent to a normal CTPA to exclude deep venous thrombosis before deciding to 
withhold treatment. The results of this study are described in chapter 4.
After establishing the diagnosis of acute PE, patients should be treated with at least 5 days 
of either weight based therapeutic doses of low molecular weight heparin or unfractionated 
heparin aiming at a 1.5 to 2.5 prolongation of the activated partial thromboplastin time, 
followed by vitamin K antagonists for a period of at least three to six months with a target 
international normalized ratio (INR) of 2.0 to 3.0.10 For patients presenting with hemodynamic 
instability, more aggressive treatment is warranted which may include administration of throm-
bolytic drugs, thrombosuction or surgical thrombectomy.10 These latter two are reserved for 
those patients in whom thrombolysis is contraindicated. Importantly, the clinical condition of 
apparently stable patients may deteriorate rapidly and unexpectedly to cardiogenic shock of 
even death in the first hours or days after establishing the diagnosis of acute PE. In most cases, 
this phenomenon is caused by silent and unnoticed worsening of right ventricular function 
impairment by the viscous circle described above. It is a challenge to distinguish patients at risk 
for clinical deterioration from those with relatively mild disease since these first patients might 
benefit from more intensive clinical surveillance and treatment regimes whereas home treat-
ment may be considered for the latter patient category. It seems pathophysiologically plausible 
to include specific markers of ventricular function in risk stratification models for patients with 
acute PE. In chapters 5 to 7 of this thesis, we explore the predictive value for adverse clinical 
events of several biomarkers of ventricular overload as well as easy obtainable CT-measured 
indicators of right ventricular function in patients with acute PE.
One other important objective of clinical research in the field of acute PE concerns the patients’ 
prognosis. Patients who survive the acute embolic event face the risk of recurrent venous 
thromboembolism, bleeding complications from anticoagulant therapy, chronic emboli 
leading to pulmonary hypertension and in addition arterial cardiovascular events and detec-
tion of previously unknown cancer.11-14 However, despite the increased risk for these serious 
clinical complications compared to population controls, patients with a first episode of acute 
PE stop their anticoagulant therapy after three to six months and are from then on referred to 
their general practitioner. This is mainly due to the absence of evidence-based, well validated 
guidelines for specific screening programs, intensified clinical surveillance or prolonged treat-
ment regimens. The development of such guidelines is complicated by the lack of knowledge 
of underlying pathophysiological mechanisms and accurate risk estimates regarding these 
complications. To further study the long term prognosis of patients with acute PE, we have per-
formed a large cohort study of patients with acute PE, the so called INSHAPE study (INcidence 
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of Symptomatic chronic thromboembolic pulmonary Hypertension after Acute Pulmonary 
Embolism). The primary goal of this study was the determination of the incidence of chronic 
thromboembolic pulmonary hypertension (CTEPH) after acute PE in an unselected patient 
cohort, which is described in chapter 8. In the subsequent chapter, we have compared various 
clinical algorithms for managing dyspnoeic patients with previous PE who are suspected of 
having CTEPH. Analyses regarding the prevalence and causes of exertional dyspnea in the clini-
cal course of acute PE, further evaluation of the risk of cardiovascular events after acute PE and 
the overall prognosis of patients with acute PE including a pooled survival analysis of different 
adverse events, are presented in chapters 10, 11 and 12 respectively. Finally, in chapter 13 we 
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Comparison of the revised Geneva score with 
the Wells rule for assessing clinical probability of 
pulmonary embolism
F.A. Klok, E. Kruisman, J. Spaan, M. Nijkeuter, M. Righini, D. Aujesky, P.M. Roy, 
A. Perrier, G. Le Gal and M.V. Huisman








The revised Geneva score, a standardized clinical decision rule in the diagnosis of pulmonary 
embolism (PE), was recently developed. The Wells clinical decision is widely used but lacks full 
standardization, as it includes subjective clinician’s judgement. We have compared the perfor-
mance of the revised Geneva score with the Wells rule.
Methods
In 300 consecutive patients with suspected PE, the clinical probability of PE was assessed by the 
Wells rule and the revised Geneva score. The predictive accuracy of both scores were compared 
by the area under the curve (AUC) of receiver operating characteristic (ROC) analyses.
Results
The overall prevalence of PE was 16%. The prevalences of PE in the low-, intermediate- and 
high-probability categories as classified by the revised Geneva score were similar to those of 
the original derivation set. The AUC of the revised Geneva score was not different from that of 
the Wells rule. After three months of follow-up, no patient classified into the low or intermedi-
ate clinical probability category by the revised Geneva score and a normal D-dimer result was 
subsequently diagnosed with acute venous thromboembolism.
Conclusions
This study suggests that the performance of the revised Geneva score is equivalent to that 
of the Wells rule. In addition, it seems safe to exclude PE in patients by the combination of 
a low or intermediate clinical probability by the revised Geneva score and a normal D-dimer 
concentration.
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INTRODUCTION
Current diagnostic work-up of patients with suspected acute pulmonary embolism (PE) usu-
ally starts with the assessment of clinical pretest probability using clinical prediction rules, 
and plasma D-dimer measurement.1,2 Indeed, recent studies have demonstrated the safety of 
rejecting the diagnosis of PE by the combination of a low clinical probability and a normal 
quantitative D-dimer test result, thereby decreasing the need for further diagnostic radiologi-
cal imaging in up to 30% of patients.3
The best validated and therefore most widely used clinical decision rules are the Wells rule 
(Table 1) and the Geneva score.1,2 However, both scores have limitations. The Wells rule includes 
the physician’s judgement of whether an alternative diagnosis is more likely than PE.1 This 
criterion, which carries a major weight in the score, is subjective and cannot be standardized. 
Moreover, it has been suggested that the predictive value of the Wells rule is derived primarily 
from its subjective component.4 The Geneva score, based on 13 entirely objective variables, 
requires a blood gas analysis while breathing room air and has only been evaluated for patients 
in the emergency ward.2 Both scores appeared to have a comparable predictive value for PE.
The revised Geneva score is a simple score based entirely on clinical variables and is inde-
pendent from physicians’ implicit judgement (Table 1).5 The prevalence of PE obtained using 
the revised Geneva score in the original derivation cohort was comparable to that obtained 
using the original Geneva score and the Wells rule, i.e. 9.0% in the low clinical probability group, 
Table 1. The Wells rule and revised Geneva score.
Wells rule1 Revised Geneva score5
Items Score Items Score
Clinical signs of DVT 3 Age >65 years 1
Alternative diagnosis less likely than PE 3 Previous DVT or PE 3
Previous PE or DVT 1.5 Surgery or fracture within 1 month 2
Heart rate >100 beats/min 1.5 Active malignancy 2
Surgery or immobilization within 4 weeks 1.5 Unilateral lower limb pain 3
Hemoptysis 1 Hemoptysis 2
Active malignancy 1 Heart rate 74-94 beats/min 3
Heart rate ≥95 beats/min 5
Pain on lower limb deep vein palpation 
and unilateral edema
4
Clinical probability Clinical probability
Low <2 Low 0–3
Intermediate 2–6 Intermediate 4–10
High >6 High ≥11
PE unlikely ≤4
PE likely >4






27.5% in the intermediate clinical probability group and 71.7% in the high clinical probability 
group. However, this rule has not yet been evaluated by large clinical outcome studies. There-
fore, we assessed the revised Geneva score in a convenience sample from a prospective cohort 
study on the safety of the use of multi-detector row computed tomography (CT) in suspected 
PE.6 Furthermore, we compared its performance to that of the Wells rule, which had been 
routinely assessed in all patients.
METHODS
Patients
The clinical probability of PE was prospectively assessed using the Wells rule in consecutive 
patients with suspected PE referred to our hospital as part of a large diagnostic study.6 In 
contrast to the original publication of the Wells rule that categorized patients in 3 groups of 
increasing risk for PE, the Christopher study used a dichotomized version of this prediction rule. 
In all patients with a Wells rule indicating PE unlikely (score of 4 points or less), a quantitative 
D-dimer test was performed. When the result of this test was within normal ranges, PE was 
considered to be excluded and patients were left untreated. To establish the final diagnosis of 
PE, spiral CT-scanning was performed in all remaining patients, i.e. if PE was considered likely 
(Wells rule greater than 4 points) or in cases of an abnormal quantitative D-dimer test result. 
All patients were followed for three months to evaluate the recurrence of venous thrombo-
embolism (VTE).6
Assessment of the revised Geneva score
The revised Geneva score comprises four variables not included in the Wells rule: 1) age over 65 
years, 2) unilateral lower limb pain, 3) heart rate 75–94 beats per minute or more than 94 beats 
per minute and 4) pain on lower limb deep venous palpation and unilateral edema (Table 1). 
These items were abstracted from the patient charts after masking the final diagnosis. Values 
for each item were scored on the day of inclusion. In cases of inaccessibility of patient’s files or 
absence of relevant data, patients were excluded.
Data analysis
Frequencies of PE obtained with the revised Geneva score and original 3-level Wells rule were 
compared with those of the original Geneva score dataset by comparing the corresponding 
confidence intervals.5 The accuracy of the revised Geneva and Wells rule scores was com-
pared by the area under the curve (AUC) in receiver operating characteristic (ROC) analyses.7 
Results from the clinical rule and D-dimer tests were then combined and related to the clinical 
outcome. In particular, the VTE recurrence rate of patients with a low or intermediate clinical 
probability as calculated using the revised Geneva score and a normal D-dimer result were 
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studied. Statistical analyses were performed using SPSS software (SPSS for windows 12.0.1, Inc. 
1989–2003, Chicago, IL, USA).
RESULTS
Patients
The study included 300 patients with suspected PE. Medical records of all subjects were 
obtained and studied. There were no missing data, so the revised Geneva score could be 
calculated for all patients. Included patients were 47 ±16 years old at the time of diagnosis; 
60% were female and 96% were outpatients. The overall incidence of PE was 16%. According 
to the revised Geneva score, 157 patients (52%) had low clinical probability, 136 (45%) inter-
mediate clinical probability and 7 (2.3%) high clinical probability (Table 2). The incidence of PE 
was 8.3% (95% confidence interval [CI] 4.0–13), 23% (95% CI 16–30) and 71% (95% CI 35–99.9) 
respectively for the three probability groups. These frequencies were well comparable to those 
in the derivation and validation set of le Gal as well as in the Wells rule calculated in the Leiden 
population (Table 2).5,6
Table 2. Proportion of patients classified by, and predictive accuracy of the revised Geneva score in the 
original derivation and validation set compared to the results of the revised Geneva score and Wells rule 
in the Leiden study population.











n % % 95% CI n % % 95% CI n % % 95% CI n % % 95% CI
Low 354 37 9.0 6.6-13 229 31 7.9 5.0-12 157 52 8.3 4.0-13 133 44 4.5 1.7-9.6
Intermediate 549 57 28 24-31 463 62 29 25-33 136 45 23 16-30 154 51 23 16-30
High 53 6 72 58-82 57 8 74 61-83 7 2.3 71 35-99.9 13 3.4 62 32-86
CI=confidence interval, n=number.
Performance of the revised Geneva score
We compared the AUC of the ROC analysis for the revised Geneva score and Wells rule (Figure 
1A and B). The AUC of the continuous prediction rules between the Wells rule (0.79; 95% CI 
0.72–0.87) and the revised Geneva score (0.73; 95% CI 0.65–0.81) were comparable (difference 
0.06, 95% CI -0.03-0.09). The AUC of the categorized rules was 0.72 (95% CI 0.65–0.80) for the 
Wells rule and 0.67 (95% CI 0.59–0.76) for the revised Geneva score. These AUCs were not sig-
nificantly different as well (difference 0.05, 95% CI -0.04-0.13).
In total, 134 (45%) patients were classified differently using the Wells rule and the revised Geneva 






of awarding or not awarding 3 points for the item ‘alternative diagnosis less likely than PE’ in the 
Wells rule. Extreme disagreement, defined as patients classified into the low clinical probability 
group by one score and into the high clinical probability category by the other score, did not 
occur. In patients with CT-proven PE, 20 patients were categorized differently by the two rules: 
the Wells rule classified 15 patients into a higher clinical probability category than the revised 
Geneva score; in 5 patients it was the other way around. Among patients with a higher Wells 
rule classification, the CT-scan indicated central embolus location in four, segmental location in 
eight, and subsegmental embolus in three. Among cases of higher classification by the revised 
Geneva score, one patient had central emboli and four patients had segmental emboli. There 
was no difference between these two groups (p=0.5).
Table 3. (dis-) Similarities in clinical probability between the Wells rule and revised Geneva score in 
individual patients from our study population.
revised Geneva score Wells rule
Low Intermediate High
Low 85 48 0
Intermediate 72 78 4
High 0 10 3
D-dimer testing was performed in all patients (233) with a Wells rule of 4 points or less. After 
three months of follow-up, no patient with a low (0/98; 95% CI 0.0–2.7) or intermediate (0/34; 
95% CI 0.0–7.4) clinical probability score by the revised Geneva score and a normal D-dimer 
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Figures 1A and 1B. Receiver operating characteristic curves of the continuous (A) and categorized (B) 
outcome of the revised Geneva score and Wells rule.
Validation of the revised Geneva score 21
DISCUSSION
Our study confirms the good performance of the revised Geneva score. This conclusion 
is based on 4 observations. First, the predictive accuracy of the revised Geneva score in our 
study population was comparable to that of the original derivation and validation set of the 
score. Second, the comparison of the AUCs of the ROC analyses, a validated instrument for 
weighing the discrimination ability of a statistical method for predictive purposes, showed the 
equivalence of the revised Geneva score and Wells rule in our study population.8 Third, our 
data suggest that the combination of a low or intermediate clinical probability by the revised 
Geneva score with a normal D-dimer result can safely rule out the diagnosis of PE. Fourth, cases 
of disagreement between the Wells rule and the revised Geneva score were not explained by 
embolus location. Therefore, neither score tended to overestimate clinical probability in cases 
of subsegmental PE.
There are several additional points. First, the observed kappa statistic of 0.16 suggests 
great difference in individual classification of individual patients by the revised Geneva score 
and Wells rule. Explanations for this are the different criteria on which both scores are based 
and the subjective item of the Wells rule. We found that 97% of the cases in which individual 
patients were classified differently could be explained by this subjective item. Although 
implicit clinical judgement may improve the accuracy of a prediction rule, as was shown using 
the original Geneva score, and the subjective item of the Wells rule has been shown to be of 
high predictive value for PE in comparison to other items, the Wells rule did not perform better 
than the completely objective revised Geneva score.9,10 Second, although the patients were 
prospectively followed, the revised Geneva score was assessed retrospectively. Nonetheless, 
inclusion bias was not present since we included consecutive patients and their medical charts 
were abstracted by researchers blinded to the final diagnosis. Third, D-dimer measurements 
were only performed in patients classified as PE unlikely according to the Wells rule. Therefore, 
D-dimer results were available for only 80% (233/293) of all patients classified into the low or 
intermediate clinical probability groups by the revised Geneva score.
In summary, this study suggests that the performance of the revised Geneva score is equivalent 
to that of the Wells rule in a cohort largely dominated by outpatients. It seems safe to withhold 
oral anticoagulation therapy in patients with suspected PE, a low or intermediate clinical prob-
ability by the revised Geneva score and a normal D-dimer level. Prospective clinical outcome 
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We have evaluated a simplified version of the revised Geneva score, which is a fully standardized 
clinical decision rule (CDR) in the diagnostic work-up of suspected pulmonary embolism (PE).
Methods
Data regarding 1049 patients from 2 prospective diagnostic trials that included patients with 
suspected PE were combined. We constructed the simplified CDR by attributing 1 point to each 
item of the original CDR and compared the diagnostic accuracy of the 2 versions by receiver 
operating characteristic (ROC) analyses. We also assessed the safety of ruling out PE on the 
basis of the combination of either a low- or intermediate clinical probability (using a 3-level 
scheme) or a “PE unlikely” assessment (using a dichotomized rule) with the simplified rule in 
combination with a normal highly sensitive D-dimer test result.
Results
Area under the curve for the original revised Geneva score was comparable to that of the simpli-
fied score (0.75, 95% confidence interval [CI] 0.71-0.78 vs. 0.74, 95% CI 0.70-0.77). During a three 
months follow-up period, no patient with a combination of either a low (0%; 95% CI 0.0%-1.7%) 
or intermediate (0%; 95% CI 0.0%-2.8%) clinical probability, or a “PE unlikely” assessment (0%; 
95% CI 0.0%-1.2%) with the simplified score and a normal D-dimer test result was diagnosed 
with symptomatic venous thromboembolism.
Conclusion
This study suggests that simplification of the revised Geneva score does not lead to a decrease 
in diagnostic accuracy or clinical utility of the score, which should be confirmed in a prospective 
study.
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INTRODUCTION
A clinical decision rule (CDR) can be defined as an instrument containing variables obtained 
from history, physical examination and simple diagnostic tests quantifying the likelihood of a 
diagnosis, prognosis, or likely response to treatment in an individual patient.1 CDRs are espe-
cially utilized in clinical circumstances involving common problems to simplify and increase the 
accuracy of the clinicians’ diagnostic and prognostic assessments. Because of the nonspecific 
nature of the presenting signs and symptoms of acute pulmonary embolism (PE), this diagnosis 
is clinically suspected in many patients who report respiratory or chest distress. As a result of 
this, the prevalence of PE in this population is relatively low. Several CDRs have been developed 
to assist the clinician in diagnostic decision making of suspected PE.2 Correct implementation 
of CDRs in diagnostic strategies has been proven to decrease the need for expensive, time-
consuming and invasive diagnostic imaging procedures. Moreover, the venous thromboembo-
lism (VTE) failure rate is acceptably low when anticoagulant treatment is withheld in patients in 
whom PE is ruled out by various non-invasive diagnostic criteria including a CDR.3-5
Although 2 CDRs for the pretest probability of PE have been extensively validated, i.e. the 
Wells rule and the Geneva score, both have practical limitations.6-10 A fully standardized rule 
exclusively based on objective clinical items, the revised Geneva score, has been developed 
and validated recently.9,10 The revised Geneva score is independent of physicians’ implicit 
judgement, which makes this CDR objective and easily reproducible.10 The score consists of 
8 variables with different individual weights (Table 1), which might lead to miscalculations in 
acute patient care. Also, a more complicated score may be less likely to be used by clinicians or 
remembered correctly.11 Therefore, we evaluated whether a simplified version of the revised 
Geneva score in which each variable is attributed 1 point (Table 1), would retain its diagnostic 
Table 1. Simplification of the revised Geneva score.
Variable Original Simplified
Age >65 years 1 1
Previous DVT or PE 3 1
Surgery or fracture within 1 month 2 1
Active malignancy 2 1
Unilateral lower limb pain 3 1
Hemoptysis 2 1
Heart rate 74-94 beats/min 3 1
Heart rate ≥95 beats/min* 5 1
Pain on lower limb deep vein palpation and unilateral edema 4 1
*By the original score, patients are awarded 0 points (heart beat <74 beats/min), 3 points (heart rate 74-94 
beats/min) or 5 points (heart rate ≥95 beats/min); by the simplified score, patients are awarded 1 point if 
the heart rate exceeds 73 beats/min and one additional point (2 points in total) if the heart rate exceeds 






accuracy and clinical usefulness. To test this hypothesis, we compared the performance of the 
original and the simplified revised Geneva scores in 2 large patient cohorts.
METHODS
Patients
Data from 2 large prospective diagnostic trials that included patients with suspected PE were 
used and combined for the validation of the simplified revised Geneva score.3,4 In the first trial 
(study A), consecutive patients with suspected PE admitted to the emergency department 
of 3 teaching hospitals (Geneva University Hospital, Geneva, Switzerland; Angers University 
Hospital, Angers, France; and Hôpital Européen Georges-Pompidou, Paris, France) between 
August 1st 2002 and November 30th 2003 were eligible for inclusion.3 The Geneva score was 
assessed in all patients before further diagnostic testing.7 In patients with either a low or inter-
mediate probability, plasma D-dimer levels were measured using a quantitative assay (VIDAS 
D-Dimer Exclusion Test; BioMerieux, Marcy L’Etoile, France). Pulmonary embolism was ruled out 
in patients with a level below the cut-off value of 500 ng/mL. Patients with a D-dimer level 
greater than 500 ng/mL as well as patients with high clinical probability underwent proximal 
venous-compression ultrasonography of the lower limbs and multi-detector row computed 
tomography (CT). Patients with CT findings indicating PE or patients with respiratory distress 
in combination with ultrasonography that showed deep venous thrombosis received antico-
agulant treatment, whereas such therapy was withheld in patients in whom both test results 
were normal.
In the second study (study B), the clinical effectiveness of a simplified algorithm using the 
dichotomized Wells rule, D-dimer tests and CT in patients with suspected PE was evaluated.4 
Only patients from the Leiden University Medical Center who participated in that study were 
included in the present analysis. Pulmonary embolism was considered to be excluded if the 
diagnosis of PE was unlikely (Wells score ≤4 points) in combination with a normal quantita-
tive D-dimer test result. When the Wells score was 4 or less in combination with an increased 
D-dimer value or when the diagnosis of PE was likely (Wells score >4), the diagnosis of PE was 
established by CT. Patients in both studies were followed for three months. Patients with con-
firmed venous thromboembolism (VTE) were brought back for reexamination. All other patients 
were instructed to report any new signs of VTE to their general practitioner or to the emergency 
department of the participating hospitals. At the end of the three months follow-up period, all 
patients were interviewed by telephone and were asked to disclose all health-related events 
since their hospital discharge. The family physician was contacted whenever a possible event 
was disclosed by the interim history, and charts were reviewed if a patient was readmitted to 
the hospital for any cause or died during the follow-up period. Recurrent VTE was diagnosed 
according to standardized criteria.3,4 Both studies were approved by the Institutional Review 
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Board of all participating hospitals, and all patients provided written informed consent before 
they were enrolled.
In study A, D-dimer testing was part of the diagnostic work-up of all patients with either 
a low or intermediate probability according to the Geneva score. In study B, D-dimer tests 
were performed only in patients with a Wells score of 4 points or less. This resulted in missing 
D-dimer data for 69 patients in the low- and intermediate probability group and for 29 patients 
in the unlikely clinical probability group as assessed by the simplified revised Geneva score.
Assessment of the revised Geneva score
In study A, the data collection form was identical to that used in the derivation study of the 
original revised Geneva score, allowing retrospective calculation of the simplified revised 
Geneva score for each patient. In study B, the Wells rule was used for assessing clinical probabil-
ity. The revised Geneva score comprises 4 variables not included in the Wells rule: age, unilateral 
lower limb pain, heart rate, and signs of deep venous thrombosis (pain on lower limb deep 
venous palpation and unilateral edema). The 4 variables absent from the original database were 
extracted from the medical charts in a prespecified standard way by 2 independent observers 
after blinding of the diagnosis (PE or no PE) by a third person not involved in the data extrac-
tion. Lower limb pain and signs of deep venous thrombosis were routinely recorded in patient 
charts in the setting of a clinically suspected PE. Therefore, there were no missing data.10
In the simplified revised Geneva score, all variables were given 1 point if present (Table 1). 
Because of the different weights of increasing heart rate in the original score, we attributed 1 
point to a heart rate between 75 and 94 beats/min and an additional point for a heart rate of 
95 beats/min or more.
Data analysis
Patient characteristics and outcomes of both studies were combined in a single database. 
Optimal cut-off points for the simplified Geneva score were determined by receiver operating 
characteristic (ROC) analysis. To account for the existence of both 3-level (low, intermediate, or 
high clinical probability) and 2-level (PE unlikely or likely) schemes in clinical practice, we set 
cut-off points for both schemes. Diagnostic accuracy of the simplified revised Geneva score and 
the revised Geneva score was compared by means of the area under the curve (AUC) in ROC 
analyses. Contrasting the AUC for the continuous scores was designed to compare the original 
and simplified rule precisely, using all possible point scores. However, the continuous score is 
not meant for clinical use. Hence, we additionally compared the 3-level classification scheme 
of both scores. Lastly, we studied the clinical course of patients with a normal D-dimer result 
in different clinical probability categories using the simplified revised Geneva score. Statistical 
analysis was performed by using SPSS software (SPSS for Windows 14.0.2; SPSS Inc, Chicago, 








Study A included 756 outpatients. They had a mean (± standard deviation) age of 60 (±19) 
years, 454 were female (60%) and 194 patients (26%) were diagnosed with acute PE. However, 
owing to missing values mainly for heart rate, the revised Geneva score could not be computed 
for 7 patients, leaving 749 for the present analysis, including 192 patients with PE (26%). Three 
hundred patients in study B with suspected PE were included in the present study. These 
patients were 47 (±16) years old at time of diagnosis, 181 were female (60%) and 289 were 
outpatients (96%). The overall prevalence of PE in this cohort was 16% (49 patients). Taken as a 
whole, the complete study population consisted of 1049 patients with a PE prevalence of 23% 
(241 patients).
Predictive accuracy of the simplified score
After selecting the optimal cut-off points for the 3-level scheme, a low clinical probability 
was defined as a score of 0 or 1 point, an intermediate probability as 2 to 4 points, and a high 
probability as 5 points or more. With the use of these cut-off points, 378 patients (36%) were 
assigned to the low clinical probability category (prevalence of PE 7.7%, 95% confidence 
interval [CI] 5.2-11%), 629 patients (60%) to the intermediate clinical probability category 
(prevalence of PE 29%, 95% CI 26-33%), and 42 patients (4.0%) to the high clinical probability 
category (prevalence of PE 64%, 95% CI 48-79%; Table 2). The optimal cut-off point for the 
2-level scheme was 3 points. Patients with a score of 0 to 2 were categorized as being unlikely 
to have PE and those with a score of 3 or more as likely to have PE (Table 2); 681 patients (65%) 
were designated unlikely to have PE (prevalence of PE, 13%, 95% CI 11-16%) and 368 patients 
(35%) were designated likely to have PE (prevalence of PE 42%, 95% CI 37-47%).
Table 2. Score application in the study population, percentage with PE, and proportions of the population 
in the 3-level and 2-level clinical probability categories.
Three-level scheme Two-level scheme
Low Intermediate High PE unlikely PE likely
Number 378 629 42 681 368
% population 36 60 4.0 65 35
% PE 7.7 29 64 13 42
PE=pulmonary embolism.
We compared the AUC for the revised Geneva score and simplified revised Geneva score (Fig-
ures 1A and 1B). The AUC of the continuous score was 0.75 (95% CI 0.71-0.78) for the revised 
Geneva rule and 0.74 (95% CI 0.70-0.77) for the simplified revised Geneva rule. The AUC of the 
3-level classification scheme was 0.70 (95% CI 0.66-0.74) for the revised Geneva score and 0.68 
(95% CI 0.64-0.72) for the simplified revised Geneva score.
Simplification of the revised Geneva score 29
Utility of the simplified score
Finally, we studied the clinical utility of the simplified revised Geneva score. Flowcharts for 
both dichotomized and trichotomized rules are shown in Figures 2 and 3. Of all patients in 
the combined patient population with a normal result of the D-dimer test, in whom PE was 
excluded (n=361), 2 patients were lost during follow-up and an additional 10 received antico-
agulant therapy for reasons other than PE. These patients were excluded from the following 
analysis. During three months of follow-up, no patient with a low (0/219, 0%; 95% CI 0.0-1.7%) 
or intermediate (0/130, 0%; 95% CI 0.0-2.8%) clinical probability score by the simplified revised 
Geneva score and a normal D-dimer result at inclusion was subsequently diagnosed as having 
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Figures 1A and 1B. Receiver operating characteristic curves of the continuous revised Geneva score 
(RGS) and simplified RGS (A) and 3-level categorized RGS and simplified RGS (B).
0 patients with 
PE* (0%, 95% CI 
0.0-1.7)
2 patients with 
PE (22%, 95% CI 
2.8-60)
27 patients with 
PE (18%, 95% CI 
13-26)





29 patients with 
PE (48%, 95% CI 
35-62)
156 patients 
with PE (36%, 
95% CI 32-41)
0 patients with 
PE† (0%, 95% CI 
0.0-2.8)








27 patients with 
PE (64%, 95% CI 
48-79)
42 patients with high 
clinical probability
629 patients with 
intermediate CP







Figure 2. Flowchart of patients showing outcomes by 3-level simplified revised Geneva score. *One 
patient was lost to follow-up and 3 patients were treated with anticoagulant therapy for reasons other 
than pulmonary embolism (PE); †One patient was lost to follow-up and 7 patients were treated with 






(0/318, 0%; 95% CI 0.0-1.2%) was subsequently diagnosed with venous thromboembolism after 
the three months follow-up period (Figure 3).
DISCUSSION
This study shows that it is possible to simplify the revised Geneva score without decreasing the 
diagnostic accuracy of the rule. The distribution of the patient proportions by the simplified 
revised Geneva score in both trichotomized and dichotomized categories and the prevalence 
of PE in these categories were comparable to those of the original revised Geneva score as well 
as to 3 other validated CDRs: the Wells rule, the Geneva score and the rule suggested by Kline 
and colleagues.6,7,9,12 The simplified revised Geneva score is clinically useful and might safely 
rule out PE when combined with a normal D-dimer result using a highly sensitive assay. Indeed, 
in this cohort, the VTE failure rates were extremely low in patients with normal D-dimer results 
and a low or intermediate clinical probability (3-level scheme) or a “PE unlikely” assessment 
(2-level score). Furthermore, the simplified score would likely be easier to compute and may 
reduce computational errors in clinical practice in busy environments with a heavy workload.
Several studies have shown D-dimer assays to have a high negative predictive value and to 
be a sensitive but nonspecific marker of PE.13 However, different sensitivity for several D-dimer 
assays has been described in the literature.2,13-15 Less sensitive tests yield a lower negative 
predictive value for the same pretest probability of PE. Also, the negative predictive value 
of a normal D-dimer test result diminishes as disease prevalence rises.16 As a consequence, 
the proportion of patients with suspected PE in whom D-dimer testing can safely be used to 
exclude PE depends on both the prevalence of the disease and the sensitivity of the D-dimer 
assay. This is why we adopted 2 different schemes. Table 3 shows the post-test probability for 
PE in various combinations of clinical probability categories and D-dimer assays. The upper 
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Figure 3. Flowchart of patients showing outcomes with dichotomous use of the simplified revised 
Geneva score. *Two patients were lost to follow-up and 10 patients were treated with anticoagulant 
therapy for reasons other than pulmonary embolism (PE). CI indicates confidence interval.
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limit of the 95% confidence interval of the three months thromboembolic rate after negative 
pulmonary angiography is 2.7%.17 Using this percentage as the upper posttest probability limit 
above which it is no longer safe to rule out PE by the combination of clinical probability and a 
negative D-dimer result, Table 3 shows that, with a 3-level score, a less sensitive D-dimer assay 
would exclude PE safely only in low-probability patients, whereas the same assay would still be 
safe in the patients in whom PE was unlikely by using the 2-level score. For this reason, a less 
sensitive assay would rule out PE in more patients and therefore be more useful in combination 
with the dichotomized rule because there are more patients categorized as PE unlikely than 
in the low clinical probability category. Conversely, the 3-level score would be more useful 
when a highly sensitive assay is used because it would safely rule out PE in both the low and 
intermediate probability groups, which would regroup a higher number of patients than the 
PE unlikely category. In the present study, a highly sensitive quantitative D-dimer assay with a 
reported sensitivity of 95% to 98% was used, and the outcome of three months follow-up was 
good in either low- or intermediate probability as well as in the PE unlikely category.2 However, 
a physician using the simplified revised Geneva score in combination with a D-dimer assay 
with a lower sensitivity should probably restrict its use to the low clinical probability category 
of the 3-level score to exclude PE. The AUC of ROC analysis of the simplified score was similar 
to that of the original score. Given that the original score assigned very different weights to the 
individual variables, at least some loss of predictive accuracy would have been expected, and 
this might therefore seem surprising. Because this is also true for the ROC curve using all the 
score values and not only 2 cut-off values, this observation is not due to cut-off selection in this 
particular population.
This study has limitations. We performed a retrospective analysis, which can be subject to 
various biases. We acknowledge that prospectively studying the clinical utility and outcomes 
in a new sample would be the best way of testing our hypothesis. Nevertheless, the revised 
Geneva score could be calculated in more than 99% of patients. Also, the original cohorts 
prospectively included consecutive patients with minimal loss to follow-up (0.5% in study A 
and 0.1% in study B). There were some differences in general characteristics between the 2 
Table 3. Post-test probability for acute PE according to the sensitivity of D-dimer assays and clinical 
probability category as assigned by simplified revised Geneva score.
Three-level scheme Two-level scheme
Low Intermediate High PE unlikely PE likely
Prevalence of PE 8% 29% 64% 13% 42%
Posttest PE
Highly sensitive DD* 1% 3% 12% 1% 5%
Less sensitive DD† 1% 6% 23% 2% 11%
Low sensitivity DD¶ 2% 9% 29% 3% 14%
Figures for sensitivity and specificity are extracted from Di Nisio et al.16 *Sensitivity 97%, specificity 40%; 







study populations, i.e. mean age and prevalence of PE. However, the prevalence of PE according 
to the number of points in the simplified revised Geneva score was similar in the 2 groups 
(data not shown), which actually adds validity to the simplified score. Finally, by study design, 
D-dimer results were not available for all patients. Data were missing in 9 patients (2.4%) with 
low clinical probability, in 60 patients (9.5%) with intermediate clinical probability, and in 29 
patients (4.3%) designated as PE unlikely.
In summary, our data indicate that simplification of the revised Geneva score does not decrease 
the score’s diagnostic accuracy or clinical utility. Prospective outcome studies are needed, 
however, to confirm our findings.
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Chapter 4
Safety of ruling out acute pulmonary embolism 
by normal CT pulmonary angiography 
in patients with an indication for CT: 
systematic review and meta-analysis
F.A. Klok†, I.C.M. Mos†, L.J.M. Kroft, A. de Roos, O.M. Dekkers and M.V. Huisman
†Equally contributed








Several outcome studies have ruled out acute pulmonary embolism (PE) by normal computed 
tomography pulmonary angiography (CTPA). We performed a meta-analysis in order to deter-
mine the safety of this strategy in a specific group of patients with a strict indication for CTPA, 
i.e. ‘likely’ or ‘high’ clinical probability for PE, an elevated D-dimer concentration, or both.
Methods
Studies that ruled out PE in patients with a strict indication for CTPA by normal CTPA were 
searched for in Medline, EMBASE, Web of Science and the Cochrane dataset. Primary endpoint 
was the occurrence of (fatal) thromboembolic events (VTE) in a three months follow-up period.
Results
Three studies were identified that excluded PE by CTPA alone (2020 patients) and three studies 
that performed additional bilateral compression ultrasonography (CUS) of the legs after normal 
CTPA (1069 patients). The pooled incidence of VTE at three months was 1.2% (95% CI 0.8-1.8%) 
based on a normal CTPA as a sole test and 1.1% (95% CI 0.6-2.0%) based on normal CTPA and 
negative CUS, resulting in NPVs of 98.8% (95% CI 98.2-99.2%) and 98.9% (95% CI 98.0-99.4%) 
respectively. Risk of fatal PE did not differ between both diagnostic strategies (0.6% vs. 0.5%).
Conclusion
A normal CTPA alone safely excludes PE in all patients in whom CTPA is required to rule out this 
disease. There is no need for additional ultrasonography to rule out VTE in these patients.
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INTRODUCTION
Computed tomography pulmonary angiography (CTPA) is currently the preferred thoracic imag-
ing test for patients suspected of having acute pulmonary embolism (PE).1 This is the result of 
the high negative predictive value (NPV) of CTPA that was shown to range from 98.7 to 99.9%.2,3 
In addition, it has been demonstrated that it is unnecessary to perform additional imaging tests 
after a normal multi-detector row CTPA before excluding venous thromboembolic disease and 
withholding anticoagulant therapy.2,3 However, in these reports, patients with low, intermedi-
ate as well as patients with high clinical pretest probability for having PE were selected for 
CTPA. In several recent studies, it has been reported that acute PE can be ruled without the 
need for radiological imaging tests in a specific patient population with ‘low’ or ‘unlikely’ clinical 
probability for PE in combination with a normal highly sensitive D-dimer test result.4-6 Since the 
NPV of a test is dependent on the incidence of the disease in the tested population, the NPV of 
CTPA in patients in whom PE can not be ruled out by a clinical decision rule and a D-dimer test, 
i.e. with ‘likely’ or ‘high’ pretest probability for PE or an abnormal D-dimer test result (incidence 
of PE 37-47%7), is likely to be less favorable than the NPV of CTPA in the overall population sus-
pected of having PE (incidence of PE 20-26%7). Furthermore, several studies have shown that 
despite of a negative CTPA, non-symptomatic deep venous thrombosis (DVT) can be identified 
by compression ultrasonography (CUS) in a small proportion of patients with suspected PE.4,8,9 
Our objective was to perform a systematic review and meta-analysis to determine the safety of 
excluding acute PE on the basis of a normal CTPA alone for all patients with clinically suspected 
acute PE and a strict indication for CTPA. In addition, we studied the additional value of CUS 
after a normal CTPA in this specific patient cohort.
METHODS
Data sources
A literature search was performed to identify all published prospective outcome studies that 
excluded PE on the basis of a normal CTPA result. Medline, Embase, Web of Science and the 
Cochrane dataset were searched using predefined search terms. Search criteria included 
“pulmonary embolism” or “venous thromboembolism” or “venous thrombosis” and “computed 
tomography” or ”spiral CT”. Articles published from January 1990 till September 2008 were 
eligible for this analysis. Papers were not limited to the English language. All references of the 
included studies were reviewed for potential relevant articles.
Study outcome
Outcome of this meta-analysis was the NPV of CTPA and the safety of withholding anticoagu-






clinical decision rule indicating ‘likely’ or ‘high’ probability, an elevated D-dimer concentration, 
or both. Endpoints were objectively confirmed adverse thrombotic events subsequent to a 
normal CTPA including all occurrences of venous thromboembolism (VTE), i.e. both DVT and 
PE, and mortality attributable to PE.
Study selection and inclusion criteria
Mandatory for inclusion was a diagnostic strategy based on a clinical decision rule and a 
D-dimer test without additional imaging tests prior to CT scanning. In addition to studies that 
used CTPA as only imaging test, we also included studies that had used CUS of the legs follow-
ing a normal CTPA to study the additional value of CUS for ruling out VTE. Further criteria for 
selection were a prospective design, consecutive patient selection, predefined endpoints, clear 
description of inclusion and exclusion criteria, and a clinical follow-up of more than one month. 
Two reviewers independently reviewed all identified studies. In case of disagreement, a third 
reviewer was consulted.
Data abstraction
Data regarding study design, patient characteristics, diagnostic algorithm (clinical decision rule, 
D-dimer assay and CT modality), follow-up period, completeness of follow-up and endpoints 
were abstracted by two independent researchers. Guidelines proposed by the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) group were followed to extract and present 
the data.10 Individual study quality was assessed by the following items: patient enrollment, 
outcome assessment, duration of follow-up, loss to follow-up and funding source.
Statistical analysis
We identified the reported number of objectively confirmed cases of VTE and in addition all 
deaths attributed to PE for each study. Patients who received anticoagulants for reasons other 
than VTE and patients who were lost to follow-up were excluded from the analysis. A meta-
analysis was performed by pooling the proportions in a fixed effects as well as in a random 
effects model. Because the criteria for the performance of CTPA in the included studies were 
comparable, the disease incidence was expected to be similar between the studies. For this 
reason pooling of the NPV was reasonable. The proportions were weighted according to the 
inverse of the squared standard error. Shown proportions and confidence intervals (CI) in the 
text represent a fixed effects model calculated proportion. Studies with CTPA alone and with 
additional CUS following a normal CTPA were pooled separately. For assessment of hetero-
geneity, I2 was calculated for all comparisons.11 We defined the upper limit of the 95% CI of 
the fatal and non-fatal three months thromboembolic rate after a normal invasive pulmonary 
angiography as the cut-off point for the safe exclusion of PE by CTPA, thereby comparing CTPA 
with the reference standard. For assessment of the effect of the additive use of CUS following 
a normal CTPA on mortality, the weighted relative risk of fatal PE was calculated. Finally the 
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sensitivity for both diagnostic strategies was calculated. For statistical analysis SPSS version 




The literature search revealed 1075 studies; 1052 studies were excluded after review of title 
and abstract and 23 studies were identified for more detailed evaluation. After full review, 
an additional 18 studies were excluded due to a diagnostic algorithm that did not meet our 
predefined criteria, i.e. no clinical decision rule, D-dimer or CTPA performed, or performance 
of supplementary imaging tests before the CTPA. Three studies using CTPA without further 
imaging5,12,13 and three studies that incorporated CUS after CTPA4,8,9 were left for inclusion 
in this meta-analysis. No new articles were identified by reviewing the references of these six 
studies.
Quality and characteristics of the included studies
All six included studies were of a prospective design with consecutive patient enrolment. The 
duration of follow-up was three months in all studies and loss to follow-up varied between 
0.0% and 1.3% (Table 1). The demographic characteristics of patients in the studies were 
comparable (Table 2). Mean age varied from 50 to 60 years, the proportion of male gender 
ranged between 35% and 47% and the majority of patients were outpatients. Different clinical 
decision rules were used, i.e. the Geneva score, the revised Geneva score, the Wells rule or the 
Hyers criteria, in two or three level schemes.14-18 Also, different quantitative D-dimer tests were 
used: VIDAS D-dimer assay (BioMérieux, Marcy- l’Etoile, France), STA Liatest (Diagnostica Stago, 
Asnières, France, SimpliRED (Agen Biomedical Limited, Acaccia Ridge, Australia), Tinaquant 
assay (Roche Diagnostica, Mannheim, Germany) and an immunoturbimetric latex agglutina-
tion assay (IL-Test, Instrumentation Laboratory, Lexington, MA). Furthermore, the use of single- 
or multi-detector row CT modalities varied between the studies. In two studies, patients were 
randomized between two diagnostic strategies, i.e. CTPA or ventilation perfusion scintigraphy 
and CTPA or CUS preceding CTPA.4,12 Only the patients randomized to CTPA were included in 
this analysis. Overall, the fraction of patients who had an indication for CTPA was 70% (range 
35-93%; Table 3). The overall proportion of inconclusive CT scan results was reported to be 1.8% 
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Meta-analysis
Three studies were identified that excluded PE in symptomatic patients with an indication for 
CT-scanning based on a normal CTPA without additional imaging tests. Of all 2020 patients 
with an initial normal CTPA result, 25 (1.2%, 95% CI 0.80-1.8) were diagnosed with VTE in a 
three months follow-up period (Tables 3 and 4, Figure 1). Of these, 12 (12/2020; 0.60%, 95% CI 
0.40-1.1) were classified as fatal PE. Markedly, only in two of these 12 patients, an autopsy was 
performed and PE was objectively identified as cause of death. The NPV for symptomatic VTE 
in three months following a negative CTPA in patients with an indication for CTPA was 98.8% 
(95% CI 98.2-99.2). In the three studies that included CUS of the legs subsequent to a normal 
CTPA, 1069 symptomatic patients with an indication for CTPA and eventually a normal CTPA 
were identified. Twenty-one cases of DVT (21/1069; 2.4%, 95% CI 1.6-3.7) were identified by 
CUS performed shortly after the CTPA (Tables 3 and 4). During three months follow-up, nine 
additional patients (9/1048; 1.1%, 95% CI 0.60-2.0) with initially normal CTPA and CUS results 
were diagnosed with symptomatic VTE. Four of these 1048 patients in whom VTE was excluded 
and who were not treated with anticoagulants, died (4/1048; 0.50%, 95% CI 0.20-1.1) possibly 
as a consequence of PE. The NPV for symptomatic VTE in three months after a normal CTPA 
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followed by CUS was 98.9% (95% CI 98.0-99.4). Therefore, the NPV of CTPA alone was equal 
to the NPV of CTPA followed by CUS (98.8% vs. 98.9%). The pooled proportions of fatal PE in 
follow-up were comparable as well (0.6% and 0.5%, Table 4), indicating a relative risk of 1.2. 
The use of a random effects model did not materially influences the study results (Table 4). The 
pooled sensitivity for detecting PE by CTPA alone was 97.3% (95% CI 96.1-98.2), the sensitivity 
for detecting PE of CTPA combined with additional CUS was 97.4% (95% CI 95.1-98.6).
Table 4. Random and fixed model proportions of study endpoints.
Model VTE in FU after 
normal CTPA 
without CUS






to normal CTPA 
followed by CUS








Fixed 1.2 0.6 2.4 1.1 0.5
95% CI 0.8-1.8 0.4-1.1 1.6-3.7 0.6-2.0 0.2-1.1
Random 1.2 0.6 2.0 1.0 0.5
95% CI 0.8-1.8 0.4-1.1 0.7-5.2 0.4-2.3 0.2-1.1
I2 0.000 0.000 78.98 29.35 0.000
PE=pulmonary embolism, VTE=venous thromboembolism, FU=follow-up, CI=confidence interval, 
CTPA=computed tomography pulmonary angiography, CUS=compression ultrasonography.
DISCUSSION
The main finding of this study is that the NVP of CTPA to rule out PE in a patient population with 
an indication for CT scanning is 98.8% (95% CI 98.2-99.2). Furthermore, the three months fatal 
recurrent risk after a normal CTPA in this particular patient population is very low (0.6%, 95% 
CI 0.40-1.1). An invasive pulmonary angiography is the reference standard for the diagnosis of 
PE.1 The upper limit of the 95% confidence interval of the three months VTE rate after normal 
CTPA alone van Belle5 1.3                  0.8                2.0 72.00
Righini12 1.4                  0.6                3.3 19.98
Ghanima13 0.9                  0.2                3.5 8.03
CTPA followed by CUS          Anderson 20059 0.2                  0.0                3.4 25.00
Anderson 20074 0.8                  0.3                2.0 33.51
Perrier8 1.7                  0.7                4.0 41.49
Fixed 1.2                  0.8                1.8
Random 1.2                  0.8                1.8
Fixed 1.1                  0.6                2.1
Random 1.0                  0.4                2.3
Event            Lower         Upper Relative
rate               limit             limit 0.0 5.0           weight
Figure 1. Pooled proportions (fixed as well as random effects model) of the confirmed venous 
thromboembolism event rate after a normal CTPA and after a normal computed tomography pulmonary 






pulmonary angiography is 2.7%.19 Using this fraction as the upper posttest probability limit 
above which it is no longer safe to rule out PE by a diagnostic test, our data show that a normal 
CTPA alone is a valid criterion for the safe exclusion of acute PE, even in this specific population. 
Furthermore, the three months PE associated mortality rate after a normal invasive pulmonary 
angiography is 0.3% (95% CI 0.02-0.7%) which is comparable with the pooled mortality rate 
observed in our study (0.6%, 95% CI 0.40-1.1).19 Our analysis of the three studies that included 
CUS after a normal CTPA allowed us to test the additional value of CUS for ruling out VTE. In 
these three studies, the proportion of patients with CUS proved DVT in spite of a normal CTPA 
result was low (2.4%). Furthermore, the NPV for symptomatic VTE in three months of follow-up 
of CTPA alone was comparable to the NPV of CTPA followed by CUS (98.8% versus 98.9%). In 
accordance with this finding, the VTE-related mortality risk was not different between both 
diagnostic strategies.
Some additional observations require comment. We intended to study the performance of 
CTPA in all patients in whom this imaging modality is required to rule out PE. For this reason, our 
study patients had an overall moderate probability for having PE (28%). It could be reasoned 
that the NPV of the CTPA is lower in more selected patients with a higher clinical probability 
than in the population that we studied in this report. Of note, in the recent guidelines of the 
European Society of Cardiology on the diagnosis of acute PE, the safe exclusion of PE in a high 
clinical probability population by a normal CTPA result alone is being debated because of 
possible false negative CTPA results.1 Nonetheless, no current evidence exists that additional 
imaging, e.g. CUS or ventilation perfusion scintigraphy, would prevent VTE in a three months 
follow-up period in this small selected group of patients. In our analysis it was not possible to 
study this issue in more detail, since none of the included studies had reported the incidence of 
symptomatic VTE after normal CTPA result alone in a selection of high probability patients only. 
In addition, the distinction of patients with a high clinical probability for PE is clinically unpracti-
cal since this would imply a different diagnostic strategy for the same (normal) CTPA result, as 
it would be unpractical and unnecessary to distinguish patients with a ‘low’ from patients with 
a ‘less likely’ clinical probability for the interpretation of a normal D-dimer test result. Further-
more, the best threshold, i.e. clinical decision rule or D-dimer concentration cut-off points, for 
defining a high risk population in whom negative CTPA does not safely rule out PE is unknown.
We consider our results to be representative because our findings are based on a pooled 
analysis of a large cohort of over 3000 patients. Second, the analyzed studies were of high 
quality with a prospective design, including consecutive patients and using standardized diag-
nostic tests. Third, follow-up time was consistent in all studies (three months) and all endpoints 
were well defined and confirmed by objective tests by predefined criteria. Finally, demographic 
characteristics of the patients were comparable between all included studies. Even so, this 
meta-analysis has some limitations. Inherent to the design of a meta-analysis, pooling observa-
tional or non-randomized data could lead to biases. Specifically for our analysis, different clini-
cal decision rules, D-dimer assays and CT-scanners were used between the included studies. 
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The distinct use of the clinical decision rules, with either 2- (PE ‘likely’ or ‘unlikely’) or 3-level 
schemes (‘low’, ‘intermediate’ or ‘high’ probability of PE), resulted in differences in the fraction of 
patients who were eligible for CTPA without the need for D-dimer testing. Nevertheless, quan-
titative, highly sensitive D-dimer tests were used in all 6 included studies and all patients with 
an abnormal D-dime test result underwent CTPA. Thus, the different use of clinical decision 
rules did not affect the overall proportion of patients that was finally selected for CTPA. Also, 
we could not correct for differences between the performances of single- and multi-detector 
row CT scanners. In addition, all included studies reported a low number of inconclusive CTPA 
results (1.8%). We excluded these cases from our analysis. Finally, by study design, we could not 
objectively assess whether the reported VTE related mortality was actually caused by acute 
PE. Definite cause of death was only determined by autopsy in 11% of the fatal cases. As a 
consequence, our mortality rates are likely to be overestimated.
In summary, the NPV and safety of excluding acute PE in patients with an indication for CTPA, 
i.e. ‘likely’ or ‘high’ clinical probability, an elevated D-dimer concentration or both, by a normal 
CTPA without further imaging tests is comparable to the NPV and safety of a normal invasive 
pulmonary angiography. Furthermore, a strategy including CUS of the legs following a normal 
CTPA did not improve its diagnostic performance. The clinical implication of our findings is that 
anticoagulant therapy can safely be withheld in all patients with suspected PE after using CDR 
and D-dimer testing, and a normal CTPA. In our view, there is no need for additional CUS of the 
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The potential role of elevated brain-type natriuretic peptides (BNP) in the differentiation of 
patients suffering from acute pulmonary embolism (PE) at risk for adverse clinical outcome has 
not been fully established.
Methods
Articles reporting on studies that evaluated the risk of adverse outcome in patients with PE 
and elevated BNP or N-terminal-pro-BNP (NT-pro-BNP) levels were abstracted from Medline 
and EMBASE. Information on study design, patient and assay characteristics as well as clinical 
outcome was extracted. Primary endpoints were overall mortality and a predefined composite 
outcome of adverse clinical events.
Results
Data from 13 studies were included. In 51% (576/1132) of the patients, BNP or NT–pro-BNP 
levels were increased. Elevated levels of BNP or NT-pro-BNP were significantly associated with 
right ventricular dysfunction (odds ratio [OR] 39; 95% confidence interval [CI] 17-89). Patients 
with high BNP or NT–pro-BNP concentration were at higher risk of complicated in-hospital 
course (OR 6.8; 95% CI 4.4-10) and 30-day mortality (OR 7.6; 95% CI 3.4-17). Patients with a high 
BNP or NT-pro-BNP had a 10% risk of dying (68/671; 95% CI 8.0-13%), whereas 23% (209/909; 
95% CI 20-26%) had an adverse clinical outcome.
Conclusions
High concentrations of BNP or NT-pro-BNP distinguish patients with PE at higher risk of 
complicated in-hospital course and death from those with low BNP levels. Increased BNP or 
NT–pro-BNP concentrations alone, however, do not justify more invasive treatment regimens.
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INTRODUCTION
Right ventricular dysfunction on echocardiography is a common clinical finding in patients 
with acute pulmonary embolism (PE) and predicts poor outcome.1-3 Prognostic stratification 
after measuring right ventricular function in hemodynamically stable patients with acute PE 
can potentially be used for making treatment decisions: patients identified with a low risk of 
complicated outcome may be eligible for outpatient management whereas high risk patients 
may benefit from more aggressive treatment.1,2
Several cardiac biomarkers have emerged as indicator of right ventricular dysfunction and 
predictor of clinical outcome in patients with acute PE. A recent meta-analysis demonstrated 
that elevated Troponin levels identify patients with PE at high risk of short-term death and 
adverse outcome.4 Brain-type natriuretic peptide (BNP) is also a marker of ventricular dysfunc-
tion. This hormone is released in response to myocyte stretch. It is synthesized as an inactive 
prohormone (pro-BNP) that is split into the active hormone BNP and the inactive N-terminal 
fragment (NT–pro-BNP).5 Several prospective studies have been performed to identify the 
potential role of either BNP or NT–pro-BNP in the risk stratification of patients with PE.6-18 How-
ever, reported studies have limited patient numbers, used different cut-off points and involved 
different clinical endpoints. Therefore, we performed a meta-analysis of studies in patients with 
acute PE with the aim of evaluating the predictive value of elevated levels of BNP or NT–pro-
BNP for clinical outcome after PE.
METHODS
Data sources
A literature search was performed to identify all published prospective studies on BNP or 
NT–pro-BNP levels and clinical outcome in patients with acute PE. Medline and EMBASE were 
searched using predefined search terms between January 1980 and October 2007. Search 
criteria included ‘‘pulmonary embolism’’ and ‘‘pro–brain natriuretic peptide’’ or ‘‘brain natriuretic 
peptide’’ or ‘‘natriuretic peptide.’’ Also, by searching the reference lists of all established studies, 
the researchers aimed to identify additional relevant articles. Articles were not limited to the 
English language. Only complete articles were applicable for this analysis.
Study outcome
Objectively adjudicated short-term adverse clinical events were used as a primary outcome 
of this meta-analysis. Adverse clinical outcome was defined as the occurrence of any of the 
following: death, cardiopulmonary resuscitation, mechanical ventilation, use of vasopressors, 
thrombolysis, thrombosuction, open surgical embolectomy or admission to the intensive care 






Study selection and data extraction
Two independent researchers performed the study selection. In case of disagreements, a third 
researcher was consulted. Criteria for selection were as follows: prospective design, consecutive 
inclusion of patients, clear description of inclusion and exclusion criteria, objective criteria for 
diagnosis of PE, predefined endpoints, standardized treatment and the possibility of creating 
a 2 by 2 table based on BNP or NT–pro-BNP levels and clinical endpoints. Study sample size 
was not an eligibility criterion. Objective criteria for PE were positive findings on computed 
tomography (CT) or conventional pulmonary angiography, high-probability ventilation perfu-
sion scintigraphy, or clinical suspicion of PE in combination with ultrasonography proven deep 
venous thrombosis. This latter criterion is supported by the findings of Le Gal and colleagues 
who recently described that a positive compression ultrasonography of the lower limb veins 
is highly predictive of PE on CT in suspected patients.19 Data regarding patient characteris-
tics, exclusion criteria, diagnostic criteria for PE, severity of PE (inclusion of hemodynamically 
unstable patients and use of thrombolytic therapy), completeness of follow-up, immunoassay, 
timing of sampling, cut-off level, follow-up period and endpoints were abstracted.
Statistical Analysis
Data were entered in Review Manager (version 4.2 for Windows; The Nordic Cochrane Center, 7 
2003, Copenhagen, Denmark). Individual and pooled odds ratios (OR) were calculated to assess 
the relation between elevated BNP or NT–pro-BNP levels and clinical outcome. Mantel-Haenszel 
methods for combining trials were used for weighting the studies. Cochran’s Chi-Square test 
and the I2 test for heterogeneity were used to assess interstudy heterogeneity. The Chi-Square 
test assesses whether observed differences in results are compatible with chance alone. The 
I2 describes the percentage of the variability in effect estimates that is due to heterogeneity 
rather than sampling error. Statistically significant heterogeneity was considered present at 
Chi-Square p<0.10 and I2>50%.
RESULTS
Study selection
After the literature search, 124 potentially relevant studies were identified. Articles were 
excluded by review of title and abstract in case of review articles (48), animal studies (2), case 
reports (5), editorials, letters or author replies (13), studies not covering the clinical course of 
PE (6) and if the article concerned studies on other diseases than PE (17). After full review, an 
additional 20 studies were excluded because our predefined endpoints were not reported (17) 
or cut-off points were not mentioned (3). The remaining 13 studies met our criteria and were 
included in this meta-analysis.6-18
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Characteristics of included studies
Demographic characteristics of the patients were comparable between all included stud-
ies (Table 1). Mean age of the patients varied between 53 and 75 years; the proportion of 
females ranged from 36 to 74%. In most patients, the diagnosis of PE was confirmed by CT, 
high-probability ventilation perfusion scintigraphy or pulmonary angiography. In three studies, 
hemodynamically unstable patients were excluded.7,11,17 Noticeably, in two of these latter stud-
ies, some patients received thrombolytic therapy during their hospital stay.7,11 Two included 
studies reported on partially overlapping patient cohorts.16,18 Because one of these studies 
used BNP16 and the other NT-pro-BNP18 levels as an outcome parameter, both studies could be 
incorporated into subgroup analyses based on type of BNP testing.
Assays and cut-off points
As shown in Table 1, all studies reporting NT-pro-BNP levels used a Roche analyzer (two types: 
Elecsys 2010 analyzer, Meylan France; electro-chemiluminescence method-ECLIA, Roche Diag-
nostics GmbH, Mannheim, Germany), with three different cut-off levels, varying from 500 to 
1000 pg/mL. In the BNP studies, two assays with four different cut-off levels varying between 75 
and 100 pg/mL were used. In all included studies, the timing of sampling was comparable. Cut-
off levels were not predefined in 10 studies. In these articles, receiver operating characteristic 
(ROC) analyses were performed to retrospectively determine optimal cut-off values with regard 
to complicated PE. Normal levels are defined as levels beneath or equal to the cut-off point.
Clinical outcome
Overall, in 51% (576/1132) of the patients, the assays showed elevated plasma concentrations 
of BNP or NT-pro-BNP. Data on overall mortality were reported in four studies using BNP10,11,14,17 
and four studies using NT–pro-BNP.8,12,13,15 In the BNP cohort, 17 of 123 patients (14%; 95% 
confidence interval [CI] 8.3–21%) with elevated BNP levels died compared with 3 of 138 (2.2%; 
95% CI 0.45–6.2%) of those with normal BNP levels. This resulted in an overall OR for death of 6.5 
(95% CI 2.0–21; Figure 1). One study had a follow-up of three months17, as compared with the 
other three, which had only in-hospital follow-up. If this single study was left out of the analysis, 
overall OR decreased to 3.3 (95% CI 0.6–18). In the NT-pro-BNP cohort, 46 of 250 patients (18%; 
95% CI 14-24%) with elevated NT–pro-BNP levels died in comparison with 2 of 160 (1.3%; 95% 
CI 0.15–4.4%) of those with normal NT–pro-BNP levels; OR for death was 8.7 (95% CI 2.8–27%; 
Figure 1). Numbers on PE-related mortality were only available in three studies.11,13,17 Because 
follow-up time was dissimilar between these studies and not all mortality cases were adjudi-
cated by an independent, blinded committee to determine the cause of death, we could not 
include PE-related mortality as an outcome of this meta-analysis.
Ten studies provided data on adverse clinical outcome6,8-13,15,16,18 of which six had NT-pro-
BNP levels as an outcome parameter.6,8,12,13,15,18 Overall, criteria for adverse clinical outcome 
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28-46%) patients with elevated BNP levels had adverse advents during follow-up in comparison 
with 28 of 208 (13%; 95% CI 9.1-19%) patients with normal plasma concentrations. High BNP 
levels were associated with a higher risk of occurrence of adverse clinical events (OR 6.3; 95% 
CI 3.6–11; Figure 2). This OR was even higher (9.5; 95% CI 3.5-25) after exclusion of one study 
with six months of follow-up9, thereby limiting the outcome to in-hospital clinical course. Of 
the 318 patients with elevated NT-pro-BNP levels, 102 experienced short-term adverse events 
(32%; 95% CI 27-38%) as compared with 12 of 225 (5.3%; 95% CI 2.8-9.1%) patients with normal 
NT-pro-BNP levels. Patients with high NT-pro-BNP serum concentration were at higher risk of 
complicated in-hospital course compared with patients with normal levels (OR 7.5; 95% CI 3.8-
15; Figure 2). Pooled data of all assays showed elevated BNP or NT-pro-BNP levels in 52% of the 
patients with a risk of 23% (209/909; 95% CI 20–26%) and an OR of 6.8 (95% CI 4.4-10) toward 
complicated clinical course.
Right ventricular dysfunction
Data on right ventricular dysfunction were reported in six studies (Figure 3). Four studies 
were evaluating BNP (243 patients)7,11,14,16 and two studies evaluated NT–pro-BNP levels (197 
patients).12,18 The incidence of right ventricular dysfunction was 85% (116/137; 95% CI 78-90%) 
and 12% (13/106; 95% CI 6.7-20%) in patients with and without elevated BNP levels respectively. 
A positive association was found between increased concentration of BNP and the presence of 
right ventricular dysfunction (OR 81; 95% CI 27-238). In the NT-pro-BNP studies, the incidence of 
right ventricular dysfunction was 45% (49/109; 95% CI 35-55%) in patients with elevated NT-pro-
BNP levels compared with 4.5% (4/88; 95% CI 1.3-11%) in patients with normal NT-pro-BNP levels. 
Elevated NT-pro-BNP levels were associated with the presence of right ventricular dysfunction 
(OR 17; 95% CI 5.7–49). Pooled data of all assays revealed a combined OR of 39 (95% CI 17-89).
DISCUSSION
This meta-analysis demonstrates a significant relation between high levels of BNP or NT-pro-
BNP and deterioration of clinical condition in patients with acute PE. This is physiologically 
plausible because BNP is released in reaction to right ventricular stress, which has been shown 
to predict a non-benign course in patients with PE.1-3 This latter relation is also demonstrated in 
this analysis: we found a very strong correlation between increased levels of BNP or NT-pro-BNP 
and right ventricular dysfunction on echocardiography (Figure 3).
There are some points for discussion if BNP or NT-pro-BNP levels would be incorporated 
in clinical risk stratification and treatment strategies for patients with acute PE. First, timing 
of blood sampling has consequences for the established BNP concentration. The BNP pro-
hormone (pro-BNP) in normal ventricular myocytes is not stored to a significant amount. As a 
consequence, it takes several hours for the plasma natriuretic peptide levels to increase after 
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the onset of acute myocardial stretch.20 A very recent onset of complaints could therefore result 
in false-negative BNP or NT–pro-BNP test results. Second, many different cut-off levels for BNP 
or NT–pro-BNP are proposed in the literature.21,22 The variation may be related to patient selec-
tion, sex, and age.22 Nonetheless, despite the different cut-off levels and different assays, the 
prognostic value of both NT–pro-BNP and BNP was consistent in all included studies.
What are the potential implications of our findings? First, normal levels of BNP have a high 
negative predictive value for unfavorable clinical outcome. Therefore, patients with normal 
levels of BNP or NT-pro-BNP have low risks for death as well as for hemodynamic deteriora-
tion resulting in any adverse events. Conversely, elevated concentrations of B-type natriuretic 
peptides are a non-specific finding occurring in more than half of the patients. An explanation 
for this phenomenon is the elevation of natriuretic peptides in a multitude of other conditions, 
including preexisting left ventricular dysfunction, older age, renal impairment and chronic 
lung disease.23 The combination of BNP with other clinical risk factors for adverse outcome 
may improve sensitivity and positive predictive value for clinical deterioration. Such algorithms 
for risk stratification would be clinically useful if they were able to identify patients eligible for 
outpatient management or for standard or intensive in-hospital treatment. Proposals for such 
algorithms including markers or biomarkers of right ventricular function (e.g. BNP or NT–pro-
BNP, Troponin, Growth Differentiation Factor-15 or heart-type fatty acid-binding protein) have 
been made but not yet validated prospectively in clinical outcome studies.4,8,12,13,24,25 Future 
studies are required to determine the clinical benefits of more aggressive treatments in patients 
with adverse prognosis as identified by these risk stratifications and less intensive treatment, 
including out of hospital treatment, in patients with normal values of BNP.
This meta-analysis has limitations. First, included studies used different assays with different 
retrospectively calculated cut-off points. Second, duration of follow-up and definitions of end-
points varied among the studies. In addition, most studies did not mention completeness of 
follow-up. Nonetheless, we have included a large cohort of prospectively followed patients and 
our analysis showed no evidence of heterogeneity between the outcomes of the incorporated 
studies. Third, the relative risk for mortality is not adjusted for confounding factors, thus part 
of the effect ascribed to high BNP values may be related to clinical conditions associated with 
PE. Fourth, we could not determine the ideal cut-off for the two BNP tests because we did not 
retrieve the raw data of the included studies to perform ROC and other analyses. Finally, in the 
included studies, it is not stated whether thrombolytic therapy or intensive care unit admission 
was the result of the clinical condition or a high BNP or NT-pro-BNP value.
In summary, elevated levels of BNP or NT-pro-BNP are indicators of right ventricular dysfunction 
in patients with acute PE and strong risk factors for short term mortality as well as for overall short 
term complicated clinical outcome. It remains to be demonstrated whether it could play a role 
in risk stratification algorithms identifying patients who could benefit from differentiated forms 
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To compare the clinical utility of right ventricular enlargement assessed by multi-detector 
row computed tomography (CT) and elevation of cardiac biomarkers for predicting adverse 
outcome after acute pulmonary embolism (PE).
Methods
We included 113 consecutive normotensive patients with CT pulmonary angiography (CTPA) 
proven PE and 226 consecutive patients in whom PE was suspected but ruled out. The follow-
ing predictors of complicated clinical course were studied: right/left ventricular ratios (RV/
LV-ratios) on axial and reconstructed 4-chamber (4-CH) CT-views >1.0, D-dimer >3000 pg/mL 
FEU, Troponin-T >0.09 ng/mL and NT-pro-BNP >600 pg/mL.
Results
All predictors were associated with adverse outcome in patients with and without PE, with odds 
ratios of 3.7 (axial), 9.0 (4-CH), 3.5 (D-dimer), 6.3 (Troponin-T) and 31 (NT-pro-BNP) for patients 
with PE. Area under the receiver operator characteristic curve for PE patients of NT-pro-BNP was 
higher (0.85; 95% CI 0.73-0.97) than that of axial RV/LV-ratio (0.64, 95% CI 0.47-0.81; p=0.14), 
4-CH RV/LV-ratio (0.64, 95% CI 0.48-0.81; p=0.15), D-dimer (0.64, 95% CI 0.46-0.82; p=0.048) and 
Troponin-T (0.62, 95% CI 0.41-0.82; p=0.037). 72% of patients had a NT-pro-BNP ≤600 pg/mL 
with a negative predictive value (NPV) of 99%. 4-CH RV/LV-ratio <1 had equally excellent NPV 
(98%), but less patients were categorized as having low risk for complications (43%; p<0.001).
Conclusion
NT-pro-BNP had the highest discriminative power and clinical utility as predictor of adverse 
events after PE in our study population. Future studies should confirm these findings and evalu-
ate the safety of home-treatment based on low NT-pro-BNP levels or RV/LV-ratios.
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INTRODUCTION
Mortality rates in hemodynamically stable patients with acute pulmonary embolism (PE) 
range from 2% to 6% and increase considerably to 30% or more in patients presenting with 
hemodynamic instability or shock.1 For this latter patient category, invasive treatment regimes 
including thrombolysis, thrombosuction or surgical embolectomy might be life saving.2,3 In 
contrast, outpatient treatment may be considered for hemodynamically stable patients with 
relatively mild disease.2,4 It is however challenging to identify those patients who present in a 
hemodynamically stable state but who are at high risk for clinical deterioration and death in the 
first period after the diagnosis of PE and start of anticoagulation therapy. These patients might 
benefit from more intensive clinical surveillance or even thrombolysis, whereas outpatient 
treatment is contraindicated.2,5-7
One of the main causes of early death after PE is right ventricular failure.1 Hence, it seems 
very plausible to use indicators of right ventricular function as predictors of short term clinical 
outcome after acute PE. Especially tests for the evaluation of ventricular function that are easy 
to obtain and widely available are of particular interest for clinical use, since these are likely to 
aid the physicians in performing rapid risk stratification and determining treatment strategy. 
Retrospective studies have previously shown that right ventricular enlargement on computed 
tomography pulmonary angiography (CTPA; Odds Ratio [OR] 4.0) and elevated levels of cardiac 
biomarkers such as NT-pro-BNP (OR 6.8) and Troponin (OR 7.0) are predictive for the occurrence 
of adverse events and early mortality after acute PE.8-11 This is also true for highly elevated 
D-dimer levels as indicator of high embolus load (OR 7.3), which is associated with increased 
risk of right ventricular impairment.12-14 Importantly, the ability of these different predictors 
to identify patients at risk for adverse clinical outcome has not yet been directly compared 
in a prospective outcome study. Furthermore, a recent paper demonstrated that results from 
previous studies should be interpreted and compared with caution because of the clinical and 
methodological diversity of these studies.15
Therefore, the purpose of this prospective cohort study was to compare the predictive 
accuracy and clinical utility of easy right ventricular function tests, i.e. CT-derived right-to-left 
ventricular diameter ratios (RV/LV-ratio) and NT-pro-BNP and Troponin-T, as well as D-dimer 
levels, for predicting adverse events in the short term clinical course of acute PE.
METHODS
Patients
Consecutive, hemodynamically stable in- and outpatients who presented to our hospital with 
suspected acute PE between September 1st 2005 and December 1st 2008, and with a strict 






clinical probability by the Wells Rule (>4 points total) or an abnormal D-dimer blood test (>500 
ng/mL FEU).16 Only patients with an unlikely probability in combination with a normal D-dimer 
test result did not undergo CTPA since PE can be safely ruled out in that patient category.16 
These latter patients could therefore not be included in this study. Patients diagnosed with 
acute PE by CTPA were initially treated with therapeutic unfractionated or low-molecular-
weight heparin for at least 5 days, followed by vitamin K antagonists for a period of at least 
three months aiming at an INR of 2.0-3.0.2 In case of severe PE or clinical deterioration, admis-
sion to the intensive care unit and/or administration of thrombolytic drugs was considered, 
according to the judgment of the attending clinician. Exclusion criteria for the study were: 
impossibility of follow-up, age younger than 18 years, pregnancy, known allergy to intravenous 
application of iodine contrast media or hemodynamic instability at initial presentation. This 
study was approved by the Institutional Review Board of our hospital and all patients provided 
written informed consent.
Endpoints
All patients were followed for 6 weeks. Follow-up consisted of a scheduled visit to our vascular 
medicine outpatient clinic for the patients with confirmed acute PE and a telephone interview 
for all patients in whom PE was ruled out by CTPA. The primary study outcome was the occur-
rence of one or more adverse clinical events in the first 6 weeks following study inclusion. 
Adverse events were defined as the occurrence of any of the following: all cause mortality, 
resuscitation after respiratory or cardiac arrest, admittance to intensive care unit, need for 
mechanical ventilation or use of inotropic agents, and administration of thrombolytic drugs.
Procedures
All patients underwent multi-detector row CTPA (Aquilion 64; Toshiba Medical Systems, Ota-
wara, Japan) of the chest during breath-hold at inspiration. CTPA was performed after bolus 
injection of iodinated contrast agent (80-100 mL Xenetix 300, Guerbet, Aulnay-sous-Bois, 
France, or 60-80 mL Iomeron 400 mg/mL, Bracco, Milan, Italy) via antecubital vein injection with 
a flow rate of 4.0 mL/sec using an automatic injector (Stellant CT, MedRad, Pittsburgh, USA). 
Bolus tracking was performed by placing a region of interest in the pulmonary trunk. Image 
acquisition was automatically started 5 seconds after reaching a predefined threshold differ-
ence of 100 HU using SureStart (Toshiba Medical Systems, Otawara, Japan). Scan parameters 
were: rotation time 0.5 sec, pitch factor 53.0, tube voltage 100 kV and tube current depending 
on patient size and shape. Images were reconstructed with a slice thickness of 1.0 or 0.5 mm.
Analysis of RV/LV-ratios was performed on a post-processing workstation (Vitrea, version 2, 
Vital Images, Minnetonka, USA) in standard axial views and in reconstructed 4-chamber (4-CH) 
views (Figure 1) by one observer with two years of experience and supervised by a radiologist 
with 10 years of experience in thoracic CT imaging. The 4-CH view was reconstructed by using 
2-dimensional multiplanar reformats of the original axial source data as was suggested by 
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Quiroz et al.11 Right and left ventricular dimensions were measured by identifying the maximal 
distance between the ventricular endocardium and the interventricular septum, perpendicular 
to the long axis.10,11 The RV/LV-ratio was then calculated. Right ventricular enlargement was 
considered present when the RV/LV-ratio was greater than 1.0.10
Venous plasma and serum samples were obtained on admission and were immediately 
stored at –80°C. After all patients were included, samples were analyzed in batches after a 
single thaw. Troponin-T and NT-pro-BNP levels were determined with the use of quantitative 
immunoassays (Elecsys 2010 analyzer, Roche Diagnostics, Mannheim, Germany). For Troponin-
T, a reference value of 0.09 ng/mL was used to distinguish between normal and elevated levels 
as proposed by the manufacturer. For NT-pro-BNP, the prognostically relevant cut-off level was 
set at 600 pg/mL.17 D-dimer levels were determined using a quantitative, automated immuno-
assay (STA LIA D-dimeer assay; Roche, Mannheim, Germany). D-dimer levels exceeding 3000 
ng/mL FEU were defined to be a poor prognostic sign.13
Figure 1. Measurement of right ventricular (RV) and left ventricular (LV) dimensions in axial (A, C) and 
reconstructed computed tomography 4-chamber views (B, D). A and B represent the same patient with 
acute pulmonary embolism (PE) and RV/LV-ratio ≤1.0. Note the right sided pleural effusion, bilateral 
atelectasis, and diaphragmatic hernia (A, B). Panels C and D represent a patient with acute PE and RV/LV-ratio 






The study was performed in blinded fashion: since both the CT measurements of ventricular 
function as well as the biomarker blood levels were assessed post-hoc, the treating physicians 
were unaware of these results, precluding information bias. Also, the researchers who mea-
sured the ventricular ratios and the biomarker levels were blinded for the clinical course of the 
study patients.
Statistics
The sample size calculation was primarily based on RV/LV-ratios with the following assump-
tions: a 20% risk on the primary study outcome in case of a RV/LV-ratio >1.0, a <3% risk in case 
of a RV/LV-ratio ≤1 and a 50% prevalence of RV/LV-ratio >1.0 in patients with acute PE.1,8,10,11,18 
To detect this risk difference with a power of 80% and a two-tailed alpha of 0.05, we needed 110 
included subjects with PE.
For logistic and financial reasons, we determined before the start of the study that the mea-
surements of ventricular function and biomarkers were to be performed in all patients with 
acute PE diagnosed within the study period, and in twice that number of patients in whom PE 
was ruled out by CTPA, but not in all of these latter patients. The cohort of patients without PE 
that was included in the following analyses consisted of consecutive patients from the start of 
the study until this double number was achieved.
First, we studied the association of right ventricular enlargement, biomarkers and acute 
PE by calculating ORs by logistic regression for elevated RV/LV-ratios and biomarker levels 
between patients with and without acute PE, adjusted for age, gender, active malignancy and 
presence of cardiopulmonary comorbidity. Second, we studied the association between RV/
LV-ratios, biomarkers and adverse clinical outcome in patients with established PE as well as 
in those without PE separately. Also, we weighed the discriminatory ability of the predefined 
cut-off levels of the RV/LV-ratio and biomarkers for adverse clinical outcome by comparing the 
area under the curve (AUC) in receiver operator characteristic (ROC) analyses for patients with 
established acute PE only.19 In addition, we used these ROC curves to evaluate whether the pre-
defined cut-off points of our predictors were chosen optimally for predicting adverse outcome. 
Furthermore, we evaluated the clinical utility of RV/LV-ratios and biomarkers by assessing and 
comparing the specific test characteristics for predicting adverse clinical outcome for each 
predictor individually. These analyses were performed for all patients and for a selected cohort 
of outpatients only. Finally, we studied whether combing different tests would have additional 
predictive value and clinical applicability compared to the individual tests. Differences between 
categorical variables were studied using the Chi-Square test en continuous variables using an 
independent samples T-test. SPSS version 14.02 (SPSS Inc, Chicago, IL) was used for all analysis. 
A two-sided p-value <0.05 was considered to indicate a significant difference.
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RESULTS
Patients
Within the study period, 113 of the included 439 patients were diagnosed with acute PE. All 113 
patients with PE and the first 226 patients in whom PE was ruled out by CTPA were selected for 
further analysis. The baseline characteristics of these patients are depicted in Table 1. The mean 
age in the overall study population was 56 years. Patients with PE had a higher proportion of 
males (53% vs. 42%) and had more often previous venous thromboembolism (22% vs. 19%) 
and recent immobility, surgery, trauma or were in postpartum period (31% vs. 13%) than the 
patients without PE. The patients without PE had a higher prevalence of chronic obstructive 
pulmonary disease (COPD; 6.2% vs. 16%), left sided hart failure (4.4% vs. 7.5%) and were more 
often inpatients (18% vs. 25%).





Age (years ±SD) 56 ±17 56 ±21
Male sex (n, %) 60 (53) 95 (42)
Previous PE or DVT (n, %) 25 (22) 43 (19)
Immobility, surgery, trauma, postpartum (n, %) 35 (31)* 29 (13)*
Known thrombophilia† (n, %) 3 (2.7) 10 (4.4)
Active malignancy (n, %) 24 (21) 56 (25)
COPD (n, %) 7 (6.2)* 36 (16)*
Left sided heart failure (n, %) 5 (4.4) 17 (7.5)
Inpatient (n, %) 20 (18) 57 (25)
†In our hospital, patients are not routinely screened for thrombophilia; *p<0.05 on Chi-Square test. 
PE=pulmonary embolism, DVT=deep vein thrombosis, COPD=chronic obstructive pulmonary disease, 
SD=standard deviation, n=number.
Adverse events
Of the 113 patients with established acute PE, 10 had a complicated clinical course (8.9%; 95% CI 
4.3-16%; Table 2). Four patients experienced clinical deterioration necessitating cardiopulmonary 
resuscitation within 12 days after diagnosis: of those, 2 died immediately, 1 died after 9 days of 
acute PE and severe cerebral hemorrhage, and one was successfully resuscitated and completed 
the follow-up period without further complications. One patient received thrombolytic therapy 
because of a large saddle embolus and one patient died after 10 days of hospital acquired pneu-
monia and PE. Three patients died of progressive cancer on days 15, 21 and 39 respectively. Finally, 
one patient suffered from acute PE after major abdominal surgery. After 10 days a large hepatic 
hematoma was discovered. Following this, this patient underwent new surgery and was admitted 
to the intensive care unit. She recovered completely without further complications. Overall, death 






Fifteen of the 226 patients without PE died during the follow-up period. Cause of death was 
malignancy in 11 patients and renal failure, pulmonary fibrosis, pneumonia and heart failure in 
the other patients respectively. In addition, 3 patients were admitted to the intensive care unit 
after heart surgery and one patient was lost to follow-up. Two patients in whom PE was initially 
ruled out had recurrent complaints and underwent a second CTPA. PE was established in one of 
these 2 patients. Patients with established PE were at slightly higher risk for complicated clinical 
course then patients in whom PE was ruled out: OR adjusted for age, gender, active malignancy 
and presence of cardiopulmonary comorbidity was 1.5 (95% CI 0.63-3.6).























Female 80 Out day 1: unsuccessful resuscitation 
after saddle embolus, pulmo-
nary embolism attributable 
death
3.1 3.2 >5000 <0.01 1964
Female 55 Out day 1: thrombolysis because of 
large saddle embolus
1.5 1.5 >5000 0.03 5059
Female 83 Out day 2: successful resuscitation 
followed by thrombolysis, me-
chanical ventilation and admit-
tance to the ICU. Patient died at 
day 9 of pulmonary embolism 
and cerebral bleeding.
1.7 2.0 >5000 <0.01 6540
Male 70 Out day 2: successful resuscitation 1.2 1.1 >5000 0.11 4245
Male 80 Out day 10: patient died of severe 
pneumonia and pulmonary 
embolism
0.87 1.0 976 0.11 2979
Female 50 In day 10: (PE occurred 1 day post 
major abdominal-surgery) re-
operation and admittance to the 
ICU because of major bleeding.
1.2 1.3 4736 <0.01 2520
Female 80 Out day 12: unsuccessful resuscita-
tion, autopsy proven pulmonary 
embolism attributable death
1.4 1.5 1281 0.21 5026
Female 59 Out day 15: patient died of progres-
sive malignancy of unknown 
origin
0.94 1.04 >5000 0.10 1619
Male 47 In day 21: patient died of progres-
sive non-Hodgkin lymphoma
1.3 1.2 1332 <0.01 623
Male 68 Out day 39: patient died of progres-
sive prostate cancer
1.2 1.3 >5000 <0.01 151
Overall, death was attributed to pulmonary embolism in 4 patients. RV/LV-ratio=ventricular volume ratio, 
4-CH=four chamber, PE=pulmonary embolism, ICU=intensive care unit.
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RV/LV-ratios and biomarkers in patients with and without PE
RV/LV-ratio was higher in patient with PE than in patients without PE for both axial (1.1 vs. 0.89; 
p<0.001) as well as reconstructed 4-CH views (1.1 vs. 0.86; p<0.001). In addition, adjusted ORs 
for increased RV/LV-ratio were increased for patients with established acute PE for axial (OR 6.6, 
95% CI 3.8-11) along with 4-CH views (OR 14, 95% CI 7.3-25). Adjusted OR for elevated levels 
of Troponin-T (3.6, 95% CI 1.3-10), NT-pro-BNP (1.5, 95% CI 0.87-2.7) and D-dimer (5.6, 95 %CI 
3.1-9.9) were also increased for patients with PE. Thus, acute PE was independently associated 
with increased right ventricular dimensions and elevated biomarker levels.
RV/LV-ratio and biomarkers as predictors for adverse events
Blood levels of Troponin-T, D-dimer, NT-pro-BNP and RV/LV-ratios in both views were higher 
in the patients with acute PE who suffered adverse clinical events than in those with uncom-
plicated clinical course (Table 3). Following this, right ventricular enlargement and elevated 
biomarkers increased the risk of adverse events with adjusted ORs of 3.7 (95% CI 0.74-19), 9.0 
(95% CI 1.1-79), 3.5 (95% CI 0.86-15), 6.3 (95% CI 1.3-31) and 31 (95% CI 3.6-257) for axial RV/
LV-ratios, 4-CH RV/LV-ratios, D-dimer, Troponin-T and NT-pro-BNP respectively. Furthermore, 
we identified an increased risk for adverse events associated with right ventricular enlargement 
and elevated biomarkers in the patients in whom PE was ruled out, although less pronounced 
than in patients with PE, with adjusted ORs ranging from 2.0 to 3.8 (Table 3).
Table 3. Medians and interquartile range for ventricular volume ratio and biomarkers in patients with and 



































Adjusted OR for adverse events† 3.7 (0.74-19) 9.0 (1.1-79) 3.5 (0.86-15) 6.3 (1.3-31) 31 (3.6-257)
PE ruled out by CT, uncomplicated 























Adjusted OR for adverse events† 3.2 (1.1-9.4) 3.3 (1.1-9.8) 2.3 (0.74-7.4) 2.0 (0.22-18) 3.8 (1.4-10)
Mann-Whitney-U tests were performed between uncomplicated and complicated clinical course for 
patients with PE and without PE separately: *p<0.05, **p<0.01; †from predefined cut-off values. RV/LV-
ratio=ventricular volume ratio, 4-CH=four chamber, CT=computed tomography, IQR=interquartile range.
Discriminatory ability and clinical utility of RV/LV-ratio and biomarkers for predicating adverse clinical 
outcome in patients with acute PE
ROC analyses revealed that from the 5 predictors of adverse events, NT-pro-BNP had higher AUC 






4-CH RV/LV-ratios (0.64, 95% CI 0.48-0.81; p=0.15), D-dimer (0.64, 95% CI 0.47-0.81; p=0.048) 
and Troponin-T (0.62, 95% CI 0.41-0.82; p=0.037). Of note, changing the thresholds of these 5 
predictors did not improve the prognostic performance of any of them (data not shown).
The high discriminative power of NT-pro-BNP levels exceeding 600 pg/mL was underlined 
by a high sensitivity (90%, 95% CI 56-99.8) and specificity (78%, 95% CI 70-84) for adverse clini-
cal outcome compared to the remaining 4 predictors (Table 4). RV/LV-ratio >1.0 on 4-CH view 
had equally high sensitivity (90%, 95% CI 56-99.8) but lower specificity (46%, 95% CI 36-57, 
p<0.001). Furthermore, although the specificity of elevated Troponin-T levels was higher (93%, 
95% CI 86-97; p=0.004), this was accompanied by a significantly lower sensitivity (40%, 95% CI 
12-74) than that of NT-pro-BNP (p=0.022).
None of the 5 predictors was able to identify patients at very high risk for adverse events, 
with low positive predictive values in the range of 14% to 30% (Table 4). On the other hand, 
negative predictive values were over 90% for all predictors and highest for NT-pro-BNP (99%, 
95% CI 92-99.9) and RV/LV-ratio on 4-CH view (98%, 95% CI 86-99.8). Low Troponin-T (91%) and 
NT-pro-BNP levels (72%) categorized more patients as having a low risk on complications than 
normal RV/LV-ratio on axial (44%) and 4-CH view (43%; p<0.001 compared to low Troponin-T 
and NT-pro-BNP levels) and D-Dimer levels under 3000 ng/mL FEU (58%; p<0.01 compared to 
low Troponin-T levels and p=0.041 compared to low NT-pro-BNP levels). Elevated NT-pro-BNP 
levels in combination with LV/RV-ratio >1.0 on 4-CH views had a sensitivity of 80% (95% CI 
44-96), a specificity of 88% (95% CI 0.78-93), a positive predicting value of 42% (95% CI 21-67) 
and a negative predicative value of 97% (95% CI 90-99.6), resulting in an AUC of 0.84 (95% CI 
0.69-0.99). These test performances were not different from that of NT-pro-BNP alone.
Finally, we calculated the test characteristics of all 5 predictors of adverse clinical outcome for 
outpatients only. D-dimer levels below 3000 ng/mL FEU were found in 55% of the outpatients 
Table 4. Test characteristics of CT measured right ventricular enlargement and elevated biomarkers for 





















Sensitivity (%, 95% CI) 80 (44-96) 90 (56-99.8) 70 (35-93) 40 (12-74) 90 (56-99.8)
Specificity (%, 95% CI) 48 (38-58) 46 (36-57) 60 (50-70) 93 (86-97) 78 (70-84)
Proportion identified as high risk 
(%, 95% CI)
56 (46-66) 57 (47-67) 42 (33-52) 8.9 (4.4-16) 28 (20-38)
Proportion identified as low risk 
(%, 95% CI)
44 (34-54) 43 (33-53) 58 (48-67) 91 (84-97) 72 (62-80)
Negative predictive value
(%, 95% CI)
96 (86-99.5) 98 (86-99.8) 95 (86-99) 93 (86-97) 99 (92-99.9)
Positive predictive value
(%, 95% CI)
13 (5.7-24) 16 (7.8-28) 15 (6.5-28) 30 (8.1-65) 29 (15-48)
RV/LV-ratio=ventricular volume ratio, 4-CH=four chamber, CT=computed tomography, CI=confidence 
interval.
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with a negative predictive value of 96% (95% CI 90-99.5), low Troponin-T levels in 91% (negative 
predictive value 94%, 95% CI 87-98), low NT-pro-BNP levels in 77% (negative predictive value 
99%, 95% CI 90-99.9), RV/LV-ratio <1.0 on axial view in 45% (negative predicative value 95%; 
95% CI 82-99) and RV/LV-ratio <1.0 on 4-CH view in 44% of the out-patients (negative predic-
tive value 97%, 95% CI 85-99.9).
DISCUSSION
This prospective cohort study has three important findings. First, acute PE is associated with an 
increased incidence of right ventricular enlargement and higher levels of cardiac biomarkers 
compared to patients in whom PE is ruled out by CTPA. Second, right ventricular enlargement 
and elevated levels of cardiac biomarkers predict adverse clinical events in both patients with 
PE as well as in those without PE. Finally, easy obtainable markers for right ventricular dysfunc-
tion such as RV/LV-ratios and cardiac biomarkers can be used for risk stratification, that is for 
identification of patients with PE who are at low risk for complications. Although all studied 
predictors had high negative predictive values for adverse events after acute PE, low levels 
of NT-pro-BNP were found to have superior clinical discriminatory ability and clinical utility 
compared to the other 4 predictors in our study population.
This clinical utility of the tests under study is determined by the ability of accurately distin-
guishing PE patients at high or low risk of early complications, thereby identifying a specific 
patient group that profits from customized, more aggressive treatment, i.e. more intensive 
clinical surveillance or thrombolysis, or less stringent treatment, i.e. outpatient treatment. ROC 
analysis showed that NT-pro-BNP levels over 600 pg/mL were found to have the highest AUC. 
Moreover, its negative predictive value was 99%, indicating a risk for adverse events lower 
than 1.0% for 72% of the patients with PE. The results from NT-pro-BNP analysis are usually 
available within the hour and since NT-pro-BNP has evolved to be an increasingly important 
diagnostic and prognostic tool for patients with heart failure, the assays are widely available. 
Increased RV/LV-ratio on 4-CH view had comparable excellent sensitivity and negative predic-
tive value compared to elevated NT-pro-BNP levels. In addition, this is presumably the easiest 
and cheapest test of the two, since this can be performed in all standard CTPA scans, which 
have become the imaging test of choice for establishing the diagnosis of acute PE in recent 
years.10,11,16 Measuring RV/LV-ratios does not require additional administration of contrast 
material or increased radiation dose, and takes only a few minutes of time. Nonetheless, RV/LV-
ratios had significantly lower specificity than elevated levels of NT-pro-BNP and classified only 
43% and 44% of the patients in the low risk category. Therefore, the accuracy and clinical utility 
of NT-pro-BNP for identification of PE patients with low risk of adverse events was superior to 
that of RV/LV-ratios. Markedly, risk stratification based on the combination of NT-pro-BNP levels 






alone. Finally, although high Troponin-T levels categorized 91% of the patients in the low-risk 
category, its negative predictive value was only 93% due to a lower sensitivity of 40%.
The underlying mechanism for increased right ventricular dimensions, decreased right ven-
tricular function and acute PE has been well established.1 Even so, to our knowledge this is the 
first prospective study describing the association of right ventricular enlargement and elevated 
cardiac biomarkers in patients with acute PE in contrast to patients in whom this diagnosis was 
suspected but ruled out. Furthermore, this is the first report directly comparing various cardiac 
biomarkers and RV/LV-ratios for predicting adverse outcome after acute PE.
What is the clinical applicability of our results? A recent meta-analysis20 has shown that 
treatment with low molecular weight heparin is at least as effective and safe as treatment with 
unfractionated heparin for the initial treatment of non-massive PE, enabling start of treatment 
at an outpatient basis of these patients. This approach may imply great benefits such as sav-
ing costs and increasing patient satisfaction.21 Reduction in iatrogenic problems might be a 
third beneficial effect.22 Relatively small prospective outcome studies have demonstrated that 
outpatient treatment might be feasible, although these patients were selected for outpatient 
treatment based on clinical intuition, and not on explicit predefined criteria.4,21 Identification 
of patients accessible for outpatient treatment based on well-defined, standardized selection 
criteria may help improving safety and more widespread acceptance of outpatient manage-
ment. Our study demonstrates that from 5 easily obtainable tests of adverse clinical outcome, 
NT-pro-BNP is the best tool for selecting patients with a low risk for adverse outcome, who can 
be considered for outpatient treatment.
The main limitation of this study is that since the sample size of this study was primarily based 
on RV/LV-ratio on CTPA, the results observed for the other parameters might be underpowered, 
leading to wide confidence intervals. Furthermore, the fraction of males and the mean age of 
the patients with acute PE was slightly different compared to previous studies.11,14,17,23,24 This 
could affect the generalizability of our study results and therefore, these should be accordingly 
interpreted. Nonetheless, we consider our data representative for several reasons. First, our 
study was of prospective design including consecutive patients with suspected acute PE, and 
by blinding both the attending physicians as well as the researchers, there was no information 
bias. Second, we had very low lost to follow-up rates: 0 of 113 patients with PE and 1 of 226 of 
the patients without PE. Third, we used predefined cut-off points for our predictors that were 
established by previous studies. Furthermore, post-hoc analyses in our data confirmed these 
thresholds to have the highest discriminatory ability (data not shown). Fourth, the ORs for 
adverse events regarding the 5 studied predictors calculated from our data are in accordance 
with the confidence intervals of those reported in previous studies.
Finally, although signs of right ventricular dysfunction on echocardiography are clearly 
associated with adverse events after PE1,11,23,24, we have not incorporated echocardiography 
in our study design. The main reason for this decision was that in our hospital, as well as in 
many other hospitals, it is not possible to perform echocardiography as a clinical routine in all 
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patients diagnosed with acute PE. Additionally, the performance of RV/LV-ratios on 4-CH views 
has been demonstrated to be comparable to that of echocardiography.11
In summary, right ventricular enlargement and elevated cardiac biomarkers, that are indepen-
dently associated with acute PE, are predictive for a complicated clinical course in patients with 
acute PE and also in patients who were suspected of this disease but in whom PE was ruled 
out by CTPA. These tests are especially valuable in identifying patients with low risk of adverse 
events after acute PE is diagnosed. NT-pro-BNP levels below 600 pg/mL have the highest clini-
cal discriminatory ability and clinical utility as compared to D-dimer levels below 3000 ng/mL 
FEU, Troponin-T levels below 0.09 ng/mL and RV/LV-ratios less than 1.0 for both axial as well as 
4-CH views in our study population. Future outcome studies should confirm these results and 
the safety of home-treatment based on low NT-pro-BNP levels and/or RV/LV-ratios.
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Chapter 7
Usefulness of ECG-synchronized MDCT assessed 
right and left ventricular function for predicting 
short term clinical outcome in patients with 
clinically suspected acute pulmonary embolism
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To assess whether right and left ventricular (RV and LV) ejection fraction (EF) by electrocardi-
ography (ECG)-synchronized multi-detector row computed tomography (CT) predict the short 
term clinical outcome after acute pulmonary embolism (PE).
Methods
In addition to standard CT pulmonary angiography, 439 consecutive patients presenting with 
clinically suspected acute PE underwent ECG-synchronized dynamic cardiac CT to assess RV 
and LV function. Predefined thresholds for decreased RV and LV function were used to predict 
adverse events.
Results
113 patients were diagnosed with PE. RVEF was decreased and RV/LV volume as well as dimen-
sion ratios were increased in patients with versus patients without PE (p<0.001 for all). RVEF 
<47% had a very high odds ratio (36, 95% confidence interval [CI] 2.2-590) and a higher area 
under the receiver operator characteristic curve (0.75, 95% CI 0.56-0.88) for predicting adverse 
outcome after PE than LVEF <57% (difference 0.11, 95% CI 0.04-0.18), end-diastolic RV/LV 
>1.2 (difference 0.08, 95% CI -0.7-0.23), end-systolic RV/LV ratio >1.4 (difference 0.14, 95% CI 
0.07-0.21) and axial RV/LV ratio >1 (difference 0.11, 95% CI 0.02-0.21). All studied CT measured 
markers of ventricular function had comparable high negative predictive values (94-98%) and 
limited positive predictive values (9.6-18%) for adverse outcome after PE. Importantly, cardiac 
CT was associated with increased exposure to radiation and contrast dye.
Conclusion
CT assessed RVEF has a high predictive value as well as a high sensitivity for adverse clinical 
outcome after PE although the potential benefit of ECG-synchronized cardiac CT compared to 
standard CT-imaging is low and may not outweigh its disadvantages.
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INTRODUCTION
Acute pulmonary embolism (PE) is a common and potentially fatal condition. The mortality 
rate in hemodynamically stable patients with acute PE is 2-6%.1,2 Right ventricle (RV) failure is 
the main cause of death within the first period after the acute event.3-5 Early echocardiographic 
evaluation of RV function has been shown predictive for adverse clinical outcome.6-10 Nowadays, 
computed tomography (CT) pulmonary angiography is the diagnostic test of first choice in the 
work-up of patients with suspected acute PE by direct visualization of the pulmonary emboli.11 
From the same CT scan, information concerning possible RV dilatation can be easily obtained 
by measuring right-to-left ventricular dimension ratios in transverse and/or reconstructed four 
chamber views. Several studies have shown the prognostic value of RV dilatation on clinical 
outcome identified with standard CT pulmonary angiography.3,12,13 However, these dimension 
ratios obtained from standard non-electrocardiographic (ECG)-synchronized scans are no direct 
measure of RV function. It has been shown that with ECG-synchronized cardiac CT, RV function 
can be assessed with high accuracy and reproducibility as compared to echocardiography and 
magnetic resonance imaging, the latter being the current reference standard for ventricular 
volume measurements.14,15 Only two studies have investigated the use of ECG-synchronized CT 
in small patient groups with suspected acute PE. One study showed that assessing ventricular 
function with ECG-synchronized CT was of additional value in stratifying patients with PE.16 
In the other study, ECG-synchronized cardiac CT showed minimal improvement in predicting 
30-day mortality.17 Larger prospective outcome studies are however needed to definitively 
establish the clinical usefulness of ECG-synchronized cardiac CT with functional analysis in 
patients with clinically suspected acute PE. Accordingly, the purpose of the present study was 
to assess to what extent the assessment of ventricular function with ECG-synchronized cardiac 
CT has additional clinical value to standard CT pulmonary angiography in patients with clini-
cally suspected acute PE.
METHODS
Study population
For this prospective cohort study, 430 consecutive hemodynamically stable in- and outpatients 
presenting with suspected acute PE between September 2005 and December 2008 were 
included for analysis. All patients underwent standard CT pulmonary angiography and ECG-
synchronized dynamic cardiac multi-detector row CT under strict indications: Wells rule >4 
points or an abnormal D-dimer blood test of >500 ng/mL FEU.11 Inclusion criteria for the study 
were: clinically suspected acute PE, age ≥18 years and willingness to participate. Exclusion 
criteria were: impossibility to follow-up, known allergy to intravenous application of iodinated 






hemodynamic instability at presentation with setting of cardiopulmonary resuscitation, life 
expectancy less than three months and failure to obtain written informed consent. Under these 
conditions, 439 patients were eligible for the study. In nine patients, the dynamic cardiac CT 
scan had failed due to technical problems, arrhythmia or insufficient contrast. These patients 
were excluded. The study was approved by the Institutional Review Board of our hospital and 
all patients provided written informed consent.
Image acquisition
All patients underwent standard contrast-enhanced CT pulmonary angiography to confirm or 
exclude the diagnosis of acute PE followed within the same session by dynamic cardiac CT for 
the assessment of biventricular function using a 16-, 64- or 320-slice multi-detector row CT 
scanner (Aquilion 16CFX; Aquilion 64; Aquilion ONE, all scanners: Toshiba Medical Systems, Ota-
wara, Japan). CT pulmonary angiography was performed during breath-hold at inspiration after 
administration of iodinated contrast agent (80-100 mL Xenetix 300, Guerbet, Aulnay-sous-Bois, 
France, or 60-80 mL Iomeron 400 mg/mL, Bracco, Milan, Italy) into an antecubital vein with a 
flow rate of 4.0 mL/sec. An automatic power injector was used (Stellant CT, MedRad, Pittsburgh, 
USA) for contrast administration. A region of interest was placed in the main pulmonary artery 
for bolus tracking and after reaching a predefined threshold difference of 100 HU with use of 
SureStart (Toshiba Medical Systems), image acquisition was started automatically after a fixed 
delay of 5 seconds. Scan parameters were: rotation time 0.5 sec, pitch factor 53.0, tube voltage 
100 kV. Tube current was dependent on patient size and shape. Estimated radiation dose was 
3.3 mSv for CT pulmonary angiography. Images were reconstructed with 1.0 or 0.5 mm slice 
thickness and sent to the PACS system.
Then, ECG-synchronized dynamic cardiac CT was performed after administration of 35-40 
mL contrast agent with a flow rate of 2.5-3.0 mL/sec, followed by a 30 mL saline bolus chaser 
and a fixed delay of 15 seconds. Scan parameters were: tube voltage 120 kV and tube current 
200 mA. Depending on heart rate, the optimal rotation time and pitch factor were automatically 
determined to obtain optimal temporal resolution for helical scanning. Estimated radiation 
dose was 3.6 mSv for ECG-synchronized cardiac CT. Images for cardiac functional analysis were 
reconstructed in twenty cardiac phases (every 5% of the RR-interval, ranging from 0-95%) by 
using a segmental reconstruction algorithm. Adjacent 2 mm thick sections were retrospectively 
reconstructed in a 512x512 matrix by using a 200-240 mm field-of-view. The entire heart from 
aortic root to cardiac apex was covered within the reconstructed sections per cardiac phase 
point. The reconstructed volumes were transferred to a dedicated workstation running on 
Linux software.
Diagnosis of PE
CT pulmonary angiography scans were evaluated on a PACS workstation. The presence of PE 
was defined as at least one filling defect in the pulmonary artery tree. The degree of pulmonary 
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arterial obstruction was quantified by the method of Qanadli et al.18 An obstruction index of 
40% or greater was used as cut-off value for the identification of patients at risk for adverse 
clinical outcome.18
Cardiac function
Analysis of ventricular function by volumetric measures on ECG-synchronized cardiac CT was 
performed by using dedicated cardiac function analysis software (CT-MASS; Medical Imaging 
Systems, Leiden, The Netherlands). First, the phases with the largest and smallest RV volumes 
were selected by inspecting running cine movies on midventricular level and represented the 
end-diastolic and end-systolic phase, respectively. Endocardial borders for the RV as well as for 
the left ventricle (LV) were drawn on every other transverse section in end-diastolic and end-
systolic phases. The entire volume of the ventricles from the apex to the level of the pulmonary 
outflow tract was covered for both phases. End-diastolic and end-systolic volumes, stroke 
volume and ejection fraction were calculated. Thresholds for RV (<47%) and LV dysfunction 
(<57%), as well as increased end-diastolic RV/LV (>1.2) and end-systolic RV/LV volume ratios 
(>1.4) were set at the lower respectively higher borders of the 95% confidence interval of these 
values determined in healthy persons.19 Assessment of ventricular ratios by diameter measures 
on standard CT pulmonary angiography was performed on a post-processing workstation (Vit-
rea, version 2, Vital Images, Minnetonka, USA). RV and LV diameters (i.e. the maximum diameter 
between the ventricular endocardium and interventricular septum for the RV and the LV) were 
measured in standard axial views as previously described.12 RV dysfunction was defined as a 
RV/LV dimension ratio of greater than 1.0.13 All contours were drawn after the patients had 
completed their follow-up and by researchers who were blinded for the final diagnosis and 
clinical outcome of the study patients.
Clinical outcome
Follow-up consisted of a scheduled visit to the vascular medicine outpatient clinic in patients 
with confirmed diagnosis of acute PE. A follow-up telephone interview was performed in all 
patients where acute PE was ruled out. Adverse clinical outcome was defined as the occurrence 
of one or more of the following: death, cardiopulmonary resuscitation, admittance to intensive 
care unit, need for mechanical ventilation and/or administration of inotropic or anticoagulant 
agents. A 6 week follow-up period was chosen since we considered this to reflect the acute 
consequences of the acute PE best.
Statistical analysis
Statistical analysis was performed using SPSS version 16.0 for windows (SPSS, Chicago, Illinois, 
USA). Dependent on normal or skewed distribution, mean and standard deviations or medians 
and interquartile ranges (IQR) were calculated for RV and LV ejection fraction, end-diastolic 






obstruction index. For the comparison of cardiac function between the patients with and with-
out PE, logarithmic transformation was applied for skewed distributed variables to allow use of 
an independent samples T-test. A Chi-Square test was applied to evaluate differences between 
patients with and without the occurrence of adverse clinical outcome, using our predefined 
thresholds. Receiver operator characteristic (ROC) analysis was applied to assess and compare 
the discriminatory ability of the predefined cut-off values for RV ejection fraction, RV/LV-ratios 
and vascular obstruction index in predicting clinical outcome by comparing the area under 
the curve (AUC).20 Furthermore, sensitivity, specificity, positive predictive value and negative 




In total, 430 patients with suspected acute PE were included. Mean age was 55 ±17 years and 
45% were males (Table 1). Pulmonary embolism was confirmed in 113 patients (26%) on CT pul-
monary angiography. The median degree of pulmonary artery obstruction was 25% (IQR 10%-
50%). The patient cohort with PE was 56 ±17 years and included 60 male patients. Furthermore, 
22% had a history of venous thromboembolism (VTE), 31% of immobility, recent surgery or 
trauma, and 21% suffered from active malignancy. Finally, 6.2% of the patients were previously 
diagnosed with COPD and 4.4% with left sided heart failure. The patients without acute PE 
were less often male (42%), had less frequently previous VTE (13%) and a history of immobility, 
trauma or recent surgery (21%). Preexisting COPD was more frequent in the patients without 
PE (16%, Table 1).







Age (years ±SD) 56 ±17 55 ±17 55 ±17
Male sex (n, %) 60 (53)* 133 (42)* 193 (45)
Previous PE or DVT (n, %) 25 (22)* 42 (13)* 67 (16)
Immobility, surgery, trauma (n, %) 35 (31)* 67 (21)* 102 (24)
Active malignancy (n, %) 24 (21) 77 (24) 101 (24)
COPD (n, %) 7 (6.2)* 51 (16)* 58 (14)
Left sided heart failure (n, %) 5 (4.4) 28 (8.8) 33 (8)
*p<0.05 on Chi-Square test. PE=pulmonary embolism, n=number, DVT=deep vein thrombosis, 
COPD=chronic obstructive pulmonary disease, SD=standard deviation.
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Cardiac function
Table 2 shows the results of the ECG-synchronized volumetric dynamic CT and non-synchronized 
CT pulmonary angiography diameter ratios. Patients diagnosed with acute PE had significantly 
lower RV ejection fraction than patients without PE (49.1% vs. 51.8%, p<0.001). End-diastolic 
and end-systolic RV/LV volume ratios were higher in patients with PE as well. For the LV function 
measurements, no significant differences were found between patients with and without PE 
(Table 2). Finally, the RV/LV dimension ratios measured on standard CT pulmonary angiography 
were significantly higher in patients with PE than in patients without PE (1.0 vs. 0.86, p<0.001).
Table 2. Ventricular ejection fraction and RV/LV volume as well as diameter ratios in patients with and 







RV ejection fraction (median, IQR) 49.1 (39-54) 51.8 (47-57) <0.001
LV ejection fraction (median, IQR ) 54.8 (49-59) 55.4 (48-61) 0.64
End-diastolic RV/LV volume ratio (median, IQR ) 1.1 (1.0-1.4) 1.1 (0.97-1.2) 0.001
End-systolic RV/LV volume ratio (median, IQR) 1.3 (1.0-1.7) 1.1 (0.98-1.4) <0.001
Non-synchronized CT pulmonary angiography
RV/LV diameter ratio on axial view (median, 
IQR )
1.0 (0.92-1.2) 0.86 (0.77-0.94) <0.001
*Independent samples T-test after logarithmic transformation of the skewed distributed variables. 
PE=pulmonary embolism, RV=right ventricle, LV=left ventricle, SD=standard deviation, IQR=interquartile 
range.
Clinical outcome
Follow-up after six weeks was completed in all 113 patients with PE. Two of the 317 without 
PE were lost to follow-up (0.63%). Adverse clinical outcome was reported in 10 of 113 patients 
(8.9%) with acute PE. Seven patients died: four deaths were attributed to acute PE and three 
patients died of progressive cancer. Furthermore, one patient received thrombolytic therapy 
because of a saddle embolus, one patient was successfully resuscitated and one patient was 
admitted to the intensive care unit due to complicated post-surgical course. Of the 317 patients 
without PE, 22 died during follow-up. Causes of death were malignancy (n=15), pneumonia 
(n=2), heart failure (n=2), renal failure (n=1), pulmonary fibrosis (n=1) and hemorrhage (n=1).
Table 3 and Figure 1 show the results for ventricular volume ratios and diameter ratios in 
patients with PE based on clinical outcome. In patients with PE, RV ejection fraction (38.9% vs. 
49.7%, p=0.008) and LV ejection fraction (45.7% vs. 55.0%, p<0.05) were both significantly lower 
in patients who experienced adverse clinical outcome than in patients with an uncomplicated 
clinical course. Furthermore, axial RV/LV dimension ratios (1.3 vs. 1.0, p=0.007) and end-diastolic 
and end-systolic RV/LV dimension ratios were both significantly higher in patients with PE and 
















RV ejection fraction (median, IQR) 49.7 (41-55) 38.9 (28-46) 0.005
LV ejection fraction (median, IQR) 55.0 (50-59) 45.7 (33-55) 0.041
End-diastolic RV/LV volume ratio (median, IQR) 1.1 (1.0-1.3) 1.4 (1.4-2.5) 0.047
End-systolic RV/LV volume ratio (median, IQR) 1.3 (1.0-1.6) 1.8 (1.2-2.6) 0.040
Non-synchronized CT pulmonary angiography
RV/LV diameter ratio on axial view (median, IQR) 1.0 (0.92-1.1) 1.3 (1.1-1.6) 0.007
Obstruction index (median, IQR) 25 (10-50) 35 (8-63) 0.93


































Figure 1. Distribution of the left and right ventricular (LV and RV) ejection fractions, ventricular ratios and 
obstruction index in the patients with acute pulmonary embolism. Horizontal bars represent medians, 
black circles represent patients with adverse clinical outcome. ESV=end-systolic volume, EDV=end-systolic 
volume.
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Table 4 shows the predictive values for clinical outcome for the ventricular ejection fractions 
and RV/LV ratios. The sensitivity of the studied predictors ranged between 50% and 90%, with 
the highest for RV and LV ejection fraction. Overall, the specificity was lower than the sensitivity, 
ranging from 37%-69% and was best for the pulmonary obstruction index. The best predictor 
for adverse clinical events in our population was RV ejection fraction <47% with an adjusted 
odds ratio of 36 (95% confidence interval [CI] 2.2-590), an AUC of 0.75 (95% CI 0.62-0.88), a 
positive predictive value of 18% (95% CI 8.6-31%) and a negative predictive value of 98% (95% 
CI 91- >99.9%). AUCs of LV ejection fraction <57% (difference 0.11; 95% CI 0.04-0.18), end-
diastolic RV/LV >1.2 (difference 0.8; 95% CI -0.7-0.23), end-systolic RV/LV ratio >1.4 (difference 
0.14; 95% CI 0.07-0.21), axial RV/LV ratio >1 (difference 0.11; 95% CI 0.02-0.21) and pulmonary 
artery obstruction index >40% (0.16; 95% CI 0.05-0.26) were lower. The AUCs of the ventricular 
volume and dimension ratios were comparable. Altering the thresholds of our predictors 
(decrease for RV and LV ejection fraction and increase for the ventricular ratio’s and obstruction 
index) changed the sensitivity/specificity ratio in favor of the specificity, but did not result in 
significant increase in AUC of ROC analysis for any of the parameters. Finally, ROC analysis of the 
parameters of RV and LV function in the patients without PE resulted in poor overall predictive 
accuracy with AUCs ranging from 0.49-0.64.












RV ejection fraction <47% 90 (56-99.8) 60 (50-69) 18 (8.6-31) 98 (91- >99.9) 0.75 (0.62-0.88)
LV ejection fraction <57% 90 (56-99.8) 37 (28-47) 9.6 (3.6-19) 97 (88-99.9) 0.64 (0.48-0.79)
ED RV/LV volume ratio >1.2 70 (35-39) 64 (54-73) 16 (6.6-30) 96 (88-99) 0.67 (0.50-0.84)
ES RV/LV volume ratio >1.4 60 (26-88) 62 (52-71) 13 (5.1-27) 94 (85-98) 0.61 (0.42-0.79)
Axial RV/LV dimension ratio >1.0 80 (44-96) 48 (38-58) 13 (5.7-24) 96 (86-99.5) 0.64 (0.47-0.81)
Obstruction index >40% 50 (19-81) 69 (59-77) 13 (4.4-28) 93 (85-98) 0.59 (0.40-0.78)
AUC=area under the curve, PPV=positive predictive value, NPV=negative predictive value, RV=right 
ventricle, LV=left ventricle, ED=end-diastolic, ES=end-systolic.
DISCUSSION
The main findings of this study were that RV ejection fraction assessed by ECG-synchronized 
cardiac CT is an important predictor for clinical outcome in patients with acute PE. Furthermore, 
RV ejection fraction had a superior predictive accuracy compared to LV ejection fraction in this 
context. Also, ECG-synchronized RV/LV volumes were not better predictors of adverse outcome 
than static CT assessed RV/LV dimension ratios. Finally, all studied CT measured markers of ven-






high negative predictive values (94-98%) and limited positive predictive values (9.6-18%) for 
adverse outcome after PE
Two earlier studies investigated the additional value of ECG-synchronized cardiac CT in 
patients with acute PE. In one study, cardiac ventricular measurements obtained with standard 
CT pulmonary angiography and ECG-synchronized cardiac CT were compared in 30 patients 
with PE, and a statistical model was developed to evaluate the potential improvement in pre-
dicting mortality.17 The mean difference between ECG-synchronized measurements and the 
non-ECG-gated axial RV/LV ratios was 8%, suggesting an improvement in specificity. Another 
study that evaluated 29 patients with acute PE found that RV ejection fraction measured by 
ECG-synchronized CT scans was correlated to the location of the pulmonary emboli and there-
fore possibly of clinical use in predicting prognosis of patients with acute PE.16 Both studies 
had low sample sizes and did not have follow-up data. Our prospective outcome study adds 
to these findings that RV ejection fraction lower than 47% was indeed associated with poor 
prognosis (adjusted odds ratio 36) and predicted adverse outcome with high sensitivity (90%) 
and negative predictive value (98%). Therefore, our results indicate that the risk of adverse 
events is very low in normotensive patients diagnosed with acute PE but with a RV ejection 
fraction of 47% or higher. However, although the overall accuracy assessed with ROC analyses 
showed that RV ejection fraction had a higher ability to correctly classify patients at risk for 
adverse events than simple RV/LV dimension ratios, the negative predictive values of both 
tests were similarly high, confirming previous studies that earlier reported a high negative 
predictive value of ventricular dimension ratios for adverse outcome in patients suffering from 
PE.3,12,13 Consequently, the potential additional clinical value achieved by cardiac CT on top of 
the routine CT-scan in patients with PE was mainly derived from gained specificity. Even so, 
its positive predictive value (18%) was still insufficient to justify more invasive treatment mea-
sures. Notably, in patients without PE, which comprised 74% of our population, no substantial 
additional value was obtained by ECG-synchronized cardiac CT as well.
As RV/LV dimension ratios, end-diastolic and end-systolic RV/LV volume ratios were also 
found predictive for clinical outcome. Although volumetric measurements may have been 
expected to represent a more accurate estimation of RV/LV dimensions, the diagnostic perfor-
mance of simple RV/LV diameter ratios derived from CT pulmonary angiography was equivalent 
to that of the RV/LV volume ratios in this study. Apparently, end-diastolic or end-systolic volume 
ratios alone did not have additional value in representing RV systolic function to ventricular 
dimension ratios. Remarkably, in our patients with PE, each of the cardiac parameters had 
better discriminatory value in predicting adverse clinical outcome than the pulmonary artery 
obstruction index, emphasizing the importance of ventricular evaluation in patients with PE.
Some important clinical issues regarding ECG-synchronized cardiac CT need to be addressed. 
Radiation exposure was increased by acquiring extra ECG-synchronized CT as compared to CT 
pulmonary angiography alone (increase of 3-4 mSv), which should be justified when apply-
ing the technique. In addition, a small but extra amount of contrast agent was needed for the 
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cardiac scan (35-40 mL). This might imply a contraindication for patients with renal function 
impairment. Furthermore, although acquisition of ECG-synchronized data is a fast technique, 
advanced post-processing is needed for obtaining dynamic volumetric ventricular function 
by ejection fraction. That process is much more time-consuming than obtaining simple RV/LV 
diameter ratios from CT pulmonary angiography scans. Therefore, we suggest that with the cur-
rent techniques and based on this study, the potential benefit of ECG-synchronized cardiac CT 
for obtaining ventricular function may not outweigh its disadvantages. It remains to be studied 
whether this technique might be beneficial for selected patient groups with PE and otherwise 
poor prognosis due to older age or comorbid conditions. Due to the relatively limited study 
sample, we could not further evaluate this latter hypothesis.
Although previous studies have shown the prognostic value of RV dysfunction on clinical 
outcome in patients with acute PE3,5,8, this is to our knowledge the first large prospective study 
that investigated the predictive value for short term clinical outcome of ECG-gated cardiac CT 
in patients with and without acute PE. Still, one study limitations remains. Although the lost 
to follow-up rate was very low (0% and 0.63% for patients with and without PE respectively), 
the total sample size and the number of adverse events reported in this study were relatively 
limited, contributing to the high negative predictive values with broad confidence intervals.
In conclusion, RV ejection fraction, obtained with ECG-synchronized cardiac CT was found the 
best predictor for clinical outcome in patients with acute PE, although only of weak additional 
value to axial RV/LV diameter ratios obtained with standard CT pulmonary angiography.
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Chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE) 
is associated with high morbidity and mortality. Understanding the incidence of CTEPH after 
PE is important for evaluating the need for screening but also debated as a result of different 
inclusion criteria among previous studies. We determined the incidence of CTEPH after acute 
PE in an unselected patient cohort, and the utility of a screening program for this disease.
Methods
A cohort screening study in an unselected series of consecutive patients (n=866) diagnosed 
with acute PE between January 2001 and July 2007 was conducted. All patients who were 
not previously diagnosed with pulmonary hypertension (PH) and had survived until study 
inclusion were invited for echocardiography. Patients with echocardiographic suspicion of PH 
underwent complete work-up for CTEPH, including ventilation-perfusion scintigraphy and 
right heart catheterization.
Results
After an average follow-up of 34 months and from all 866 patients, PH was diagnosed in 19 
patients by routine clinical care and in 10 by our screening program; 4 patients had CTEPH, who 
were all diagnosed by routine clinical care. The cumulative incidence of CTEPH after all cause 
PE was 0.57% (95% confidence interval [CI] 0.02-1.2%) and after unprovoked PE 1.5% (95% CI 
0.08-3.1%).
Conclusion
The incidence of CTEPH after PE in our large and unselected patient cohort was 0.57%. Because 
of this low incidence and the very low yield of the echocardiography based screening program, 
wide scale implementation of prolonged follow-up including echocardiography of all patients 
with PE to detect CTEPH seems not warranted.
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INTRODUCTION
Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition 
characterized by intraluminal thrombus organization and fibrous stenosis or complete oblitera-
tion of the pulmonary arteries.1 CTEPH has commonly been associated with acute pulmonary 
embolism (PE), although the pathogenesis of impaired clearance of acute thrombi and the 
resulting vascular remodeling is unknown, and a history of symptomatic venous thromboem-
bolism (VTE) is lacking in 31–42% of the patients diagnosed with CTEPH.1-3
The incidence of CTEPH has been reported to be between 0.1% and 8.8% in patients after 
acute PE.1,4-7 This wide range can be explained by important differences in the inclusion and 
diagnostic criteria between these previous studies: selection of patients was often based on the 
etiology of the acute PE, patients with other comorbid conditions associated with pulmonary 
hypertension were frequently excluded and the diagnosis of CTEPH was not always confirmed 
by right heart catheterization.1,4-7
Since CTEPH is a very serious but potentially treatable disease, the exact incidence of CTEPH 
in the clinical course of acute PE is of particular interest. High frequencies of 3.8 to 8.8%4,6 would 
suggest the need for prolonged follow-up after discontinuation of anticoagulant therapy 
including specific screening programs for CTEPH by echocardiography, whereas lower frequen-
cies would not.
The purpose of this study was to evaluate the efficacy of a screening program for CTEPH 
in patients after acute PE. This evaluation was based on the overall incidence of CTEPH and 
the additional utility of this screening program on top of standard clinical care. Accordingly, 
we performed a prospective cohort screening study evaluating the occurrence of CTEPH in an 
unselected large series of patients diagnosed with acute PE.
METHODS
Patients
Consecutive patients diagnosed with a first or recurrent episode of acute PE in the period 
between January 1st 2001 and July 1st 2007 of an academic (Leiden University Medical Center, 
Leiden, the Netherlands) and affiliated teaching hospital (Medical Center Haaglanden, The 
Hague, the Netherlands) were eligible for study inclusion, irrespective of age, medical history or 
comorbid conditions. Neither of these 2 hospitals serves as a tertiary referral center for CTEPH. 
All patients diagnosed and treated for acute PE are registered in a database by physicians of all 
clinical specialties of both hospitals. For the purpose of this study, we have crosschecked this 
database with data from the radiology department to ensure no patients were missing. The 
diagnosis of acute PE was verified for all registered patients according to predefined criteria 






pulmonary angiography (CTPA), high probability ventilation perfusion scintigraphy (VQ-scan) 
or intermediate probability VQ-scan in combination with objectively diagnosed deep venous 
thrombosis (DVT).8 All patients fulfilling these criteria were included in this analysis. Unpro-
voked PE was defined as PE occurring in the absence of the following risk factors: active malig-
nancy, immobility more than 3 days or recent long flight, recent surgery or fracture of extremity, 
pregnancy or peri-partum period, hormone replacement therapy and use of oral contraception. 
Patients were initially treated with at least 5 days of either unfractioned heparin aiming at a 1.5 
to 2.5 prolongation of the activated partial thromboplastin time, or weight based therapeutic 
doses of LMWH, followed by vitamin K antagonists for a period of at least 6 months with a target 
international normalized ratio (INR) of 2.0 to 3.0.9 In patients with severe acute PE, anticoagulant 
treatment was preceded by administration of thrombolytic drugs, thrombosuction or surgical 
embolectomy according to the judgment of the attending clinician. Clinical follow-up and 
treatment monitoring after hospital discharge were performed in the local pulmonary, internal 
or vascular medicine outpatient clinic as well as in the anticoagulation clinic.
Outcome
Primary outcomes of this study were the incidence of CTEPH and the effectiveness of our 
screening program. Criteria for the diagnosis of CTEPH were mean pulmonary artery pressures 
assessed by right heart catheterization exceeding 25 mmHg and normal pulmonary capillary 
wedge pressure in combination with an abnormal perfusion scintigram and signs for distal or 
central CTEPH on conventional pulmonary angiography.10,11 CTEPH was considered excluded 
in case of a normal perfusion scintigram.10,11
Procedures
The original admission and outpatient medical charts of all patients diagnosed with acute PE 
in the registration period were systematically reviewed using predefined criteria. Only patients 
with geographical inaccessibility (living outside the Netherlands) precluding follow-up were 
excluded from study participation. Data regarding diagnostic management, etiology, treatment 
and documented clinical course of the acute PE at registration as well as recurrent episodes, 
and established diagnosis of pulmonary hypertension were assembled. For all eligible patients 
who had died before study inclusion (July 2007), time and cause of death were extracted from 
the autopsy report or verified with the treating physician or general practitioner. All surviving 
patients not identified as having pulmonary hypertension were interviewed by telephone 
to obtain a detailed medical history, presence of clinical symptoms suggestive of pulmonary 
hypertension and if applicable, results of recent echocardiography. In addition, information on 
known risk factors for venous thromboembolism (VTE) and CTEPH were noted down. The latter 
includes large central emboli, unprovoked VTE, splenectomy, presence of lupus anticoagulant 
or antiphospholipid antibodies, chronic inflammatory conditions and ventriculo-atrial shunts.12 
Furthermore, all these latter patients were invited for a single visit to our vascular medicine 
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outpatient clinic for a pulmonary hypertension screening by echocardiography. This visit was 
scheduled between July 1st 2007 and January 1st 2009 and planned at least one year after the 
index event, or one year after a recurrent thromboembolic episode, to rule out the initial effect 
of acute PE. All patients who responded to our invitation underwent physical examination and 
standardized transthoracic echocardiography performed by an experienced technician. This 
echocardiography was reviewed by an independent expert cardiologist, without knowledge 
of the patient’s medical condition. Echocardiographic criteria for suspected pulmonary hyper-
tension were one or more of the following: 1) maximal tricuspid regurgitation velocity >2.8 
m/s, 2) estimated systolic pulmonary artery pressure ≥35 mmHg (maximal pressure gradient 
across the tricuspid valve calculated by the modified Bernoulli equation plus the estimated 
right atrium pressure), 3) estimated mean pulmonary artery pressure ≥25 mmHg (estimated 
systolic pressure plus 2 times enddiastolic pressure as estimated by pulmonary regurgitation 
enddiastolic velocity divided by 3), 4) borderline value of criterion 1 or 2 in combination with a 
right ventricular TEI index >0.36 (isovolumic contraction time plus isovolumic relaxation time 
divided by ejection time), 5) secondary changes associated with pulmonary hypertension, e.g. 
systolic septal flattening, right ventricular hypertrophy or W-pattern in the right ventricular 
outflow curve, 6) AcT (acceleration time ) <120 or AcT/RVET (right ventricular ejection time) 
<0.40.11,13,14 All patients who met one or more of these 6 criteria were suspected of having pul-
monary hypertension and underwent further standardized work-up including perfusion lung 
scintigraphy and right heart catheterization for pressure measurements. The final diagnosis 
was assessed by an independent expert panel according to our predefined criteria. This study 
was approved by the Institutional Review Board of both participating hospitals and all patients 
provided written informed consent.
Statistical analysis
Patients were categorized in 4 sub-groups according to their medical history of single or recur-
rent and provoked or unprovoked PE. The cumulative incidence of CTEPH after acute PE for all 4 
study groups was calculated by the Kaplan-Meier life table method. In addition, we calculated 
the incidence rates of CTEPH. The number of patient years (py) for both analyses was calculated 
from the date of the index event until diagnosis of CTEPH was established or ruled out or else 
until death had occurred, whichever came first. SPSS version 14.02 (SPSS Inc, Chicago, IL) was 
used for all analysis.
RESULTS
Patients
In 877 patients the diagnosis of acute PE had been established between January 1st 2001 and 






866 patients for study inclusion. General characteristics of these patients are shown in Table 1: 
mean age at registration was 56 years, 410 (47%) were males and 308 patients (36%) had suf-
fered an unprovoked episode of PE. More than 90% of the patients were initially treated with 
either unfractionated heparin or LMWH alone. A small number of patients additionally received 
thrombolytic therapy, had a vena cava filter inserted or had surgical embolectomy performed 
(Table 1). The average follow-up period was 2.8 years.
Table 1. Characteristics of included patients.
Study patients
(n=866)
Age at registration event (years ±SD) 56 ±19
Male sex (n, %) 410 (47)
Unprovoked PE (n, %) 308 (36)
Initial treatment first PE
Low molecular/unfractioned heparin (n, %) 808 (93)
Thrombolysis (n, %) 38 (4.4)
Surgery, VCF or both (n, %) 20 (2.3)
COPD (n, %) 83 (9.6)
Left sided heart failure (n, %) 42 (4.8)
Overall mortality§ (n, %) 259 (30)
PE related mortality (n, %) 67 (7.7)
Malignancy related mortality (n, %) 110 (13)
Other (n, %) 82 (9.4)
Number of patient years‡ 2427
‡Number of years from registration date until diagnosis of CTEPH was established or ruled out, or until 
death had occurred; §mortality between registration date and July 1st 2007. PE=Pulmonary embolism, 
SD=standard deviation, n=number, VCF=vena cava filter, COPD=chronic obstructive pulmonary disease.
Chart review
After reviewing the medical charts of all patients, 19 cases of previously diagnosed pulmonary 
hypertension were identified (Figure 1) of whom 4 had CTEPH. During the study period 259 
patients died, 67 (7.7%) as a direct result of acute (recurrent) PE, 110 (13%) of malignant disease 
and 82 (9.4%) by other conditions. Of these 259 patients, 185 (71%) had died within the first 
year after the acute PE, 216 (83%) within 2 years, 238 (92%) within 3 years and 247 (95%) within 
4 years. In 69 patients, autopsy reports or echocardiography performed before the patients’ 
death ruled out the presence of pulmonary hypertension. Further, pulmonary hypertension 
was not adjudicated as cause of death in any of these patients. Therefore, and in accordance 
with criteria from previous studies4-7, we assumed that none of these patients had developed 
CTEPH.
The remaining 588 patients were invited for our screening program. We were able to com-
plete this program in 402 (68%) of them. None of these patients had clinically suspected acute 
PE at the moment of echocardiography. Echocardiographic criteria for suspected pulmonary 
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hypertension were met by 25 patients. After further clinical work-up and right heart catheter-
ization, pulmonary hypertension was diagnosed in 10 of these patients.
From the 186 patients who did not respond to our invitation, 38 had undergone echo-
cardiography for clinical reasons other than our screening study. None of these patients was 
diagnosed with pulmonary hypertension. Objective testing for pulmonary hypertension was 
not performed in the remaining 148 surviving patients. Of these, 97 declared to be in excellent 
health without any physical complaints and to have no time to be involved in any clinical trials. 
The final 51 patients were unable to visit our hospital due to old age or comorbid conditions. 
Most of these patients were over the age of 80 years and suffered from severe cancer. Of these 
latter 51 patients, 10 reported exertional dyspnea that was reasonably explained by previously 
diagnosed cardiopulmonary diseases, i.e. chronic obstructive pulmonary disease (COPD), 
systolic left-sided heart failure, pulmonary cancer, severe anemia or a combination of these 
conditions. Since none of these patients had unexplained dyspnea4-6 we assumed that CTEPH 
was not present in these patients for the purpose of the incidence calculation.
Incidence of CTEPH
Upon study inclusion, 19 patients with a history of PE were already diagnosed with pulmonary 
hypertension of various causes. Among these, 4 had been diagnosed with CTEPH by routine 
clinical care, and CTEPH was ruled out by perfusion scintigraphy or pulmonary angiography 
in the remaining 15 patients. Our screening program identified an additional 10 patients with 
pulmonary hypertension, but distal or central CTEPH was ruled out in all of these patients after 
Chart review for previously diagnosed PH 
 
19 Pulmonary hypertension 
 4  CTEPH 
Screening program (n=402) 
 
392    Pulmonary hypertension ruled out  
 
10      Pulmonary hypertension 




 0 CTEPH  
11 excluded because of 
geographically inaccessibility 
for follow-up. 
877 patients registered with 
acute PE between January 1st 
2001 and July 1st 2007 
259 died 
 
69 Autopsy or echocardiography negative for PH 
 
0 PH reported as cause of death 
 0  CTEPH 
No objective testing (n=148) 
 
97      No time/no complaints 
 
51      Age or comorbid conditions, 10  
           patients reported exertional dyspnea‡ 
   0 CTEPH  
588 eligible for screening program
Figure 1. Flowchart of the cohort study. ‡In all 10 patients (100%) with dyspnea, previously diagnosed 
cardiopulmonary disease reasonably explaining the dyspnea was reported. PE=pulmonary hypertension, 
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normal perfusion scintigraphy or pulmonary angiography. All 4 patients with CTEPH returned 
to their physician within 2 years after their first acute PE because of typical symptoms of 
CTEPH, including exertional dyspnea (Table 2). None of them was found to have additional 
risk factors for CTEPH or other comorbidity causing pulmonary hypertension. The diagnoses 
were confirmed by right heart catheterization and measurement of pulmonary artery pressure. 
Mean time to diagnosis was 260 days. The cumulative incidence of CTEPH in our cohort was 
0.57% (4/866, 95% CI 0.02-1.2%) in the overall population, 1.5% (4/308, 95% CI 0.08-3.1%) in the 
patients with unprovoked PE and 0.0% (0/558) in the patients with provoked PE (Table 3, Figure 
2). Incidence rate of CTEPH was 0.16/100 py (95% CI 0.04-0.42/100 py) for the overall popula-
tion, 0.44/100 py (95% CI 0.12-1.1/100 py) for patients with unprovoked PE and 0.0/100 py (95% 
CI 0.0-0.24/100 py) for patients with provoked PE (Table 3). Incidences following a single event 
or recurrent disease were not different between the study groups (Table 3).




























Figure 2. Cumulative incidence of chronic thromboembolic pulmonary hypertension.
Follow-up of patients with CTEPH
Because of distal pulmonary artery involvement, only 1 of the 4 patients with CTEPH was 
considered suitable for pulmonary endarterectomy. However, this patient refused surgery for 
personal reasons and was treated with the oral dual endothelin receptor antagonist bosentan.15 
Two additional patients were treated with bosentan of whom one developed severe elevation 
of transaminases. As a consequence, this treatment was stopped in the latter patient. The final 
patient did not receive treatment because of the benign clinical presentation of CTEPH (NYHA 
Class II, satisfactory exercise tolerance without severe desaturation during maximal exercise). 
At the moment of drafting this paper (April 1st 2009) and after a mean follow-up of 43 months 






Efficacy of the screening program
Ten patients with pulmonary hypertension were identified by the screening program in the 
402 patients with a history of acute PE but without established pulmonary hypertension, with 
a mean of 2.8 years after the index thromboembolic event. Pulmonary angiography did not 
reveal CTEPH in these 10 patients: the pulmonary hypertension was caused by left sided heart 
disease in 5 patients and by COPD in the remaining 5 patients. All patients with CTEPH from our 
total study population were previously diagnosed by routine clinical practice.
DISCUSSION
This study has two main findings. First, we observed a 0.57% incidence of CTEPH after acute 
PE in an unselected large patient series. Second, the yield of a standard screening program to 
detect CTEPH in patients after acute PE is low, since additional cases of CTEPH to cases identi-
fied by routine clinical care, were not detected in our study population.
Understanding of the CTEPH incidence is important to guide the screening and diagnostic 
strategy in patients after acute PE. The incidence of CTEPH we observed challenges other 
studies reporting higher incidences ranging from 3.8 to 8.8%.4-7 There are several reasons for 
these discrepancies. These previous studies included selected patient cohorts, e.g. excluding 
patients with transient or permanent risk factors for PE5 and excluding patients with other 
conditions associated with pulmonary hypertension.4-6 In addition, the diagnosis of CTEPH 
was partly based on results from echocardiography alone without confirmation by right heart 
catheterization.6 An incidence of 3.8% was reported in the widely quoted study by Pengo et al, 
which is considerably higher than the incidence observed in our population.4 That study and 
our study mainly differed in inclusion criteria: whereas we only excluded patients who were 
geographically inaccessible, Pengo additionally excluded all patients with other diseases that 
could have caused non-thromboembolic pulmonary hypertension (e.g. COPD) or had preexist-
ing exertional dyspnea. Although by design of our study, we are unable to precisely estimate 
the prevalence of those latter patients in our cohort, they provide a considerable contribution 
to our sample size. The selection criteria applied by Pengo may have influenced his results, lead-
ing to a higher incidence of CTEPH. The duration to diagnosis (within 2 years after diagnosis of 
PE) on the other hand was well comparable between the 2 studies.
We consider our results to be representative for several reasons. First, we included all 
patients that presented to the participating hospitals, independently on etiology or severity 
of the acute PE or presence of comorbid conditions. Our study comprised about 3 times the 
number of previous reports. All patients received up-to-date anticoagulant treatment regimes 
with a duration of at least 6 months. Our study involved well over 2400 patient years and only 
11 patients (1.3%) were excluded for geographical reasons. Second, we studied all patients with 
PE, irrespective of persistent symptoms at follow-up and used very sensitive echocardiographic 
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criteria for establishing the suspicion of pulmonary hypertension.11,13,14 Third, all cases of 
CTEPH were diagnosed after invasive hemodynamic measurements and pulmonary artery 
angiography. Fourth, all patients with CTEPH presented with typical symptoms of pulmonary 
hypertension and were diagnosed with CTEPH within the first 2 years after their first acute PE. 
These observations are consistent with the results of earlier studies.4-7 Finally, the incidence 
of CTEPH in patients with unprovoked PE in our study was 1.5%. This is in accordance with or 
within the lower limit of the confidence interval of the incidences described in studies focusing 
solely on patients with unprovoked PE.4,5
It could be reasoned that our estimation of 0.57% represents an underestimation of the inci-
dence of CTEPH since objective testing to confirm or reject this diagnosis was not performed in 
the complete study population. However, this same issue can be applied to all previous reports 
on this subject. The vast majority of the non-survivors in our study died within one year after 
the PE was diagnosed, and a reasonable alternative cause of death was reported in all of them. 
Furthermore, all cases of CTEPH presented with symptoms of cardiopulmonary impairment. 
Hence, it is unlikely that we missed cases of CTEPH in the asymptomatic patients who were 
not able to visit our outpatient clinic or in the patients that had died. Also, plausible alterna-
tive diagnoses for dyspnea were confirmed in all 10 patients who reported exertional dyspnea 
but did not visit our outpatient clinic. Importantly, our estimated incidence of 0.57% is only 
applicable to patients with a history of acute PE, and not to a more general population.
In this study, a cardiopulmonary screening program to detect CTEPH was evaluated. 
Although completed by 402 patients, this screening program did not result in any additional 
patients being detected with a diagnosis of CTEPH beside those patients that were identified 
by routine clinical practice. In combination with the low frequency of CTEPH, this leads to the 
conclusion that wide scale implementation of screening programs for CTEPH after acute PE is 
not warranted and echocardiography to rule out or establish CTEPH should be restricted to 
patients presenting with characteristic symptoms.
We conclude that CTEPH is a rare complication of acute PE (incidence 0.57%) and that this 
diagnosis is more frequent in patients with unprovoked acute PE (incidence 1.5%). CTEPH 
becomes clinically apparent and is diagnosed within the first 2 years following acute PE. Wide 
scale screening for CTEPH after acute PE results in a very low yield. Although CTEPH occurs 
infrequently in the clinical course of acute PE, physicians should be aware of this potentially 
lethal but treatable disease, especially in those patients with unprovoked disease and persistent 
dyspnea. The direct clinical consequence of our study is that because of the very low incidence 
of CTEPH after PE, the implementation of extensive follow-up programs for the detection of 
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Chapter 9
A simple non-invasive diagnostic algorithm 
for ruling out chronic thromboembolic 
pulmonary hypertension in patients after 
acute pulmonary embolism
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Our aim was to construct a diagnostic model for ruling out chronic thromboembolic pulmo-
nary hypertension (CTEPH) in symptomatic patients after acute pulmonary embolism (PE) that 
is based on simple, non-invasive tests.
Methods
Plasma levels of various CTEPH associated biomarkers and conventional ECG criteria for right 
ventricular hypertrophy were assessed in 82 consecutive patients with confirmed CTEPH and 
160 consecutive patients with a history of PE who were suspected to have CTEPH, but in whom 
this disease was ruled out.
Results
ECG criteria of right ventricular hypertrophy were detected more frequently in the patients 
with CTEPH (77%) than in the patients without CTEPH (11%, Odds ratio 26, 95% confidence 
interval [CI] 13-53). Also, clotting factor FVIII activity and the levels of N-terminal-pro-brain-
type natriuretic peptide (NT-pro-BNP), Growth Differentiation Factor-15, C-reactive protein and 
urate, but not D-dimer level, were higher in patients with CTEPH. A diagnostic model including 
ECG criteria and NT-pro-BNP levels had a sensitivity of 94% (95% CI 86-98%) and a specificity of 
65% (95% CI 56-72%). The area under the receiver-operator-characteristic curve was 0.80 (95% 
CI 0.74-0.85) for the diagnosis of CTEPH. Even with high disease prevalences of up to 10%, the 
negative predictive value of this model proved to be very high (99%, 95% CI 97- >99.9%).
Conclusions
Ruling out CTEPH in patients after acute PE seems to be safe without additional diagnostic 
testing in absence of ECG criteria indicative of right ventricular hypertrophy and a normal NT-
pro-BNP level.
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INTRODUCTION
Chronic thromboembolic pulmonary hypertension (CTEPH) results from chronic obstruction 
of the pulmonary vascular bed by organized thrombi.1 The incidence of CTEPH in patients 
who suffered from acute pulmonary embolism (PE) has been reported to be in the range of 
0.5-3.8%, depending on the selection criteria applied in the individual studies.1-3 The prognosis 
of patients with CTEPH is poor, unless a successful pulmonary endarterectomy is possible.1,4 
Therefore, early recognition of this disease is crucial for timely referral to a center specialized 
in the management of pulmonary hypertension, allowing swift and adequate therapeutical 
intervention.
The clinical presentation of CTEPH is characterized by non-specific symptoms and include 
exercise intolerance and dyspnea, fatigue, chest pain and syncope (at exercise). These symptoms 
are also consistent with other, more common cardiopulmonary conditions such as asthma, 
chronic obstructive pulmonary disease (COPD), interstitial lung disease, coronary artery dis-
ease, cardiac arrhythmia or heart failure not caused by chronic pulmonary thrombi.1,5,6 These 
non-specific symptoms are commonly reported by patients who suffered from an acute PE and 
therefore, the possibility of CTEPH can be frequently considered.7 The diagnostic management 
of CTEPH is complex. In many patients pulmonary perfusion scintigraphy, transthoracic echo-
cardiography and conventional pulmonary angiography with determination of pulmonary 
hemodynamics need to be performed before the diagnosis of CTEPH can be refuted. Thus, 
there is great need for more simple, easily available, less invasive and less expensive tests to 
safely rule out CTEPH.1 These tests may include conventional 12-lead electrocardiography 
(ECG) and biomarkers of heart failure, inflammation or thrombosis that are associated with 
the pathogenesis or prognosis of CTEPH, and which are widely available for and applicable to 
outpatient medical care.8-13 Although the prognostic value of these biomarker levels for CTEPH 
and/or other entities of pulmonary hypertension are well described, their diagnostic potential 
has not been systematically studied.8-13
In the present study, we examined whether CTEPH can be ruled out in symptomatic patients 
with a documented history of acute PE by using ECG assessment and measurement of several 
biomarkers, i.e. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP), Growth Differentiation 
Factor-15 (GDF-15), C-reactive protein (CRP), urate, plasma factor VIII coagulant activity (FVIII:C) 
and D-dimer, or a combination of these tests.
METHODS
Patients
We studied patients from a large follow-up study of patients with acute PE in an academic 






(Medical Center Haaglanden, The Hague, the Netherlands).3 This study included all patients who 
were diagnosed with acute PE between January 2001 and July 2007. The diagnosis of acute PE 
was based on intraluminal filling defects on pulmonary angiography or computed tomography 
pulmonary angiography (CTPA), high probability ventilation perfusion scintigraphy (VQ-scan) 
or intermediate probability VQ-scan in combination with objectively diagnosed deep vein 
thrombosis (DVT).14 All patients were treated with at least 5 days of either unfractionated hepa-
rin or weight based therapeutic doses of low molecular weight heparin, followed by vitamin K 
antagonists for a period of at least 6 months. From the 877 consecutive patients diagnosed with 
PE, 259 had died before the start of the study, 11 were living abroad and therefore were lost 
to follow-up, 19 were previously diagnosed with pulmonary hypertension and 186 declined 
participation. For the present analysis, we only studied the remaining patients who reported 
exertional dyspnea and decreased exercise performance and therefore were suspected of 
having CTEPH. We additionally included 82 consecutive patients from a CTEPH referral center 
(Academic Medical Center, Amsterdam, the Netherlands) who were previously diagnosed with 
CTEPH by regular clinical care. This study was approved by the Institutional Review Board of all 
participating hospitals and all patients provided informed consent.
Procedures
The routine diagnostic work-up of patients with suspected CTEPH consisted of echocardiog-
raphy and pulmonary perfusion scintigraphy. If these tests were suggestive of CTEPH, the 
diagnosis was confirmed or refuted by pulmonary angiography in combination with right heart 
catheterization. Criteria for the diagnosis of CTEPH were a mean pulmonary artery pressure 
(mPAP) assessed by right heart catheterization exceeding 25 mmHg and a normal pulmonary 
capillary wedge pressure in combination with segmental of subsegmental perfusion defects 
on perfusion scintigram and signs of CTEPH on conventional pulmonary angiography.1,15 All 
patients were classified according to the modified New York Heart Association (NYHA) classifi-
cation of the World Health Organization. Conventional 12-lead ECGs were obtained and blood 
samples were drawn and stored on the day that the participants of the follow-up study were 
screened for pulmonary hypertension, or before pulmonary endarterectomy was performed 
or medical treatment was initiated in the patients with established CTEPH. The ECGs were 
recorded with the patient in supine position for a 10-second period using the standard 12-lead 
electrode configuration at a conventional speed (25 mm/s) and sensitivity (1 mV/10 mm). All 
ECGs were evaluated for the presence of one or more of the following three criteria of right 
ventricular hypertrophy that have been demonstrated by multivariate logistic regression to 
predict the presence of pulmonary hypertension optimally: 1) rSR’ or rSr’ pattern in lead V1, 2) 
R:S >1 in lead V1 with R >0.5mV and 3) QRS axis >90°.16
All blood samples were analyzed in batches after a single thaw. Levels of NT-pro-BNP 
were measured with the use of quantitative immunoassays (Hitachi Modular E 170 unit, 
Roche Diagnostics, Mannheim, Germany). GDF-15 serum concentrations were assessed by 
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immunoradiometric assays using a polyclonal GDF-15 affinity-chromatography-purified, goat 
anti-human GDF-15 IgG antibody (AF957) from R&D Systems (Minneapolis, MN).17 CRP and 
urate measurements were performed using a Hitachi Modular system according the recom-
mendations of the reagent manufacturer (Roche, Diagnostics, Mannheim, Germany). FVIII:C 
was measured in a one-stage APTT-based clotting assay using immunodepleted FVIII-deficient 
plasma and automated APTT (BioMerieux, Boxtel, the Netherlands) on an automated coagula-
tion analyzer (STA-R Evolution, Diagnostica Stago, Roche Diagnostics). Results for FVIII:C are 
expressed as international units (IU) per dL with reference to a normal pooled plasma calibrated 
against the 4th WHO international standard FVIII/VWF plasma (97/586) (NIBSC, Potters Bar, 
UK). The D-dimers were measured on the same analyzer using the STA-Liatest D-dimer assay 
(Diagnostica Stago). The detection range was ≥50 pg/mL for NT-pro-BNP, ≥20 ng/L for GDF-15, 
≥1.0 mg/mL for CRP and ≥250 ≤20000 ng/mL for D-dimer. All biomarker measurements were 
performed by investigators who were blinded to the patients’ diagnosis. We used predefined 
reference values for the biomarkers under study to predict the presence of CTEPH: NT-pro-BNP 
dependent on age and sex as suggested by the manufacturer, GDF-15 ≥1200 ng/L, CRP ≥3.0 
mg/L, urate >0.34 mmol/L for female and >0.42 mmol/L for male patients as suggested by the 
manufacturer, FVIII:C ≥150 IU/dL, and D-dimer >500 ng/mL FEU being the optimal predictor of 
thrombosis.17-19
Statistics
We calculated the sensitivity and specificity of the conventional ECG criteria of right ventricular 
hypertrophy and the biomarkers under study for the presence of CTEPH in all patients. Patients 
from the screening study who were identified as having pulmonary hypertension of other 
etiology than CTEPH were excluded from further analysis. Differences between the study 
groups were analyzed using independent samples T-tests for normally distributed continuous 
variables, Mann-Whitney-U tests for skewed distributed continuous variables and Chi-Square 
tests for categorical variables. Further, starting with the clinical test with the highest area under 
the receiver operator characteristic (AUC of ROC) curve and thus with the highest predictive 
accuracy, we derived 7 additional clinical models by including consecutive diagnostic tests 
with decreasing AUC in a model to identify the most favorable combination of clinical tests for 
this purpose. AUC of ROC analyses were compared by the method described by Hanley and 
McNeil.20 Our final diagnostic model was based on the combination of diagnostic tests with 
the optimal combination of sensitivity and thus negative predictive value, and specificity for 
efficacy reasons. Finally, we used the following formula to calculate the negative predictive 
value of the newly constructed optimal model according to increasing assumed prevalences of 
CTEPH: (specificity*(1-prevelence))/{((1-sensitivity)*prevalence) + (specificity*(1-prevalence))}. 
SPSS version 14.02 (SPSS Inc, Chicago, IL) was used for all analysis. A p-value of <0.05 was 








We included 170 patients with a history of acute PE and clinically suspected CTEPH. Of these 
patients, 10 were diagnosed with pulmonary hypertension by right heart catheterization, but 
none with CTEPH. Therefore, these 10 patients were excluded from further analysis. Pulmonary 
hypertension was ruled out in the remaining 160 patients. An alternative explanation for the 
dyspnea was found in the majority of the patients, and was previously established or newly 
diagnosed heart or lung disease, anemia, morbid obesity or a combination of these conditions. 
The study population was completed by 82 consecutive patients with established CTEPH. The 
baseline characteristics of the study patients are presented in Table 1.
Table 1. Patient characteristics.
Patients with CTEPH
(n=82)
Patients in whom 
CTEPH was ruled out
(n=160)
p-value
Age (years ±SD) 57 ±14 57 ±16 NS
Male sex (n, %) 32 (39) 73 (46) NS
Active malignancy (n, %) 8 (9.8) 22 (14) NS
COPD (n, %) 6 (7.3) 35 (22) 0.04
Left sided heart disease (n, %) 6 (7.3) 22 (14) <0.001
BMI, kg/m2 (mean, ±SD) 28 ±6.0 29 ±5.2 NS
mPAP, mmHg (mean, ±SD) 44 ±11 - NA
CTEPH=chronic thromboembolic pulmonary hypertension, n=number, SD=standard deviation, 
COPD=chronic obstructive pulmonary disease, BMI=body mass index, NS=no statistical significance, 
NA=not applicable, mPAP=invasively measured mean pulmonary artery pressure.
ECG characteristics and biomarker levels
The typical predefined electrocardiographic signs of pulmonary hypertension were detected 
significantly more often in patients with CTEPH (77%) than in the symptomatic patients with-
out pulmonary hypertension (11%; Odds ratio 26, 95% confidence interval [CI] 13-53). A closer 
look at the distribution of the 3 ECG characteristics revealed that right axis was observed most 
frequently in patients with CTEPH (55%), followed by rSR’ or rSr’ pattern in lead V1 (45%) and 
R:S >1 in lead V1 with R >0.5mV (28%); 31 (38%) patients with CTEPH had more than one of 
the three prespecified ECG characteristics. Circulating levels of NT-pro-BNP, GDF-15, CRP and 
urate were significantly higher in patients with CTEPH than in the other study group (Table 2 
and Figure 1). On the other hand, D-dimer levels were not different between the two study 
groups, with over 50% of the values beneath the detection level of the used assays (Table 2 
and Figure 1).
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Table 2. Biomarker levels in the study population.
Patients with CTEPH
(n=82)
Patients in whom 
CTEPH was ruled out
(n=160)
p-value
NT-pro-BNP (pg/mL) 756 (161-2563) 103 (53-214) <0.001
GDF-15 (ng/L) 1580 (1058-2741) 1200 (813-1789) <0.001
CRP (mg/L) 4.5 (1.7-8.3) 2.5 (1.3-4.6) <0.001
Urate (mmol/L) 0.34 (0.24-0.45) 0.31 (0.27-0.38) <0.001
FVIII:C (IU/dL) 2.0 (1.7-2.5) 1.7 (1.4-2.0) <0.001
D-dimer (ng/mL FEU) <250 (<250-432) <250 (<250-457) NS
Medians and interquartile range are presented. NS=no statistical significance.
NT-pro-BNP (pg/mL) GDF-15 (ng/L)








































Figure 1. Biomarker levels in the 2 study groups: horizontal bars represent medians, circles patients with 
CTEPH and triangles patients without pulmonary hypertension. FVIII:C levels were missing for 29 patients 
with CTEPH; *p<0.001.
Derivation of a diagnostic model
Clear differences between the sensitivity and specificity and AUC of the ROC analyses were 
observed between the ECG-characteristics and the biomarkers under study using our pre-
defined cut-off points (Table 3). The sensitivity of the ECG criteria (77%, 95% CI 67-86), elevated 
NT-pro-BNP levels (82%, 95% CI 72-89) and high FVIII:C (83%, 95% CI 70-92) were higher than 
those of elevated GDF-15 (63%, 95% CI 52-74), CRP (64%, 95% CI 53-75), urate (46%, 95% CI 






ECG-criteria (89%, 95% CI 83-93) and elevated urate levels (80%, 95% CI 73-86). The area under 
the ROC curve was slightly higher for the ECG-criteria (0.83, 95% CI 0.77-0.89) than for NT-
pro-BNP (difference 0.09, 95% CI -0.04-0.17), and significantly higher than GDF-15 (difference 
0.21, 95% CI 0.09-0.30), CRP (difference 0.21, 95% CI 0.08-0.32), urate (difference 0.21, 95% CI 
0.11-0.21), FVIII:C (difference 0.26, 95% CI 0.12-0.35) and D-dimer levels (difference 0.35, 95% CI 
0.18-0.41; Table 3).
We calculated the additional diagnostic value of the biomarkers to ECG assessment, which 
proved to be the most discriminative test for CTEPH (Table 4). After including NT-pro-BNP to 
the model (i.e. either one of the 3 ECG criteria positive or NT-pro-BNP levels elevated), the 
sensitivity increased significantly (+17%, 95% CI 5.4-29), at the cost of specificity (-24%, 95% CI 
-15 to -33). The AUC of the ROC analysis did not change significantly. By including the remain-
ing tests one after the other to the model, the specificity decreased considerably to 39% and 
even lower, whereas the sensitivity increased only marginally leading to significantly decreased 
AUC in model C which consists of ECG assessment, NT-pro-BNP and CRP level measurements 
(difference 0.17, 95% CI 0.06-0.30), and in all further models. Therefore, we determined that 
Table 3. Test characteristics of ECG and biomarkers for the diagnosis of CTEPH in symptomatic patients 







ECG criteria† 77 (67-86) 89 (83-93) 0.83 (0.77-0.89)
NT-pro-BNP¶ 82 (72-89) 70 (62-77) 0.74 (0.66-0.82)
GDF-15‡ 63 (52-74) 50 (42-58) 0.62 (0.49-0.64)
CRP¥ 64 (53-75) 61 (52-68) 0.62 (0.53-0.71)
Urate¶ 46 (35-57) 80 (73-86) 0.62 (0.52-0.71)
FVIII:CΔ 83 (70-92) 32 (25-40) 0.57 (0.48-0.66)
D-dimer§ 24 (16-35) 78 (70-84) 0.48 (0.39-0.57)
†Presence of at least 1 of the following criteria: rSR’ or rSr’ pattern in lead V1, R:S >1 in lead V1 with R 
>0.5mV and QRS axis >90°; ¶sex and age dependent threshold; ‡threshold 1200 ng/L; ¥threshold 3.0 mg/L; 
Δthreshold 150 IU/dL; §threshold 500 ng/mL FEU. CI=confidence interval, ECG=electrocardiography, 
AUC=area under the receiver operator characteristic curve.







A ECG criteria 77 (67-86) 89 (83-93) 0.83 (0.77-0.89)
B NT-pro-BNP + model A 94 (86-98) 65 (56-72) 0.80 (0.74-0.85)
C CRP + model B 94 (86-98) 39 (31-47) 0.66 (0.60-0.73)
D Urate + model C 94 (86-98) 33 (26-41) 0.64 (0.56-0.71)
E GDF-15 + model D 96 (90-99) 23 (17-30) 0.60 (0.53-0.67)
F FVIII:C + model E 98 (91-99.7) 13 (7.8-19) 0.55 (0.48-0.63)
G D-dimer + model F 99 (93- >99.9) 12 (7.3-18) 0.55 (0.48-0.63)
ECG=electrocardiography, AUC=area under the receiver operator characteristic curve, CI=confidence 
interval.
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model B, which includes ECG-assessment as well as NT-pro-BNP testing, was the most optimal 
diagnostic model for ruling out CTEPH. This model identified all patients with mPAP greater 
than 30 mmHg. False negative test results only occurred in a small number of the patients with 
relatively mild disease (mPAP between 26 and 30 mmHg). Interestingly, one of these latter 
patients even had normal results from all tests.
Effectiveness of the diagnostic model
To test the effectiveness of our diagnostic model, we calculated its negative predictive value for 
hypothetically increasing disease prevalences (Table 5). In case of a normal NT-pro-BNP level 
and in the absence of typical ECG characteristics of pulmonary hypertension, it is very unlikely 
that a dyspnoeic patient with a history of acute PE suffers from CTEPH with negative predictive 
values of 99% or higher, even in the presence of very high incidences of CTEPH (up to 10%).
Table 5. Negative predictive value of our final algorithm (model B) for increasing assumed prevalences of 
CTEPH.
Hypothetical incidence of CTEPH Negative predictive value
(%, 95% CI)
0.5% 99.9 (99.9- >99.9)










Our results demonstrate that a simple diagnostic model based on ECG-evaluation and NT-
pro-BNP measurements can rule out CTEPH with a high level of confidence in patients with 
a documented history of acute PE and clinically suspected CTEPH. Additional more expensive 
and invasive tests in these patients to rule out CTEPH seem therefore not necessary.
The sensitivity of the ECG criteria alone was 77%, which confirms earlier studies describing 
the insufficient diagnostic potential of these ECG criteria for pulmonary hypertension screen-
ing purposes.16,21 The sensitivity, specificity and AUC of the 3 ECG parameters in our cohort 
were even lower than previously reported.16 This is likely due to the higher fraction of patients 






higher, but still insufficient sensitivity for CTEPH. Combining the 3 ECG criteria with NT-pro-BNP 
levels, we obtained a higher sensitivity (94%) with an acceptable specificity.
Although the overall prevalence of CTEPH after acute PE - irrespective of complaints - ranges 
from 0.5% to 3.8%, this number likely increases 2 or 3 fold in selected patients with prior acute 
PE who present with clinically suspected CTEPH.1-3 To facilitate correct interpretation and use of 
our study results for different clinical settings and patient cohorts, we observed high negative 
predictive values of our diagnostic model for different hypothetical incidences ranging from 
0.5 to 15%, thereby enabling physicians to distinguish the negative predictive value applicable 
to their specific practice. Importantly, the specificity of our model was not sufficient to confirm 
CTEPH: patients with suspected CTEPH and one or more ECG characteristics of pulmonary 
hypertension or elevated blood levels of NT-pro-BNP should therefore be subjected to further 
diagnostic tests, including echocardiography and right heart catheterization.
Although all biochemical tests under study have been shown to be correlated to the 
presence and/or prognosis of pulmonary hypertension8-13, and almost all tests were more 
increased in patients with CTEPH than in the patients without this disease, their diagnostic 
value for CTEPH proved to be limited, with the exception of NT-pro-BNP. There are 3 plausible 
explanations for this observation: 1) the studied biomarkers are especially elevated during 
acute thrombotic states or during acute heart failure while CTEPH is a chronic disease charac-
terized by relatively slow progression, 2) all studied biomarkers are established prognostic fac-
tors for CTEPH and therefore, mostly present in the patients with severe or worsening disease 
and 3) a considerable proportion of our patient population without CTEPH had co-existing 
cardiopulmonary and malignant diseases, which are associated with elevation of one or more 
of the studied biomarkers as well. For instance, GDF-15, a stress-responsive, transforming 
growth factor-β-related cytokine, is weakly produced under baseline conditions in most tis-
sues but its production increases sharply in response to hemodynamic stress, inflammation, 
and tissue injury.22 Elevated circulating levels of GDF-15 have been reported in patients with 
acute PE and idiopathic pulmonary arterial hypertension and have been shown to provide 
strong and independent prognostic information in these conditions.8,23 However, elevated 
levels of GDF-15 can also be detected in other cardiovascular disease states and in patients 
with malignant tumors. Therefore, and possibly due to the relatively mildly elevated mPAP in 
some of our patients, GDF-15 proved to be a poor diagnostic test for CTEPH in our popula-
tion. CRP is a well-known marker of inflammation and tissue damage that recently has been 
shown to predict the severity and the outcome in patients with pulmonary hypertension.9 
Also, serum urate or uric acid, the final product of purine degradation, has been proposed 
to be a prognostic marker for hypoxic states such as chronic heart failure and pulmonary 
hypertension.10 Nonetheless, the arguments raised to explain the limited diagnostic accuracy 
of GDF-15 can also explain the lack of discriminative power of urate and CRP levels for CTEPH. 
Finally, D-Dimer is a global indicator of coagulation activation and fibrinolysis. D-dimers and 
FVIII:C are known to be increased during and after acute PE, but also in a wide variety of other 
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diseases as infection or inflammatory and malignant conditions.24,25 Both D-dimer and FVIII:C 
were shown to have very limited diagnostic value for CTEPH in our patient cohort. Altering our 
predefined thresholds for GDF-15, CRP, urate, FVIII:C or D-dimer did not significantly change 
our observations (data not shown).
Strengths of this study include the analysis of a large patient cohort with and without CTEPH 
and the standardized and blinded assessment of ECG characteristics and biomarker levels, 
thereby increasing the likelihood of generalizability of our results and precluding important 
biases. Notably, none of the patients with suspected CTEPH from the screening study was 
diagnosed with CTEPH. One important explanation for this low prevalence is that all patients 
who were diagnosed with CTEPH prior to the start of our study were included in the CTEPH 
cohort and consequently, not in the screening study. Our study also had limitations. In spite of 
the narrow confidence intervals, our conclusions should be confirmed in a future prospective 
trial since ours was an exploratory but not an outcome study, and therefore, the sensitivity and 
specificity of the diagnostic tests were calculated retrospectively.
In conclusion, the present study shows that a diagnostic model based on ECG assessment and 
NT-pro-BNP measurements can be used to rule out CTEPH in patients with a history of acute 
PE and clinically suspected CTEPH. Therefore, more invasive tests to rule out this disease do 
not seem necessary in patients without three specific ECG criteria of right ventricular pressure 
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Prevalence and determinants of exertional 
dyspnea after acute pulmonary embolism
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The exact prevalence and etiology of exertional dyspnea in the clinical course of acute pulmo-
nary embolism (PE) have not yet been established.
Methods
A large cohort of consecutive patients diagnosed with acute PE was subjected to a dyspnea 
questionnaire and invited for cardiopulmonary work-up including the 6-minute walk test, 
spirometry and echocardiography. The prevalence, severity, determinants and underlying 
diseases of exertional dyspnea were evaluated.
Results
Of the registered 877 patients, 259 (30%) had died and 11 (1.3%) were excluded for geographi-
cal reasons. From the remaining 607 patients, 217 reported exertional dyspnea (36%; 95% CI 
32-40%) 3.6 ±1.7 years after the PE. 421 patients completed the cardiopulmonary work-up. After 
multivariate analysis, cardiopulmonary comorbidity (OR 12; 95% CI 6.5-20), advanced age (OR 
1.02 per year; 95% CI 1.01-1.03), higher BMI (OR 1.06 per kg/m2; 95% CI 1.01-1.1) and a smok-
ing history (OR 1.6; 95% CI 1.02-2.6) were identified as independent predictors of exertional 
dyspnea. A predefined dyspnea explaining diagnosis could be established in all patients with 
exertional dyspnea. In only 4 patients, this diagnosis was directly correlated to the acute PE. 
Increased severity of dyspnea was significantly correlated to decreased exercise performance 
(p<0.001) and the number of dyspnea-related diagnoses (p<0.001).
Conclusion
Exertional dyspnea is a frequent symptom in the long term clinical course of acute PE. More 
severe dyspnea results in decreased exercise capacity and increased burden of cardiopulmo-
nary comorbidity. This dyspnea is not related to the past thromboembolic event in the vast 
majority of patients.
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INTRODUCTION
Dyspnea is a term used to characterize a subjective experience of breathing discomfort that 
is comprised of qualitatively distinct sensations that vary in intensity.1 Exertional dyspnea 
or breathing discomfort is a common and distressing symptom expressed by many patients 
and its etiology may prove elusive.1-4 The majority of patients with exertional dyspnea can 
be diagnosed with one of four diagnoses: asthma, chronic obstructive pulmonary disease 
(COPD), interstitial lung disease or heart failure.2-4 Exertional dyspnea after acute pulmonary 
embolism (PE) represents a particular clinical challenge since this frequent observation requires 
distinguishing PE related from the above stated causes of dyspnea. In recent studies, exertional 
dyspnea was observed in 50-60% of the patients after they were diagnosed with acute PE.5,6 
Importantly, 70% of these patients related their symptoms to the acute thromboembolic 
event suggesting a causal relation between both.5 PE associated conditions causing exertional 
dyspnea include ventilation–perfusion mismatch leading to increased dead-space ventilation 
or chronic thromboembolic pulmonary hypertension (CTEPH) resulting from chronic emboli.5-9 
A third diagnosis could be recurrent PE, although these patients present with more acute or 
sub-acute worsening symptoms in the majority of cases.10,11 The relevance of the distinction 
between PE and non-PE related disease causing dyspnea is underlined by apparent differences 
in the required diagnostic strategies, treatment and prognosis.
We sought to assess the exact prevalence and etiology of exertional dyspnea in patients with 
prior acute PE. Therefore, we have interviewed a large cohort of consecutive patients surviving 
an acute episode of PE and in addition, subjected these patients to a cardiopulmonary work-up.
METHODS
Patients
Consecutive patients who were diagnosed with acute PE in the period between January 1st 2001 
and July 1st 2007 in an academic (Leiden University Medical Center, Leiden, the Netherlands) 
and affiliated teaching hospital (Medical Center Haaglanden, The Hague, The Netherlands) 
were studied.12 Eligible patients were identified from the hospital records of the radiology 
department and the departments of internal, pulmonary and emergency medicine. Acute PE 
was confirmed by pulmonary angiography, computed tomography pulmonary angiography 
(CTPA) or ventilation perfusion scintigraphy (VQ-scan).13 Patients were initially treated with 
at least 5 days of either unfractionated or weight based therapeutic doses of low molecular 
weight heparin, followed by oral anticoagulant therapy for a period of at least 6 months. The 
current survival status and contact information of each eligible patient was retrieved from 
the hospital administrative database or local municipal registries. All patients who survived 







presence and severity of dyspnea. Furthermore, they were invited for a single visit to our vascu-
lar medicine outpatient clinic for cardiopulmonary work-up including the 6-minute walk test, 
spirometry and echocardiography. This visit was scheduled between July 1st 2007 and January 
1st 2009 and planned at least one full year after the index event. Patients who were diagnosed 
with pulmonary hypertension prior to the start of our study were telephonically interviewed 
but not invited for a visit, since extensive cardiopulmonary tests were already performed in 
the diagnostic work-up of these patients. This study was approved by the Institutional Review 
Board of both participating hospitals and all patients provided informed consent.
Procedures
Patients were telephonically asked to complete a short medical questionnaire that was specifi-
cally designed to assess the presence, severity and possible causes of exertional dyspnea in the 
clinical follow-up of patients with acute PE.5 In the patients who responded to our invitation for 
a single visit to our outpatient clinic, the 6-minute walk test was performed in accordance with 
the ATS guidelines.14 Results of this 6-minute walk test are presented in percentage of the refer-
ence standard.15 Ventilatory function was measured using a turbine spirometer (Microlab 3300, 
Sensormedics. Ltd Rochester, UK). Forced vital capacity (FVC), forced expiratory volume in one 
second (FEV1) and peak expiratory flow (PEF) were measured until three reproducible record-
ings (with a difference of less than 5%) were obtained. The highest of these 3 values was used 
for analysis. A VIVID-I portable ultrasound machine (GE Healthcare, Chalfont St. Giles, Bucks, 
UK) was used for transthoracic echocardiography. Echocardiography included cross sectional, 
M-mode and Doppler studies, and was performed by an experienced technician according to 
a standardized protocol. All echocardiographs were reviewed by an independent expert cardi-
ologist. If necessary for establishing a diagnosis in symptomatic patients, further routine clinical 
work-up consisting of laboratory-, more extensive pulmonary function- or imaging tests was 
performed under supervision of an independent expert panel. In case of suspected pulmonary 
hypertension, this further work-up included right heart catheterization at all times.
Outcome
Our primary endpoint was the prevalence of exertional dyspnea as reported by patients sur-
viving an episode of acute PE. Our second endpoint was the assessment of determinants for 
the presence of exertional dyspnea in the clinical follow-up of acute PE. We studied several 
variables as possible determinants of exertional dyspnea in the clinical course of acute PE. 
Length of the follow-up period, centrally located PE, invasive treatment for PE (i.e. administra-
tion of thrombolytic drugs, vena cava filter or surgical removal of the embolus) and recurrent PE 
were included as PE related determinants. Age, gender, body mass index (BMI), smoking status 
and history of cardiopulmonary disease other than PE were assessed as non-PE related deter-
minants. Our third endpoint included the evaluation of the severity of the reported dyspnea. 
For the purpose of this analysis, patients were classified according to the criteria of the New 
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York Heart Association (NYHA) functional classification, although not strictly applicable to a 
non heart failure population.16 This classification comprises 4 categories of increasing exercise 
impairment: no limitation of physical activity by shortness of breath (class I, no symptoms), 
ordinary physical activity results in dyspnea (class II, mild symptoms), comfortable at rest, but 
less than ordinary activity causes dyspnea (class III, moderate symptoms) and symptoms of 
cardiac insufficiency at rest, inability to carry out any physical activity without discomfort (class 
IV, severe symptoms). In addition to the NYHA classification, the total distance covered during 
the 6-minute walk test and the modified Borg dyspnea scale were considered to represent the 
severity of the dyspnea and exercise intolerance.17 Our final endpoint was the identification of 
the exact diagnoses causing dyspnea following acute PE. We considered the following diag-
noses to be a sufficient justification for the presence of exertional dyspnea: asthma diagnosed 
according to the NIH guidelines, COPD classified as GOLD II or worse in accordance with the 
NHLBI/WHO criteria, significant restrictive pulmonary function impairment (FVC <80% and dis-
tinct restrictive flow curve), all cause pulmonary hypertension, systolic or diastolic ventricular 
dysfunction as stated in the ESC guidelines, significant valvular disease according to the ACC/
AHA guidelines, anemia (woman <7.4 mmol/l; man < 8.1mmol/l) or obesity (body mass index 
>30kg/m2).18-23 The presence of further, PE-related conditions as explanation for dyspnea was 
considered unlikely if one or more of the above stated diagnoses could be established.
Statistical analysis
The overall prevalence of exertional dyspnea was assessed for all patients who completed 
the medical questionnaire. For the analysis of the further endpoints, we included the patients 
who had completed the cardiopulmonary work-up. Univariate relation between all possible 
determinants and exertional dyspnea was assessed by calculating odds ratios (OR) with 95% 
confidence intervals (95% CI). Univariate analysis was followed by multivariate analysis to 
identify the independent determinants of exertional dyspnea. For this, a conditional logistic 
regression model was used evaluating all possible determinants. Fisher’s analysis of variance 
(ANOVA) with least significant difference post-hoc tests was used to detect differences among 
the 4 NYHA classes. A p-value <0.05 was used to define statistical significance. SPSS version 
14.02 (SPSS Inc, Chicago, IL) was used for all analysis.
RESULTS
Patients and prevalence of dyspnea
In total, 877 patients were diagnosed with acute PE between January 1st 2001 and July 1st 2007 
in the two participating hospitals. Of these, 259 (30%) had died before July 1st 2007 and 11 
patients (1.3%) were lost to follow-up. Deaths were attributed to malignancies in 110 patients 







(0.69%), cardiovascular disease in 30 patients (3.5%), non-malignant pulmonary disease in 
11 patients (1.3%) and other causes in 35 patients (4.2%). The remaining 607 patients were 
successfully contacted after a median period of 3.6 years (interquartile range 2.1-5.1 years). Of 
those, 30 (4.9%) declared to be in excellent health with no dyspnea, but refused to complete 
the questionnaire. An additional 156 patients declined visiting our hospital for cardiopulmo-
nary work-up. Finally, 19 patients were diagnosed with pulmonary hypertension prior to the 
start of our study. Pulmonary function tests, echocardiography and the 6-minute walk test 
were routinely performed in these patients, and therefore these patients were not invited for 
further cardiopulmonary work-up. The remaining 402 patients visited our outpatient clinic and 
completed the cardiopulmonary function tests.
On questioning, 217 of the surviving patients reported dyspnea, resulting in an overall dys-
pnea prevalence of 36% (217/607; 95% CI 32-40%). From the 217 patients reporting dyspnea, 
165 (76%) specified that the dyspnea had developed or worsened after the acute PE.
Predictors of dyspnea
The general characteristics at diagnosis of PE of the 421 patients with complete cardiopulmo-
nary data, i.e. 19 patients previously diagnosed with pulmonary hypertension and 402 who 
completed the cardiopulmonary work-up, are depicted in Table 1: mean age was 55 years, 225 
(53%) were males, 143 (34%) were diagnosed with centrally located PE, 23 (5.5%) patients had 
received invasive treatment for the PE, recurrent VTE was diagnosed in 64 (15%) patients, 116 
(28%) were previously diagnosed with cardiopulmonary disease, mean BMI was 28 kg/m2 and 













Age (years ±SD) 55 ±16 52 ±16 58 ±16 1.02 (1.01-1.04)
Male sex (n, %) 225 (53) 127 (55) 98 (52)
Central localisation first PE (n, %) 143 (34) 78 (34) 65 (34)
Thrombolysis, Surgery or VCF for first acute PE (n, %) 23 (5.5) 13 (5.6) 10 (5.3)
Recurrent VTE (n, %) 64 (15) 30 (13) 34 (18)
Known history of cardiopulmonary disease (n, %) 116 (28) 22 (9.5) 94 (50) 10.4 (6.1-18)
Body Mass Index (kg/m2 ±SD) 28 ±5.3 28 ±6.0 29 ±5.1 1.05 (1.01-1.1)
Smoking history
Current (n, %) 77 (18) 41 (18) 36 (19)
Former (n, %) 178 (42) 93 (40) 85 (45)
Never (n, %) 166 (39) 100 (43) 66 (35) 0.64 (0.43-0.96)
Number of pack years (mean ±SD) 14 ±17 10 ±13 18 ±20 1.03 (1.02-1.04)
†Only for significant determinants of dyspnea after univariate analysis (per unit for continuous variables). 
PE=Pulmonary embolism, VCF=vena cava filter, VTE=venous thromboembolism, SD=standard deviation, 
n=number, OR=odds ratio, CI=confidence interval.
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255 (61%) patients were current or former smokers. Univariate analysis indicated that none of 
the PE-related factors was a predictor of dyspnea. In contrast, advanced age, larger BMI, smok-
ing and a history of cardiopulmonary disease were all significantly predictive for dyspnea (Table 
1). Importantly, the follow-up period was not different between patients with and without 
dyspnea (mean 3.4 years [interquartile range 1.9-4.8] vs. 3.8 years [interquartile range 2.1-5.3] 
respectively). After multivariate analysis, a history of cardiopulmonary disease (OR 12, 95% CI 
6.5-20), advanced age (OR 1.02 per year, 95% CI 1.01-1.03), higher BMI (OR 1.06 per kg/m2, 95% 
CI 1.01-1.1) and a smoking history (OR 1.6, 95% CI 1.02-2.6) at diagnosis were demonstrated to 
be independent predictors of exertional dyspnea after acute PE.
Severity and causes of dyspnea
Of the 421 patients with complete cardiopulmonary data, 189 reported dyspnea (45%, 95% CI 
40-50%): 151 (80%, 95% CI 73-85%) were classified as NYHA II, 31 (16%, 95% CI 11-22%) as NYHA 
III and 7 (3.7%, 95% CI 1.5-7.5) as NYHA IV. The mean percentage of predicted walking distance 
in the 6-minute walk test decreased in subsequent NYHA classes: 99 ±11% in NYHA class I, 96 
±12% in NYHA II class, 77 ±21% in NYHA III class and 35 ±8.4% in NYHA IV class (p=0.017 for 
the first step, p<0.001 for the last 2 steps). In addition to this observation, the modified Borg 
dyspnea score after the 6-minute walk test increased in the subsequent NYHA classes: 1.2 ±1.1, 
2.5 ±1.5, 4.6 ±1.8 and 6.6 ±1.3 respectively (p<0.001 for the first 2 steps, p=0.002 for the last 
step). The 6-minute walk test could not be performed in 47 patients because of immobility or 
other reasons.
The final dyspnea related diagnoses established in the study patients are presented in Table 
2. All patients with exertional dyspnea were diagnosed with at least one of the predefined 
dyspnea explaining conditions. On average, patients in NYHA class II were diagnosed with 1.5, 
in NYHA class III with 3.0 and patients in NYHA class IV with 3.4 different diagnoses (p<0.001). 









Asthma (n, %) 5 (2.2) 12 (7.9) 3 (9.7) 1 (14)
COPD† (n, %) 6 (2.6) 29 (19) 13 (42) 3 (43)
Restrictive pulmonary function impairment (n, %) 10 (4.3) 9 (6.0) 1 (3.2) 1 (14)
Pulmonary hypertension (n, %) 0 (0) 6 (4.0) 20 (65) 3 (43)
CTEPH (n, %) 0 (0) 1 (0.66) 3 (9.7) 0 (0)
Systolic cardiac dysfunction (n, %) 6 (2.6) 19 (13) 11 (68) 3 (43)
Diastolic cardiac dysfunction (n, %) 66 (28) 59 (39) 19 (35) 5 (71)
Significant valvular heart disease (n, %) 1 (0.43) 3 (2.0) 2 (6.5) 2 (29)
Anemia (n, %) 8 (3.4) 26 (17) 4 (13) 1 (14)
Obesity* (n, %) 65 (28) 50 (33) 18 (58) 3 (43)
Patients can be diagnosed with more than one dyspnea-related disease. †Classification GOLD II or worse; 







Only in 4 patients this diagnosis could be causally related to the past acute PE. These patients 
were diagnosed with CTEPH after right heart catheterization and pulmonary angiography. 
CTEPH was ruled out in the remaining 25 patients with pulmonary hypertension after perfusion 
scintigraphy or pulmonary angiography. Notably, the prevalence of dyspnea related diagnoses 
in asymptomatic patients was 47%, mainly as a result of 66 cases of diastolic ventricular dys-
function.
DISCUSSION
This study demonstrates that the prevalence of exertional dyspnea in the long term clinical 
course of acute PE is 36%. This dyspnea was however not related to the past thromboembolic 
event in the vast majority of the patients. The clinical relevance of the subjective symptom 
of shortness of breath is underscored by the decreased exercise tolerance and increased 
prevalence of dyspnea related comorbidity that we found in patients who presented with more 
severe symptoms.
Although we observed that the majority of symptomatic patients correlated their exertional 
dyspnea to the acute PE, we could not establish pathophysiological grounds for this observa-
tion for two important reasons. First, single and multivariate analysis excluded predefined PE 
related characteristics as determinants for the presence of exertional dyspnea. Second, the 
included patients underwent extensive cardio- and pulmonary function tests. PE-related dis-
ease was indentified in only 4 patients and all remaining symptomatic patients were diagnosed 
with at least one non-PE related dyspnea explaining condition. We therefore hypothesized that 
the psychological impact of this serious cardiovascular event and the resulting deconditioning 
might very well contribute to subsequent increased perception of dyspnea. Hence, it would 
be interesting to study the effect of cardiopulmonary rehabilitation programs on long term 
dyspnea and physical fitness of patients with acute PE. Such programs have been shown very 
effective after other acute cardiovascular events.24,25
A different explanation for the reported temporal relation between PE and the occurrence 
or worsening of dyspnea was provided by a previous study, that reported either an abnormal 
right ventricular function on echocardiography or decreased exercise performance in 41% 
of previously healthy patients 6 months after acute PE was diagnosed.6 Notably, 15% of the 
patients with normal baseline echocardiography had subsequently developed right ventricular 
dysfunction during the follow-up period. These findings suggest that a PE can cause persistent 
right ventricular injury or initiate a pathophysiological process damaging the right ventricle 
over time.6 Since our study lacks baseline measurements of cardiac and pulmonary function, 
we were unable to support this interesting hypothesis. Although our results did not provide 
evidence for unexplained right ventricular dysfunction on large scale in our study population, 
this hypothesis requires further study.
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Our results are in accordance with previous reports on exertional dyspnea in other patient 
cohorts: the independent determinants of dyspnea and the specific diagnoses established in 
our study are well comparable to those described in the literature.1-4 Furthermore, our observa-
tion that patients with objectively confirmed dyspnea-related disease as asthma or COPD did 
not report any symptoms at all, is a well known phenomenon.1-4 Nonetheless, some aspects of 
this study require comment. First, a considerable number of eligible patients declined visiting 
our hospital, reducing the external validity of our results. Second, we could not put our results 
in perspective due to the lack of a control population without PE. Third, the risk of CTEPH after 
PE reported in this study is lower than previously reported.7,8 This might be explained by dif-
ferent selection and diagnostic criteria applied in those studies, or by underdiagnosis of CTEPH 
in our cohort. Indeed, due to our study design, objective testing to rule out CTEPH could not 
be performed in all study patients. Since the diagnostic management of CTEPH is complex 
and involves right heart catheterization, there is great need for future studies to focus on the 
utilization of simple and noninvasive diagnostic tests for ruling out this very serious condition.
In summary, exertional dyspnea is a frequent symptom in the long term clinical course of acute 
PE. Increased sensation of dyspnea is accompanied by higher burden of cardiopulmonary 
comorbidity and decreased exercise capacity. This dyspnea could not be related to PE in the 
majority of patients. The clinical consequence of our study is that exertional dyspnea in the 
clinical course of acute PE is mainly caused by pre-existing comorbid conditions and alarming 
direct complications of PE such as CTEPH are rare. Nonetheless, physicians should remain alert 








 1. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic 
Society. Am J Respir Crit Care Med 1999; 159:321
 2. Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary 
disease clinic. Arch Intern Med 1989; 149:2277-82
 3. Mahler DA, Horowitz MB. Clinical evaluation of exertional dyspnea. Clin Chest Med 1994; 15:259-69
 4. Tobin MJ. Dyspnea. Pathophysiologic basis, clinical presentation, and management. Arch Intern Med 
1990; 150:1604-13
 5. Klok FA, Tijmensen JE, Haeck ML, et al. Persistent dyspnea complaints at long-term follow-up after an 
episode of acute pulmonary embolism: results of a questionnaire. Eur J Intern Med 2008; 19:625-9
 6. Stevinson BG, Hernandez-Nino J, Rose G, Kline JA. Echocardiographic and functional cardiopulmo-
nary problems 6 months after first-time pulmonary embolism in previously healthy patients. Eur 
Heart J 2007; 28:2517-24
 7. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. 
Circulation 2006; 113:2011-20
 8. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension 
after pulmonary embolism. N Engl J Med 2004; 350:2257-64
 9. Ciurzyński M, Kurzyna M, Bochowicz A, et al. Long-term effects of acute pulmonary embolism on 
echocardiographic Doppler indices and functional capacity. Clin Cardiol 2004; 27:693-7
 10. van Beek EJ, Kuijer PM, Büller HR, et al. The clinical course of patients with suspected pulmonary 
embolism. Arch Intern Med 1997; 157:2593-8
 11. Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent 
venous thromboembolism. Arch Intern Med 2004; 164:92-6
 12. Klok FA, van Kralingen KW, van Dijk APJ, et al. Prospective cardiopulmonary screening program to 
detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embo-
lism. Haematologica 2009; in press
 13. Huisman MV, Klok FA. Diagnostic management of clinically suspected acute pulmonary embolism. J 
Thromb Haemost 2009, 7(Suppl. 1):312-7
 14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS state-
ment: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-7
 15. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit 
Care Med 1998; 158:1384-7
 16. Rich S. Primary pulmonary hypertension: executive summary from the World Symposium on Primary 
Pulmonary Hypertension. Evian, France: WHO;1998.
 17. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-81
 18. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diag-
nosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007
 19. Pauwels RA, Buist AS, Calverley PM, et al. NHLBI/WHO Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-76
 20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force 
for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society 
of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and 
endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-
2442
 21. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus state-
ment on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart 
Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 
28:2539-50
Epidemiology of exertional dyspnea after pulmonary embolism 127
 22. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 
2006 guidelines for the management of patients with valvular heart disease: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Com-
mittee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): 
endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography 
and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523-661
 23. Gibson GJ. Obesity, respiratory function and breathlessness. Thorax 2000; 55(Suppl 1):S41-4
 24. Marchionni N, Fattirolli F, Fumagalli S, et al. Improved exercise tolerance and quality of life with 
cardiac rehabilitation of older patients after myocardial infarction: results of a randomized, controlled 
trial. Circulation 2003; 107:2201-6
 25. Ståhle A, Mattsson E, Rydén L, et al. Improved physical fitness and quality of life following training 
of elderly patients after acute coronary events. A 1 year follow-up randomized controlled study. Eur 
Heart J 1999; 20:1475-84

Chapter 11
Risk of arterial cardiovascular events in patients 
after pulmonary embolism
F.A. Klok, I.C.M. Mos, L. Broek, J.T. Tamsma, F.R. Rosendaal, 










Studies have reported inconsistent evidence for an association between venous thromboem-
bolism (VTE) and arterial cardiovascular events. We further studied the association between 
both diseases by comparing the occurrence of cardiovascular events in patients diagnosed with 
acute pulmonary embolism (PE) contrasted to patients in whom PE was clinically suspected but 
ruled out.
Methods
Patients with a first provoked or unprovoked PE and patients in whom a first PE was clinically 
suspected but ruled out were followed for the occurrence of arterial cardiovascular events. 
Patients diagnosed with PE were treated with vitamin K antagonists (VKA) for six months. All 
patients with an additional indication for VKA other than PE were excluded.
Results
259 patients with provoked PE, 95 patients with unprovoked PE and 334 control patients with-
out PE were included. Median follow-up was 4.2 years. Sixty-three arterial cardiovascular events 
were registered (incidence 5.1/100 py). Adjusted hazard ratio (HR) was not different between 
patients with all cause PE and control patients (1.39, 95% CI 0.83-2.3), but increased for patients 
with unprovoked PE versus both patients with provoked PE and control patients without PE 
(HR 2.18; 95% CI 1.1-4.5 and 2.62; 95% CI 1.4-4.9 respectively). This effect was confirmed after 
redefining the study start date to the moment the VKA were discontinued.
Conclusion
Our study underlines the association between unprovoked VTE and arterial cardiovascular 
events. However, risk differences between patients with provoked PE and patients in whom PE 
was clinically suspected but ruled out could not be demonstrated.
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INTRODUCTION
Recent epidemiological studies have shown an association between venous thromboembolism 
(VTE), that is deep venous thrombosis (DVT) as well as pulmonary embolism (PE), and arterial 
cardiovascular events.1,2 This association can at least in part be explained by the presence of 
common risk factors for venous and arterial disease, such as obesity and the metabolic syn-
drome.3-5 It was previously shown that, compared to population controls, the risk of arterial 
cardiovascular events after a first DVT or a first acute PE was increased in the first year after 
the VTE as well as in 20 years of follow-up.6 Furthermore, patients with VTE of unknown origin 
(unprovoked VTE) are at higher risk of developing arterial cardiovascular events than patients 
with provoked VTE.7-9 However, evidence of the relation between VTE and arterial cardiovascu-
lar events is inconsistent. Two observational studies could not identify increased risk of overall 
or unprovoked VTE in patients with non-invasively measured subclinical atherosclerosis.10,11 
In addition, there are no reports in which the risk for arterial cardiovascular events in patients 
with VTE has been compared with this risk in controls without VTE, but with similar baseline risk 
characteristics. This is important since population controls in general have a lower a-priori risk 
for arterial disease than patients with established VTE.6
We intended to further study the association between VTE and arterial cardiovascular 
events by defining a control population with a more comparable baseline risk characteristics 
for cardiovascular disease than population controls. We hypothesized that patients in whom 
PE was clinically suspected but ruled out would provide such a control group. Accordingly, we 
assessed the incidence of arterial cardiovascular events in patients diagnosed with a first all 
cause PE as well as with provoked PE and unprovoked PE separately, and contrasted them with 
patients in whom a first suspected PE was ruled out.
METHODS
Study design
A cohort study was performed to evaluate the risk of arterial cardiovascular events and the 
event-free survival in patients with a confirmed first PE compared to a population in which a 
clinically suspected first PE was ruled out. Study endpoints were arterial cardiovascular events 
defined as otherwise unexplained death, clinically adjudicated acute myocardial infarction, 
stroke or transient ischemic attack, claudication, unstable angina, carotid endarterectomy, 
coronary artery bypass graft, peripheral arterial bypass or angioplasty.11 Both patients with 
and without PE were followed from the start dates to 1-1-2008 or the occurrence of one of 
the endpoints, whichever came first. After the study period, we searched the medical charts 
of the study patients for the occurrence of study endpoints and we contacted them by mail or 







condition. If patients could not be reached, we used the last medical report of their treating 
physician or general practitioner. When a patient with or without PE had died, the pathology 
report was scrutinized to establish the cause of death. In case autopsy was not performed, the 
likely cause of death was verified with the treating physician or general practitioner. Otherwise 
unexplained death was classified as caused by an arterial cardiovascular event. All endpoints 
were adjudicated by an independent committee. In addition to information on the endpoints, 
we also collected information on sex, age at inclusion, risk factors for PE, recurrent VTE dur-
ing the study period and medical history of cardiovascular events in both patients with and 
without PE. This study was approved by the Institutional Review Board of the Leiden University 
Medical Center and all participants provided informed consent.
Patients with acute PE
All patients with proven PE in our hospital are registered in the hospital administration data-
base. Consecutive adult patients with no medical history of VTE and who were diagnosed with 
a first PE between January 2001 and July 2004 were included in this study. The diagnosis of PE 
was based on either a positive CT angiogram or a ventilation perfusion scintigraphy indicating 
a high probability for PE. Data on risk factors for PE were derived from the discharge status 
of the patients. Unprovoked PE was defined as PE occurring in the absence of risk factors, i.e. 
active malignancy, immobility more than 3 days or recent long flight, recent surgery or fracture 
of extremity, pregnancy or peri-partum period, hormone replacement therapy and use of oral 
contraception. Patients were treated according to hospital policy, initially with therapeutic 
doses of unfractionated heparin or low molecular weight heparin followed by vitamin K 
antagonists (VKA). Since VKA therapy has been shown to reduce the risk for myocardial infarc-
tion12, patients with an additional indication for VKA therapy, in whom these anticoagulants 
could not be withdrawn after a six months treatment period, were excluded from this analysis.
Patients in whom acute PE was suspected but ruled out
The control cohort consisted of patients in whom PE was clinically suspected but ruled out by 
either an unlikely probability (Wells rule ≤4 points13) in combination with a normal D-dimer 
test or a CT scan without signs of PE, followed by a three months follow-up period without the 
occurrence of subsequent symptomatic VTE. Consecutive patients without PE were recruited 
between November 2002 and September 2004 and included in a diagnostic management 
study.14 Only patients that had presented to our hospital and without a medical history of VTE 
or indication for VKA therapy were included in the present analysis.
Statistical analysis
We assessed the incidence of subsequent arterial cardiovascular events in patients with 
provoked and unprovoked PE in comparison to patients in whom PE was ruled out. Because 
we intended to study the role of PE as risk factor for arterial cardiovascular events by defining 
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patient groups with similar baseline risk characteristics, we performed the same analysis after 
exclusion of patients who had experienced prior arterial cardiovascular events. In addition, to 
rule out the initial effect of oral anticoagulation therapy, a third analysis was performed in which 
the start date was set at the time the oral anticoagulant therapy was discontinued, i.e. the treat-
ment duration was six months, and no recurrent VTE had occurred in the patients with PE, and 
six months after PE was excluded in the control patients. The Kaplan-Meier life table method 
was used to estimate the cumulative event rate. Patients with recurrent VTE during follow-up or 
death not associated with any cardiovascular event were censored. A Cox proportional hazard 
model was used to calculate hazard ratios (HR). After multivariate analysis, these were adjusted 
for potentially important confounders including sex, age, malignancy, smoking status, blood 
pressure or lipid lowering medication, anti-platelet therapy, hormonal contraception, diabetes 




In the study period, 379 patients were diagnosed with a first PE of whom 356 patients had 
no additional indication for VKA therapy. In addition, 364 controls were registered.12 We were 
not able to collect full study information in 30 patients without PE and 2 patients with PE 
because they refused cooperation (n=2), lived abroad (n=7), were not registered with a gen-
eral practitioner (n=12) or we did not succeed in retrieving up-to-date contact specifications 
(n=11). The final diagnosis in the 334 patients in whom acute PE was suspected but ruled out 
was musculoskeletal disease in 37 patients (11%), non infectious or malignancy associated 
pulmonary disease in 43 (13%), gastrointestinal disease in 17 (5.1%), infectious disease in 84 
(25%), malignancy related in 47 (14%), cardiovascular disease in 33 (9.9%) and other/unknown 
in 73 patients (22%). Of the 33 patients with cardiovascular disease, 13 had no prior history 
of cardiovascular events and were discharged with newly prescribed secondary preventive 
medication, e.g. statins, anti-platelet or blood pressure lowering medication. The remaining 20 
patients were already treated with these medications.
General characteristics of the total study population (n=688) are depicted in Table 1. There 
was a difference in the male to female ratio, age and prevalence of active malignancy between 
the study groups. The fraction of active smokers, the prevalence of diabetes and the use of 
blood pressure lowering, anti-platelet and lipid-lowering medication was not different between 
the three study groups. The median follow-up period of the patient cohort was 1451 days 
(interquartile range 337-1867) and of the control population 1558 days (interquartile range 
1320-1789). The total number of patient years was 1284 for the controls, 817 for the patients 
















Sex (Female, %)* 211 (63) 137 (53) 49 (55)
Age (mean ±SD)*† 48 ±17 52 ±18 55 ±17
History of arterial cardiovascular events (n, %)† 40 (12) 38 (15) 17 (18)
Active malignancy (n, %)*† 46 (14) 103 (40) -
Diabetes (n, %)† 17 (5.1) 12 (4.6) 6 (6.3)
Active smoker (n, %)† 110 (33) 78 (30) 30 (32)
Use of blood pressure lowering medication (n, %)‡ 107 (32) 91 (35) 34 (36)
Use of anti platelet therapy (n, %)‡ 50 (15) 37 (14) 17 (18)
Use of lipid lowering medication (n, %)‡ 57 (17) 42 (16) 18 (19)
Number of patient years in follow-up 1284 817 349
‡After hospital discharge; †at time of presentation with clinically suspected acute PE; *significantly 
different. PE=pulmonary embolism, SD=standard deviation.
Venous events
Thirty-seven patients experienced symptomatic recurrent VTE during follow-up. Recurrent VTE 
occurred in 12 patients with unprovoked PE with a total of 55.2 patient years (py; incidence 
16/100 py), in 17 patients with provoked PE with a total of 68.4 py (8.4/100 py) and in 8 patients 
without PE with a total of 22.7 py (1.8/100 py; Table 2). The risk for recurrent VTE was increased 
in patients with unprovoked PE compared to patients with provoked PE and patients without 
PE (relative risk 1.92, 95% confidence interval [CI] 0.96-3.9 and 5.27, 95% CI 2.2-13, respectively), 
and in patients with provoked PE compared to patients without PE (2.74, 95% CI 1.2-6.3).
Table 2. Distribution of arterial cardiovascular events and (recurrent) venous thromboembolic events 






































RR 95% CI RR 95% CI RR 95% CI RR 95% CI
CVE 63 (5.1) 26 (4.1) 17 (3.4) 20 (13) 1.34 0.83-2.2 2.70 1.6-4.6 0.84 0.47-1.5 3.21 1.8-5.8
MI 14 (0.89) 4 (0.31) 4 (0.40) 6 (4.2) 2.35 0.93-6.0 5.27 1.9-14 1.29 0.42-4.0 4.09 1.5-11
ST 21 (1.3) 6 (0.87) 6 (0.92) 9 (3.7) 2.35 0.93-6.0 5.27 1.9-14 1.29 0.42-4.0 4.09 1.5-11
OT 28 (2.9) 16 (2.9) 7 (2.1) 5 (5.0) 0.71 0.34-1.5 1.10 0.41-2.9 0.56 0.24-1.4 1.95 0.63-6.0
VTE 37 (6.0) 8 (1.8) 17 (8.4) 12 (16) 3.42 1.6-7.4 5.27 2.2-13 2.74 1.2-6.3 1.92 0.96-3.9
CVE=any cardiovascular event, MI=myocardial infarction, ST=stroke, OT=other, VTE=(recurrent) venous 
thromoembolism, RR=relative risk, PE=pulmonary embolism, CI=confidence interval.
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Deaths
A total of 176 deaths were recorded during the study period. The most frequent cause of death 
was malignancy (93 cases, 53% of all deaths). Five patients died as a result of myocardial infarc-
tion and five as result of severe stroke.
Arterial cardiovascular events
In total, 63 arterial cardiovascular events occurred with a total of 125 py (incidence 5.1/100 py; 
Table 2). Patients with unprovoked PE had a higher incidence of arterial cardiovascular events 
(20 events in 44.7 py; 13/100 py) than the patients with provoked PE (17 arterial cardiovascular 
events in 28.1 py; 3.4/100 py) and control patients without PE (26 events in 52.6 py; 4.1/100 py). 
In addition, risks for the occurrence of any arterial cardiovascular event as well as for myocardial 
infarction and for stroke were increased in the patients with unprovoked PE compared to the 
patients with provoked PE and patients without PE (Table 2). Only slight, non significant differ-
ences in the incidence of arterial cardiovascular events were found between overall PE patients 
and controls.
Kaplan Meier analysis showed no differences between the event free survival of all PE 
patients compared to control patients without PE (Figure 1). Corrected for prior arterial events, 
sex, age, active malignancy and use of oral anticonceptive medication, HR of all patients with 

























Figure 1. Cumulative arterial cardiovascular event rate in PE patients and control patients without 
pulmonary embolism (PE).
When PE patients were categorized in provoked and unprovoked PE, clear differences emerged 
in the arterial cardiovascular event free survival between patients with unprovoked PE and 







much different between patients with provoked PE and control patients without PE. Adjusted 
HR of patients with unprovoked PE was increased compared to patients with provoked PE (2.18; 
95% CI 1.1-4.5) and control patients without PE (2.62; 95% CI 1.4-4.9).
Prior arterial cardiovascular events were found to be an important predictor for the reoccur-
rence of arterial cardiovascular events in the follow-up period (OR 3.10; 95% CI 1.8-5.3). When all 
study patients with and without PE with a history of arterial cardiovascular events (n=95) were 
excluded from the analysis, adjusted hazards of patients with unprovoked PE was increased 
versus both patients with provoked PE (2.73; 95% CI 1.1-7.0) and control patients without PE 
(3.72; 95% CI 1.6-8.4). No differences were detected between the patients with provoked PE and 
the control patients without PE.
The corrected HR of the third analysis six months after initial presentation and after dis-
continuation of anticoagulant therapy was not different between all patients with PE and the 
control patients without PE (1.31; 95% CI 0.74-2.3). In contrast, the cumulative arterial cardio-
vascular event rate in patients with unprovoked PE was higher than this cumulative event rate 
in patients with provoked PE (HR 3.24; 95% CI 1.4-7.7) and control patients without PE (HR 2.85; 
95% CI 1.4-5.6, Figure 3).
DISCUSSION
Our data demonstrate that the incidence of arterial cardiovascular events for all patients with PE 
was not increased compared to the control patients without PE. However, patients diagnosed 


























Figure 2. Cumulative arterial cardiovascular event rate in patients with unprovoked pulmonary embolism 
(PE), with provoked PE and in control patients without PE.
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vascular events than patients with a first provoked PE and our control population without PE. 
In addition, this event free survival disadvantage was still demonstrated after exclusion of 
all PE and control patients with prior arterial cardiovascular events and after redefining the 
study start date to the moment the VKA treatment was discontinued in the patients initially 
diagnosed with acute PE.
Our study design was different from previous reports on selection of control patients, start 
date and definition of end-points. Since our study was designed to compare the incidence of 
arterial cardiovascular events in PE patients and control patients without PE but with compa-
rable risk characteristics, the results firmly establish the earlier described increased occurrence 
of arterial cardiovascular events after unprovoked VTE.7-9 In addition, we performed an addi-
tional analysis to rule out the possible confounding effect of VKA and censored all patients 
that developed VTE during the study period. Our finding that control patients without PE and 
patients with provoked PE have the same arterial cardiovascular event-free survival supports 
the hypothesis that a shared but yet unidentified mechanism causes events in both venous and 
arterial systems. Suggested attributive factors are shared risk factors or etiological pathways as 
thrombogenesis, endothelial damage or inflammation.2 Unfortunately, our dataset does not 
allow us to determine whether unprovoked PE and (early) arterial cardiovascular events are 
each caused separately by a shared pathway or the occurrence of (early) arterial cardiovascular 
events after venous thromboembolism is related more causally. Future studies should further 
investigate the pathogenesis behind the observed associations.
Strengths of our study include the long term follow-up of a large and unselected, consecutive 




























Figure 3. Cumulative arterial cardiovascular event rate in patients with unprovoked pulmonary embolism 
(PE), with provoked PE and in control patients without PE starting after a six months treatment period for 







clinically suspected but ruled out PE.12 Third, we used clear definitions for our inclusion criteria 
and endpoints. The latter are serious medical events that are likely to be recorded accurately.
Limitations of this study comprise the lost to follow-up rate of 4.4% and the relatively limited 
number of patients in the unprovoked PE cohort. Also, although we aimed at including a con-
trol group for patients with acute PE with similar baseline risk characteristics for cardiovascular 
disease, several relevant demographics as age, sex, medical history and use of medication were 
different between the patients with and the patients without PE. Nonetheless, HRs proved 
to be significantly elevated for patients with unprovoked PE after adjusting for these factors. 
Furthermore, since contrast echocardiography was not routinely assessed after the diagnosis 
of PE, we could not evaluate the possibility of paradoxical embolism as the cause of subse-
quent arterial events in some patients. Finally, although a predefined diagnostic algorithm for 
patients with suspected acute PE has been used in all patients, we could not fully correct for 
possible differences in sensitivity of the diagnostic tests or changes in diagnostic algorithms for 
our endpoints over time.
In summary, this study demonstrates that patients with a first unprovoked PE are at higher risk 
of developing arterial cardiovascular events than patients with a first provoked PE and specific 
control patients in whom PE was clinically suspected but ruled out. These results justify large 
studies to study the underlying pathophysiological mechanisms that cause the increased risk 
of arterial cardiovascular events after PE and to identify specific patients at very high risk. These 
latter patients might benefit from modified treatment regimens to prevent the occurrence of 
arterial cardiovascular disease, including preventive use of antiplatelet and cholesterol synthe-
sis inhibiting treatment.
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To assess the long term risk for adverse events after acute pulmonary embolism (PE).
Methods
Consecutive patients diagnosed with PE between January 2001 and July 2007, and patients in 
whom PE was ruled out from a previous study were followed until July 2008 for the occurrence 
of adverse clinical events: mortality, symptomatic recurrent venous thromboembolism (VTE), 
cancer, arterial cardiovascular events and chronic thromboembolic pulmonary hypertension 
(CTEPH). Hazard ratios (HR) for all endpoints and a combined endpoint were calculated and 
adjusted for potential confounders.
Results
308 patients with unprovoked, 558 with provoked and 334 without PE were studied with a 
median follow-up period of 3.3 years. Patients with unprovoked PE had lower overall risk for 
mortality than patients with provoked PE (HR 0.59, 95% CI 0.43-0.82), but higher risk for non-
malignancy related mortality (HR 1.8, 95% CI 1.3-2.5), recurrent VTE (HR 2.1, 95% CI 1.3-3.1), can-
cer (HR 4.4, 95% CI 2.0-10), cardiovascular events (HR 2.6, 1.5-3.8) and CTEPH (1.5% vs 0%). The 
risk for the combined endpoint did not differ between both groups (HR 0.98, 95% CI 0.82-1.1). 
Patients without PE had similar risks for malignancy and cardiovascular events than patients 
with provoked PE, but lower risks for the remaining outcomes. The fraction of both patients 
with provoked and unprovoked PE without events after 1 year was only 70%, and decreased to 
fewer than 60% after 2 years and fewer than 50% after 4 years, whereas this latter was 84% for 
the control patients.
Conclusion
The clinical course of acute PE is complicated by high rates of serious adverse events, which 
occur in half of the patients within 4 years.
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INTRODUCTION
Acute pulmonary embolism (PE) is a common and potentially serious medical condition.1 The 
interaction of an extensive pulmonary artery obstruction rate and presence of cardiopulmonary 
comorbidity may lead to right ventricular dysfunction, which is associated with hemodynamic 
instability and, in severe cases, with death.2 This PE attributable mortality occurs in approxi-
mately 2-6% of patients with hemodynamically stable PE and in 30% or more of patients with 
PE presenting with hemodynamic instability or in shock.2-4 Of note, 25% of the patients do 
not survive the first year after diagnosis, although the majority of deaths during this time are 
related to underlying conditions, such as cancer or chronic heart disease, rather than to PE 
itself.3,4 Even after surviving the acute episode, the clinical course of acute PE can be compli-
cated by several thrombotic and non-thrombotic adverse events. Bleeding complications and 
recurrent episodes of venous thromboembolism (VTE) are common and chronic obstruction 
of the pulmonary vessels with organized blood clots may lead to chronic thromboembolic 
pulmonary hypertension (CTEPH).4-8 This latter disease is further characterized by pulmonary 
arteriopathy and progressive right heart failure.8 Furthermore, it has been well established that 
patients with acute PE are at higher risk of being subsequently diagnosed with cancer as well 
as with arterial cardiovascular events than population controls.9,10 The prognosis of patients 
diagnosed with unprovoked PE, i.e. PE occurring in the absence of established risk factors or 
predisposing illnesses, might be less favorable than that of patients suffering from provoked PE. 
Several studies have shown that patients with unprovoked PE are at particular risk for recurrent 
PE, CTEPH, arterial cardiovascular events and the detection of cancer.10-15
Although all individual complications of PE have been studied extensively, the combined risk 
for all adverse clinical events has not been reported yet. Knowledge of this short and long term 
prognosis after acute PE is of great importance since this should guide clinical decision making 
regarding treatment regimes, specific preventive screening programs and follow-up duration. 
Accordingly, we have performed a prospective cohort study evaluating the overall occurrence 
of complications in the clinical follow-up of patients diagnosed with acute PE. We contrasted 
the studied complication rate in patients with unprovoked PE to patients with provoked PE and 
to a control group of patients in whom PE was suspected but ruled out.
METHODS
Patients
The original admission charts of all consecutive in- and outpatients diagnosed with acute PE 
between January 1st 2001 and July 1st 2007 in an academic (Leiden University Medical Center, Lei-
den, the Netherlands) and affiliated teaching hospital (Medical Center Haaglanden, The Hague, 







acute PE, i.e. intraluminal filling defects on pulmonary angiography or computed tomography 
pulmonary angiography (CTPA), high probability ventilation perfusion scintigraphy (VQ-scan) 
or intermediate probability VQ-scan in combination with objectively diagnosed deep vein 
thrombosis (DVT).15,16 All patients fulfilling these criteria were included in this analysis. Patients 
were initially treated with at least 5 days of either unfractioned heparin or weight based thera-
peutic doses of low molecular weight heparin, followed by vitamin K antagonists for a period 
of at least 6 months with a target international normalized ratio (INR) of 2.0 to 3.0.17 In patients 
with severe acute PE presenting with hemodynamic instability, anticoagulant treatment was 
preceded by administration of thrombolytic drugs, thrombosuction or surgical embolectomy 
according to the judgment of the attending clinician. The control cohort consisted of patients 
in whom PE was clinically suspected but ruled out by either an unlikely probability (Wells rule 
≤4 points) in combination with a normal high sensitive D-dimer test or a CT scan without signs 
of PE. These patients were recruited for participation in a previous outcome study between 
November 2002 and September 2004.18
Procedures
Detailed information regarding diagnostic management, cause, treatment and documented 
clinical course of the index PE were extracted from the medical charts of the included patients 
with and without PE. When a patient had died, the pathology report was scrutinized to establish 
the cause of death. In case autopsy was not performed, the likely cause of death was verified 
with the treating physician or general practitioner. All surviving patients were contacted by 
mail or phone and were asked to complete our data with the latest information regarding their 
medical history and clinical condition. Patients living abroad or for whom up-to-date contact 
specifications were not available were excluded. This study was approved by the Institutional 
Review Board of both participating hospitals and all patients provided informed consent.
Outcome
Unprovoked PE was defined as PE occurring in the absence of the following risk factors: active 
malignancy, immobility more than 3 days or recent long flight, recent surgery or fracture of 
extremity, pregnancy or peri-partum period and use of oral contraception or hormone replace-
ment therapy.1 All cause mortality, symptomatic recurrent VTE, i.e. acute PE as well as deep vein 
thrombosis, CTEPH, arterial cardiovascular events or detection of a previously unknown malig-
nancy were considered to be adverse events in the clinical course of acute PE. Only information 
on anticoagulant related fatal bleeding was available. Recurrent PE was defined as 1) a new 
filling defect revealed by pulmonary angiography or spiral CTPA or 2) a new high probability 
perfusion defect revealed by VQ-scan or 3) any new defects after earlier normalizing of the 
scan.6,7 Criteria for the diagnosis of CTEPH were mean pulmonary artery pressures assessed by 
right heart catheterization exceeding 25 mmHg respectively and normal pulmonary capillary 
wedge pressure in combination with an abnormal perfusion scintigram and signs for CTEPH on 
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pulmonary angiography.8 Arterial cardiovascular events were defined as clinically adjudicated 
acute myocardial infarction, stroke or transient ischemic attack, claudication, unstable angina, 
carotid endarterectomy, coronary artery bypass graft, peripheral arterial bypass or angio-
plasty.13,19 Apart from standard clinical work-up for expected acute PE, the included patients 
were not systematically screened for occult cancer in neither of the 2 participating hospitals. 
Thus, the patients in whom cancer was detected had developed symptomatic malignant dis-
ease or the cancer was an accidental finding during regular clinical care.
Statistical analysis
All patients were followed from the index event to the date of death or July 1st 2008, whichever 
came first. The Kaplan-Meier life table method was used to estimate the event free survival 
for all individual study endpoints and for the combined endpoint of adverse outcome in 
patients with unprovoked, provoked and without PE. For this latter analysis, the adverse event 
that occurred first was accounted for. The Log-Rank test was used for comparing the 3 study 
groups for statistical differences. A Cox proportional hazard model was used to calculate hazard 
ratios (HR) for adverse clinical events. HRs were adjusted for age, sex and in addition all further 
relevant patient demographics; recurrent VTE and CTEPH for initial treatment; malignancy for 
active smoking; cardiovascular events for active smoking, diabetes and use of anti-platelet/
lipid-lowering/blood pressure-lowering medication; mortality for left sided heart failure, COPD 
and active malignancy; and overall adverse events for all above mentioned potential confound-
ers. SPSS version 14.02 (SPSS Inc, Chicago, IL) was used for all analysis.
RESULTS
Patients
The diagnosis of acute PE had been established in 877 patients between January 1st 2001 
and July 1st 2007 in the 2 participating hospitals. Eleven patients were excluded because of 
geographical inaccessibility (1.3%), leaving 866 patients for analysis. In addition, 334 patients 
without PE were included. The final diagnosis in the 334 patients in whom acute PE was 
suspected but ruled out was infectious disease in 84 (25%), non infectious or malignancy 
associated pulmonary disease in 43 (13%), complications of an active malignancy in 47 (14%), 
musculoskeletal disease in 37 patients (11%), cardiovascular disease in 33 (9.9%), gastrointes-
tinal disease in 17 (5.1%) and other/unknown in 73 patients (22%). General characteristics of 
the study patients are presented in Table 1: the patients without PE were significantly younger 
than the patients with provoked and unprovoked PE (48 ±17 vs. 55 ±18 and 59 ±17 years 
respectively). In addition, the fraction of male patients was lowest in the patients without PE 
(37% vs. 47% and 48% respectively). Further, the presence of comorbidity and cardiovascular 







was most frequently present in patients with provoked PE. Lastly, the patients with unprovoked 
and provoked PE received comparable anticoagulant treatment. The median follow-up period 
for the complete study population was 3.3 years.
Risk for recurrent VTE and CTEPH
Symptomatic recurrent VTE was diagnosed in 64 (21%) patients with unprovoked PE and in 
54 (9.7%) patients with provoked PE (Table 2, Figure 1) during follow-up. The adjusted HR for 
recurrent VTE was increased for patients with unprovoked versus provoked PE (2.1, 95% CI 1.3-
3.1) and versus patients without PE (10, 95% CI 4.9-28). Patients with provoked PE had higher 
risk on recurrences than the control patients as well (adjusted HR 6.0, 95% CI 2.8-13). Recurrent 
PE was fatal in 22 of the 118 patients initially diagnosed with PE (19%, 95% CI 12-27%), and in 1 
of the 4 (25%, 95% CI 0.06-81%) VTE diagnoses in the control patients. Recurrences within the 
first 3 weeks after the index diagnosis were associated with significantly higher mortality (Odds 
Ratio 7.9, 95% CI 1.2-51). CTEPH was only diagnosed in 4 patients after unprovoked acute PE 
(cumulative incidence 1.5%), and not in the patients with provoked PE or without PE (Table 2). 
The 4 patients diagnosed with CTEPH were all in stable clinical condition at the end of the 
follow-up period.
Risk for malignancy and arterial cardiovascular events
The risk for cancer was higher for the patients after unprovoked PE than for the patients with 
provoked (adjusted HR 4.4, 95% CI 2.0-10) and without PE (adjusted HR 2.5, 95% CI 1.1-2.7; 







Age at index event (years ±SD) 59 ±17*¶ 55 ±18¶ 48 ±17
Male sex (n, %) 149 (48)¶ 261 (47)¶ 123 (37)
Initial treatment†
Low molecular/unfractioned heparin (n, %) 285 (93) 523 (94) NA
Thrombolysis (n, %) 14 (4.5) 24 (4.3) NA
Surgery, VCF or both (n, %) 9 (2.9) 11 (2.0) NA
COPD† (n, %) 26 (8.4) 57 (10) 33 (9.9)
Left sided heart failure† (n, %) 16 (5.2) 26 (4.7) 11 (3.3)
Active malignancy† (n, %) 0 (0)*¶ 201 (36)¶ 46 (14)
Diabetes† (n, %) 18 (5.8) 27 (4.8) 17 (5.1)
Active smoking† (n, %) 102 (33) 172 (31) 110 (33)
Anti-platelet/lipid-lowering/blood pressure-lowering 
medication‡ (n, %)
151 (49) 240 (43) 147 (44)
†At index event; ‡at hospital discharge after index event; *p<0.05 vs. provoked PE; ¶p<0.05 vs. No PE. 
Continuous parameters were compared using ANOVA with Bonferroni post-hoc testing; bivariate 
variables were compared by the Chi-Square test. PE=pulmonary embolism, SD=standard deviation, 
n=number, VCF=vena cava filter, COPD=chronic obstructive pulmonary disease, NA=not applicable.
A pooled survival analysis of adverse events after pulmonary embolism 147
Table 2, Figure 1). There was no difference in the rate of newly diagnosed malignancies between 
patients with provoked and without PE (adjusted HR 0.78, 95% CI 0.26-1.4). In 27 of the 31 
patients with PE (87%, 95% CI 70-96%) who were diagnosed with cancer, this malignancy was 
detected within the first year after the index PE. Patients with unprovoked PE suffered severe 
cardiovascular disease 2 to 3 times more often than the patients from the other two study 
cohorts (adjusted HR 2.6, 95% CI 1.5-3.8 and 2.4, 1.2-3.7 respectively; Table 2, Figure 1). Patients 
with PE, who suffered arterial cardiovascular events or were diagnosed with cancer had case 
fatality rates of 14% (95% CI 7.0-24) and 19% (95% CI 7.5-37) respectively.
Risk for mortality
In total, 259 (30%) patients with PE died, mainly as a result of a malignancy (110 patients, 13%). 
Furthermore, 67 (7.7%) patients died of (recurrent) PE, 6 (0.69%) because of severe bleeding 
from anticoagulant therapy, 30 (3.5%) of cardiovascular disease, 11 (1.3%) of non-malignant 
pulmonary disease and 35 (4.2%) of other causes. Twenty-nine patients without PE died during 
the study period (8.7%): 1 of acute PE (0.30%), 1 of myocardial infarction (0.30%), 4 of non-
ischemic heart diseases (1.2%), 3 of non-malignant pulmonary disease (1.2%), 12 of malignan-
cies (3.6%) and 8 by other causes (2.4%). Risk for overall mortality in patients after unprovoked 
PE was lower than in patients after provoked PE (adjusted HR 0.59, 95% CI 0.43-0.82; Table 2, 
Figure 1). Intriguingly, the patients with unprovoked PE who by definition did not suffer from 
Table 2. Event free survival and hazard ratios for patients with provoked and unprovoked acute PE.











N Event free 
survival§ 
(±SE)
N Event free 
survival§ 
(±SE)
N Event free 
survival§ 
(±SE)




2.1 (1.3-3.1) 10 (4.9-28) 6.0 (2.8-13)
CTEPH 4 0.99 ±0.007 0 * 0 * * * *












2.6 (1.5-3.8) 2.4 (1.2-3.7) 1.1 (0.72-
1.5)






1.4 (1.1-1.8) 3.0 (2.0-4.5)
Adverse 
outcome‡




0.98 (0.82-1.1) 2.6 (1.9-3.6) 2.9 (2.1-3.8)
§Estimated by Kaplan-Meier life table method after 2500 days; †hazard ratio’s were adjusted for age, 
sex and in addition all further relevant patient demographics; recurrent VTE and CTEPH for initial 
treatment, malignancy for active smoking, cardiovascular events for active smoking, diabetes and use 
of anti-platelet/lipid-lowering/blood pressure-lowering medication, mortality for left sided heart failure, 
COPD and active malignancy, and overall adverse events for all above mentioned; ‡combined endpoint; 
*could not be calculated due to 0-value. PE=pulmonary embolism, VTE=venous thromboembolism, 
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active malignancies at time of the index event, were at higher risk for dying than the non-
cancer patients with provoked PE (adjusted HR 1.8, 95% CI 1.3-2.5). Patients with unprovoked as 
well as with provoked PE had higher risks for death than the control patients (adjusted HR 1.4, 
95% CI 1.1-1.8 and 2.9, 95% CI 2.1-3.8 respectively).
Risk for overall adverse outcome
The prognostic differences between patients with unprovoked and provoked PE disappeared 
after combining all adverse events to one pooled endpoint of adverse outcome (adjusted 
HR 0.98, 95% CI 0.82-1.1; Table 2, Figure 1). Nonetheless, both groups had significantly worse 
prognosis than the control patients without PE (adjusted HR 2.6, 95% CI 1.9-3.6 and 2.9, 2.1-
3.8 respectively). Importantly, the fraction of PE patients without any event after 1 year was 
only 69% and decreased to 60% after 2 years and 50% after 4 years (Table 3, Figure 1). These 
numbers were applicable to both patients with unprovoked as well as with provoked PE. The 
patients without PE had significant higher event free survival with 84% of the patients surviving 
without any of the adverse events after a follow-up period of 4 years.
Table 3. Yearly overall event free survival for patients with unprovoked, provoked and without acute PE.
Follow-up 
period
Unprovoked PE (n=308) Provoked PE (n=558) Overall PE 
(n=866)
No PE (n=334)
NLFA Event free 
survival§ (±SE)




NLFA Event free 
survival§ (±SE)
1 year 212 0.70 ±0.026 379 0.68 ±0.020 0.69 ±0.016 298 0.94 ±0.014
2 years 151 0.59 ±0.028 280 0.61 ±0.021 0.60 ±0.017 275 0.90 ±0.017
3 years 108 0.52 ±0.030 195 0.56 ±0.022 0.54 ±0.018 265 0.87 ±0.019
4 years 78 0.48 ±0.031 122 0.54 ±0.023 0.51 ±0.018 203 0.84 ±0.021
5 years 52 0.45 ±0.032 76 0.50 ±0.025 0.48 ±0.019 78 0.80 ±0.024
6 years 31 0.44 ±0.034 37 0.48 ±0.027 0.46 ±0.021 26 0.77 ±0.038
7 years 14 0.42 ±0.038 16 0.47 ±0.028 0.45 ±0.024 9 0.76 ±0.041
§Estimated by Kaplan-Meier life table method. PE=pulmonary embolism, SE=standard error, n=number, 
NLFA=number left for analysis.
DISCUSSION
We aimed to evaluate the long term overall prognosis of patients after acute PE. Two important 
conclusions can be drawn from this analysis. First, we have demonstrated that after 1 year of 
follow-up, only 70% of the patients are free of adverse outcome and notably, after a period of 
4 years, half of the patients developed one or more serious clinical complications. A control 
cohort consisting of patients in whom PE was suspected but ruled out had significantly higher 
event free survival. Second, although risks for the occurrence of specific adverse events differed 







endpoint of adverse outcome was similar between the two patient groups, both higher than 
for the control patients without PE.
The importance of our findings is underlined by the complication specific prognosis, which 
is poor for all adverse events studied in this analysis. First, the index PE itself had a mortality 
rate of 5.2%, which compares well to the existing literature.1-4 Second, recurrent VTE was diag-
nosed in 118 patients. Previous studies have shown that thrombotic recurrences are associated 
with increased mortality.6,7 The case fatality rate in our study was 19% in the complete study 
period and even 60% within the first 3 weeks after the index diagnosis. This 3 weeks mortality 
rate is comparable to the range of 51-79% that was reported in earlier studies.6,7,20 In addi-
tion, according to the latest ACCP guidelines, recurrent VTE should be treated with long term 
anticoagulant therapy (Grade 1A), which is associated with an increased risk of often severe 
bleeding complications.17 Third, cancer diagnosed at the same time as or shortly after the 
diagnosis of VTE is a bad prognostic sign, as this is associated with more advanced stages of 
cancer and a poor prognosis.21 Sørensen et al have shown that patients in whom cancer was 
diagnosed within one year after the diagnosis of VTE had an increased risk of distant metastasis 
at the time of diagnosis and a relatively low rate of survival compared to patients with cancer 
without a history of VTE.21 In our population, cancer diagnosed after the index PE proved to 
be fatal in 19% of the cases within the follow-up period. The association between unprovoked 
PE and the subsequent development of clinically overt cancer is most likely explained by the 
fact that these cancers are already present at the time of, and may even be causally related 
to the PE, although not yet detected.11 Fourth, although the exact mechanism underlying 
the association between arterial cardiovascular events and VTE is unknown, evidence exists 
that both diseases are closely linked.9,13 The observation that control patients without PE 
and patients with provoked PE have the same risk for arterial cardiovascular events, which is 
significantly lower than for patients after unprovoked PE, supports the hypothesis that a shared 
but yet unidentified mechanism causes events in both the venous and the arterial system.13 
Arterial events such as myocardial infarction or stroke have great implications for the patients’ 
health and lead to high morbidity and mortality rates and decreased quality of life.22 Lastly, four 
patients were diagnosed with CTEPH (cumulative incidence in patients with unprovoked PE 
1.5%). This percentage is relatively low compared to some recent studies reporting incidences 
of 3.8 and even 8.8% in patients after PE.14,23 This discrepancy might very well be explained 
by different selection criteria than in previous studies, or by underdiagnosis of CTEPH in our 
cohort, although the included patients with PE were systematically screened for the presence 
of pulmonary hypertension.15 Even though none of our four patients with CTEPH died during 
the study period, it has previously been shown in larger cohorts that the prognosis of patients 
with CTEPH is rather poor, unless a successful pulmonary endarterectomy is achievable.8
Thus, we have combined 4 very serious complications of PE as well as all cause mortality 
in this analysis. The pooled endpoint of adverse outcome was reached by 50% or more of the 
patients with PE after 4 years of follow-up, which is significantly more than for the control 
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patients. Remarkably, this overall prognosis is comparable for patients with unprovoked and 
patients with provoked PE. This latter observation was mainly driven by the malignancy related 
high mortality rates in the patients with provoked PE. Further analysis showed that patients 
with unprovoked PE have in fact the highest risk on non-malignancy related mortality and all 
the other included endpoints. These findings emphasize that acute PE is an important clinical 
problem with poor prognosis for short and long term survival and the occurrence of serious 
thrombotic or non-thrombotic adverse events.
Many risk stratification and screening strategies including intensified or prolonged anti-
thrombotic therapy regimes to identify and treat patients with high risk for PE-related mor-
tality, recurrent VTE or detection of cancer have been proposed, but all remain insufficient or 
controversial.17,24-27 An earlier study concluded that treatment of heparin and anticoagulants is 
not enough for all PE patients.28 Our results, although almost 30 years later, confirm this conclu-
sion and once more emphasize the poor overall prognosis of patients with acute PE. In current 
clinical practice and despite the increased risk for serious clinical complications, patients with 
a first episode of acute PE stop their anticoagulant therapy usually after three to six months.17 
From then on, they are usually no longer subject to clinical supervision by a medical specialist. 
Importantly, by lack of scientific based evidence and proven cost-efficacy, standard screening 
for classic cardiovascular risk factors, hidden cancer or CTEPH is at this moment not part of 
routine clinical work-up of patients with PE. Our results underline the importance of close clini-
cal surveillance in the first months after PE, especially in those patients with unprovoked PE, 
to evaluate the basic risks for future adverse events and in addition, treat patients accordingly. 
Therefore, future outcome studies should focus on 1) better individual assessment of the risk 
for recurrent venous thromboembolism and CTEPH to enable the physician to identify those 
patients who could benefit from prolonged anticoagulant therapy or specific screening for 
pulmonary hypertension; 2) effectiveness of cardiovascular risk factor evaluation and proper 
treatment measures to prevent arterial cardiovascular events; and 3) effect of specific screening 
programs for underlying malignancies, to achieve very early identification of hidden malignan-
cies thereby potentially improving the patients’ prognosis.
Our study has strengths and limitations. Our findings are likely to be generalizable to most 
patients with PE since we have included all consecutive patients diagnosed with this disease 
in an academic and non-academic teaching hospital independently of their clinical condition 
or comorbidity. Even though our study endpoints are severe clinical events that are likely to 
be recorded in detail, we have additionally verified the accuracy and completeness of the data 
from the medical charts with the surviving patients. Only 11 patients with PE (1.3%) who could 
not be reached due to geographical inaccessibility, were excluded. Furthermore, our findings 
are in accordance with the extensive literature on this subject, although we are the first to 
combine all adverse events into 1 pooled endpoint. We acknowledge that we were not able to 
report on all bleeding events, which are important complications in the clinical course of acute 







to the first six months after diagnosis in the majority of patients. Moreover, the most severe 
bleedings that resulted in mortality could in fact be accounted for.
We conclude that acute PE remains a very serious clinical condition with high mortality and 
high risk on PE associated severe complications. Remarkably, there was no difference in the 
pooled risk for adverse outcome of patients with unprovoked and provoked PE, although the 
risk on all separate endpoints except for overall mortality was markedly higher for the patients 
with unprovoked PE. Physicians should be well aware of the fact that in four years time, half 
of the patients diagnosed with acute PE has died or is diagnosed with cancer, recurrent VTE, 
CTEPH or arterial cardiovascular disease. The challenge of future trials remains to enable the 
treating physician to use accurate prediction tools for adjusting treatment regimes and clinical 
surveillance to the personalized prognosis of the individual patient.
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Even though quality of life (QoL) has become a key component of medical care, there is no 
instrument available that specifically measures QoL after pulmonary embolism (PE). Recently, 
the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire has been developed to 
address this gap. We have evaluated the validity of this questionnaire.
Methods
The PEmb-QoL questionnaire and the Short Form-36 (SF-36) questionnaire were distributed 
twice among consecutive subjects with a history of objectively confirmed acute PE. Internal 
consistency reliability, test-retest reliability, convergent and criterion validity, and correlations 
between the PEmb-QoL and clinical patient characteristics were assessed using standard-scale 
construction techniques.
Results
90 participants completed the questionnaires twice. Internal consistency was adequate (Cron-
bach’s α 0.62-0.94), as well as test-retest reliability (intra-class correlation coefficients 0.78-0.94). 
Furthermore, correlation between the PEmb-QoL questionnaire and the SF-36 questionnaire 
supported the convergent and criterion validity of the PEmb-QoL. Age, obesity, cardiopulmo-
nary comorbidity, centrally located PE and a family history of venous thromboembolism were 
shown to be independent determinants of disease-specific QoL.
Conclusion
The PEmb-QoL questionnaire is a reliable instrument to specifically assess QoL following PE, 
which is helpful in the identification of patients with decreased QoL following acute PE.
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INTRODUCTION
Pulmonary embolism (PE) is a common disorder characterized by the obstruction of the 
pulmonary arterial tree by floating thrombi predominantly originating from the leg or pelvic 
veins.1 Although PE has traditionally been considered to be an acute disease, the long term 
natural course in patients surviving the acute thromboembolic event can be complicated by 
recurrent episodes of PE or deep vein thrombosis, bleeding complications caused by antico-
agulant treatment, arterial cardiovascular events and in rare cases by chronic thromboembolic 
pulmonary hypertension (CTEPH).1-4 CTEPH may present as fatigue, limited exercise tolerance 
or shortness of breath and might even affect 3.8% of PE patients within 2 years following the 
initial event.3 In addition, patients often have residual dyspnea complaints years after the acute 
thromboembolic event.5
Quality of life (QoL) has become an important outcome aspect of medical care. QoL can 
be assessed by generic or disease-specific questionnaires. The latter are more sensitive than 
generic questionnaires to detect and quantify small changes that are relevant to patients. Sev-
eral disease-specific QoL instruments have been developed for deep venous thrombosis (DVT), 
a condition closely related to PE and considered a manifestation of the same disease entity.6-10 
Furthermore, there are several specific questionnaires for symptoms of the respiratory tract, 
such as the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)11 or the Chronic 
Respiratory Disease Questionnaire (CRQ).12 However, since respiratory or other symptoms that 
affect QoL after PE have never been purposely studied, we have developed a new measure 
-the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire-, based on symptoms as 
reported by 10 interviewed participants with severe complaints following PE. Details on the 
development of the PEmb-QoL questionnaire have been described previously.13
The PEmb-QoL was modelled on the quality of life after DVT (VEINES-QOL/Sym) question-
naire.6,7,9 Both questionnaires assess the frequency of symptoms, the time of day at which the 
complaints are at their worst and activities of daily living (ADL) as well as work related problems. 
However, the PEmb-QoL questionnaire is distinct from the VEINES-QOL/Sym in the inclusion of 
pulmonary specific symptoms, adding questions on limitations in daily physical activities, and 
extending the number of questions on emotional functioning. Moreover, in order not to lose 
valuable information, we decided to assess the different areas of limitations as separate dimen-
sions, instead of combining items into two subscales (symptoms and QoL), as is the case in the 
VEINES-QOL questionnaire. In the present paper, we report results from the validation study 









The PEmb-QoL in Dutch was distributed among consecutive participants of a large follow-up 
study of patients with a history of acute PE referred to the Leiden University Medical Center. 
Inclusion criteria were objectively confirmed PE diagnosed between January 1st 2001 and July 
1st 2007. All surviving patients were invited for a control visit in our outpatient clinic. We asked a 
random, consecutive subsample of 93 participants to complete the PEmb-QoL and Short-Form 
36 (SF-36) questionnaires shortly before this visit. After first review, incomplete questionnaires 
were completed at the study visit. For assessment of test-retest reliability, participants were 
instructed to complete both questionnaires for a second time (within a two week period) at 
home shortly after the visit and return these by mail. Incomplete returned questionnaires were 
completed by the patients following contact by telephone. We excluded participants with 
language barriers who could not complete the questionnaires in Dutch. The study protocol 
was approved by the Institutional Review Board of the Leiden University Medical Center and all 
patients provided written informed consent.
PEmb-QoL questionnaire
We applied the disease specific PEmb-QoL questionnaire which we developed to assess QoL 
in patients with PE.13 The PEmb-QoL questionnaire contains 6 dimensions: frequency of com-
plaints, ADL limitations, work related problems, social limitations, intensity of complaints and 
emotional complaints. Higher scores indicate worse outcome.
SF-36 questionnaire
The SF-36 is a generic QoL measure containing 8 scales (physical functioning, social function-
ing, physical role functioning, emotional role functioning, mental health, vitality, bodily pain, 
and general health), scoring 0 to 100, with higher values indicating better health.14 Two sum-
mary scores are created by combining scales into a physical health summary score and mental 
health summary score.
Outcome measures
We expected that the PEmb-QoL dimensions frequency of complaints, ADL limitations, work 
related problems, social limitations and intensity of complaints would have higher correlations 
with the physical health summary score of the SF-36, whereas emotional complaints would 
have a higher correlation with the mental health summary score. Furthermore, we did not 
expect that patient characteristics at time of the acute PE would be important determinants of 
the results of the PEmb-Qol, given the results of a previous study.15 This study showed that QoL 
after deep vein thrombosis as assessed by the VEINES-QOL and SF-36 was mostly determined 
by the presence of the postthrombotic syndrome and less by severity of the acute clinical event, 
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comorbid conditions, sex or age. To test this hypothesis, we assessed the following patient char-
acteristics and correlated those to the results from the PEmb-QoL: age, sex, obesity (body mass 
index>30kg/m2), active malignancy (cancer with ongoing treatment, treatment within the 
previous 6 months or in the palliative stages), cardiopulmonary comorbidity (clinically relevant 
obstructive or restrictive pulmonary function impairment, or systolic or diastolic ventricular 
dysfunction), centrally located PE according to the original radiological reports, family history 
of venous thromboembolism and the duration of follow-up from the index thromboembolic 
event to study inclusion.
The outcome measures of this analysis were internal consistency reliability (which assesses 
whether several items that propose to measure the same general construct produce similar 
scores), test-retest reliability, convergent validity, criterion validity (as assessed by comparing 
the PEmb-QoL dimensions with the dimensions of the SF-36 disease generic questionnaire) 
and the association of patient demographics, comorbid conditions and PE characteristics with 
higher or lower QoL in our patient population.
Statistical Analyses
Means and standard deviations were calculated for normally distributed variables. Skewed 
distributed variables were expressed in medians with ranges. We performed a factor analysis 
on the items of the PEmb-QoL with varimax rotation to examine the underlying constructs. 
Internal consistency reliability was calculated with Cronbach’s α.16 Following the recommenda-
tions of DeVellis, internal consistency reliability was considered adequate if Cronbach’s α was 
higher than 0.7.17 Test-retest reliability was expressed as intra-class correlation coefficients. 
We calculated inter-dimension correlations and criterion validity with bivariate Spearman cor-
relation coefficients. For the assessment of significant predictors of QoL in our patient cohort, 
backward conditional linear regression analyses with direct entry were performed to identify 
independent determinants of QoL. A p-value <0.05 was considered statistically significant.
RESULTS
Patients
The questionnaires were distributed amongst 93 participants, of whom 90 completed the 
questionnaire after a median period of 38 months (range 10–91 months) following PE. Three 
participants (3.2%) were excluded due to inability to complete this questionnaire in Dutch 
because of language barriers. The number of missing items was very low; however the exact 
number could not be calculated as all missing items were completed by the respondents 
following contact by phone with the researchers. The included participants were 56 ±14 
years old, 44 (47%) were males, 19 (20%) had cardiopulmonary comorbidity, 12 (13%) had 







6 (6.5%) received invasive treatment for PE and 19 (20%) suffered from recurrent episodes of 
PE (Table 1).
Scores of the 6 dimensions of the PEmb-QoL were 1.5 (interquartile range 1.1-2.4; max 5 
points) for frequency of complaints, 1.2 (1.0-1.8; max 3 points) for limitations in activities of daily 
living (ADL), 1.0 (1.0-1.5; max 2 points) for work related problems, 1.0 (1.0-1.2; max 5 points) for 
social limitations, 2.0 (1.0-3.0; max 6 points) for intensity of complaints and 1.6 (1.1-2.4; max 6 
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Legend:
FO: Frequency of complaints
AD: ADL limitations
WR: Work related problems
SL: Social limitations





FO: 1.5 (1.1-2.4) (max 5)
AD: 1.2 (1.0-1.8) (max 3)
WR: 1.0 (1.0-1.5) (max 2)
SL: 1.0 (1.0-1.2) (max 5)
IO: 2.0 (1.0-3.0) (max 6)






Figure 1. Results of the PEmb-QoL scores of patients with a history of acute pulmonary embolism. Scores 
are presented as median with interquartile range. Minimum score for all 6 subscales was 1, maximum 
scores are presented between brackets. Higher PEmb-QoL scores are associated with decreased quality of 
life. ADL=activities of daily living, Qol=quality of life.
Table 1. Demographics of included patients.
Study patients
(n=90)
Male sex (n, %) 43 (48)
Age (years ±SD) 56 ±14
Cardiopulmonary comorbidity (n, %) 18 (20)
Active malignancy (n, %) 12 (13)
Obesity* (n, %) 35 (39)
Centrally located PE (n, %) 31 (34)
Invasive treatment for PE† (n, %) 6 (6.7)
Recurrent PE (n, %) 18 (20)
Time to registration event‡ (range) 3 years and 2 months
(10 months – 7 years and 7 months)
*Body mass index >30kg/m2; †thrombolysis, Surgery or VCF for first acute PE; ‡time span between 
registration acute PE and study inclusion. PE=pulmonary embolism, n=number.
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Psychometric characteristics of the PEmb-QoL questionnaire
Factor analysis (with varimax rotation) supported the underlying dimensions producing 6 fac-
tors which accounted for 72% of the total variance. Table 2 lists the internal reliabilities of the 
dimensions, as expressed by Cronbach’s α, as well as test-retest reliability and inter-dimension 
correlations between the PEmb-QoL dimensions. Internal reliability was high (α≥0.87) for the 
dimensions frequency of complaints, ADL limitations, work related problems, and emotional 
complaints but lower for the dimension intensity of complaints (α=0.62). We assessed whether 
deletion of any of the items in the various dimensions could increase the internal reliability of 
any of the dimensions and hence, whether the PEmb-QoL questionnaire could be abridged. 
However, deletion of any of the items from the various dimensions did not lead to substantial 
improvements of the dimensions’ internal consistency reliability.




























































10 0.91 0.81*** 0.60** 0.60** 0.56** 0.63** 0.71***
*Items reversely scored (higher scores indicate more complaints); **p<0.01; ***p<0.001. ADL=activities of 
daily living, NA=not applicable.
Intra-class correlation coefficients for test-retest analysis varied between 0.78 for work related 
problems and 0.94 for frequency of complaints, indicating adequate test-retest validity. The 
highest correlations between dimensions were found between intensity of complaints and all 
other dimensions (0.60≤ r ≤0.82). Except for work related problems and frequency of complaints 
(r=0.49), all dimensions were moderately correlated (0.56≤ r ≤0.82).
The results of the criterion validity are reported in Table 3. As expected, the PEmb-QoL dimen-
sions frequency of complaints, ADL limitations, work related problems, social limitations and 
intensity of complaints had higher associations with the physical health summary score of the 







mental health summary score. Frequency of complaints was most strongly correlated with 
vitality (r=-0.56), social functioning (r=-0.55) and physical functioning (r=-0.46). The strongest 
correlations for ADL limitations were physical functioning (r=-0.78), social functioning (r=-0.61) 
and vitality (r=-0.66). Work-related problems most strongly correlated with physical role func-
tioning (r=-0.58) and physical functioning (r=-0.53). The dimension social limitations was corre-
lated with several SF-36 dimensions. We observed strong correlations with physical functioning 
(r=-0.54), social functioning (r=-0.55) and vitality (r=-0.53). Intensity of complaints was strongly 
correlated with the same SF-36 dimensions as frequency of complaints, but with higher cor-
relation coefficients. The strongest correlations for emotional complaints were mental health 
(r=-0.57), vitality (r=-0.69) and social functioning (r=-0.60).
Associations between clinical characteristics and the PEmb-QoL
After multivariate analysis including all patient demographics, comorbid conditions and 
PE-characteristics, younger age, obesity, cardiopulmonary comorbidity and centrally located 
PE were shown to be independent predictors for decreased disease-specific QoL (Table 4). 
Inversely, a family history of venous thromboembolism independently predicted lower inten-
sity of complaints and emotional complaints and also was a predictor of better social function. 
Markedly, the multivariate models including these independent determinants of QoL predicted 
the measured QoL in the individual dimensions of the PEmb-QoL only for 5.7% to 16% (linear 
regressions’ coefficient of determination).





























-0.46** -0.55** -0.33** -0.28** -0.45** -0.56** -0.42** -0.55** -0.44** -0.42**
ADL 
limitations
-0.78** -0.61** -0.53** -0.39** -0.45** -0.66** -0.49** -0.63** -0.66** -0.39**
Work related 
problems
-0.53** -0.50** -0.58** -0.43** -0.40** -0.54** -0.29** -0.53** -0.51** -0.39**
Social 
limitations
-0.54** -0.55** -0.45** -0.31** -0.38** -0.53** -0.35** -0.51** -0.50** -0.35**
Intensity of 
complaints
-0.62** -0.66** -0.44** -0.32** -0.55** -0.67** -0.49** -0.60** -0.55** -0.48**
Emotional 
complaints
-0.45** -0.60** -0.38** -0.43** -0.57** -0.69** -0.41** -0.59** -0.40** -0.57**
**p<0.01.
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Age (per year) -0.15*





Centrally located PE† 0.45* 0.23*
Follow-up period (per day)‡
Family history of VTE† -0.40* -0.50* -0.55*
Unstandardized regression (beta) coefficients with p-values only of independently significant 
determinants of quality of life are displayed. Higher PEmb-QoL scores are associated with decreased 
quality of life. †0=not present, 1=present; ‡1=male, 2=female; ∂body mass index >30kg/m2; †0=not 
present, 1=present; ‡time span between registration acute pulmonary embolism and study inclusion in 
days; *p<0.05, **p<0.01. ADL=activities of daily living.
DISCUSSION
The results from this validation study indicate that this newly developed disease-specific 
health-related QoL instrument PEmb-QoL is a valid and reliable instrument to assess QoL fol-
lowing PE. Internal reliability for all dimensions (except intensity of complaints) was adequate 
and comparable to the reliability of the VEINES-QOL/Sym scales.6 Test-retest reliability was also 
adequate. The inter-correlations between the PEmb-QoL dimensions demonstrated logical 
relationships. Intensity of complaints correlated with a worse outcome in all other dimensions. 
This was expected as this dimension might actually affect a person’s well-being in general. Also, 
its association with frequency of complaints is high, suggesting these dimensions could be 
taken together to form one summary score for symptom severity, comparable to the VEINES-
QoL/Sym summary score.
We observed a tendency towards small floor and ceiling effects in some of the PEmb-QoL 
dimensions. This was assumed to be attributable to the time between the events and comple-
tion of the questionnaires. Therefore, we expect that other patient samples including those with 
a more recent event will show less floor or ceiling effects. Furthermore, we observed that work 
related problems most strongly correlated with physical role functioning and physical function-
ing. We hypothesized that this observation is explained by the fact that both dimensions focus 
on the extent of limitations performing work or physical exercise. Emotional complaints were 
more strongly associated with mental health and vitality than to emotional role functioning. 
This is also conceivable, as the wording of the items of this PEmb-QoL dimension closely match 
the items of the SF-36 dimensions mental health and vitality. Also, the correlation between 







functioning and vitality. This is a plausible observation as well, since social activities are also 
influenced by the capability to perform exercises such as climbing stairs or walking a certain 
distance.
After multivariate analysis, several demographic and symptom factors associated with bet-
ter or worse health related QoL were identified. Higher age, obesity and comorbid conditions 
predicted decreased QoL in our study population. This is to be expected, as these factors have 
previously been shown to be important determinants of health status in healthy persons and 
patients suffering from various diseases.15,18,19 Notably, the presence of family members who 
have a history of the same condition was associated with improved social status, decreased 
intensity of complaints and a smaller amount of emotional complaints. We hypothesized that 
this phenomenon might be attributed to enhanced social support which is an important aspect 
of QoL.20,21 Although we were able to identify several significant determinants of QoL in our 
patient population, combining these in multivariate prediction models did not result in precise 
prediction of the QoL for individual patients since our models predicted only 5.7% to 16% of 
the variance in PEmb-QoL scores. This observation is in accordance with the result of a previous 
study, which indicated limited effects of patient demographics and comorbid conditions on the 
QoL of patients with DVT.15
Limitations of our study comprise the exclusion of 3 participants due to language barri-
ers and the lack of detailed comparison to healthy subjects. This comparison is difficult since 
the PEmb-QoL was designed for patients with acute PE and is by definition not applicable to 
subjects without this disease. Finally, we were unable to assess responsiveness in this cohort.
This disease specific questionnaire was developed to assist physicians in monitoring 
treatment interventions after acute PE. The advantage of disease specific questionnaires 
over generic instruments of QoL is that these can be considered to have higher sensitivity for 
detecting subtle but clinically relevant alterations in QoL caused by the studied condition or 
treatment.22 Although we were able to show correlations between the outcome of the PEmb-
QoL and the condition of patients with a history of acute PE, our study design did not allow 
assessing whether this QoL instrument could be used in treatment decisions. Hence, further 
studies are needed.
In summary, the PEmb-QoL is a valuable instrument for determining the disease-specific QoL 
in patients with previous acute PE. This questionnaire is a valid and reliable instrument of QoL 
following acute PE and discriminates patients with impaired health perception. The clinical 
applicability of the PEmb-QoL and its potential role in the management of patients with acute 
PE remains to be studied in clinical outcome studies.
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The main objectives of this thesis are to validate and simplify current diagnostic strategies for 
clinically suspected acute pulmonary embolism (PE) and to predict the short and long term 
prognosis of patients diagnosed with and treated for acute PE. Therefore, several studies were 
performed focusing on the safety of different diagnostic algorithms and several aspects of the 
patients’ prognosis. Chapter 1 provides a general introduction to the pathophysiology of acute 
PE and its associated clinical course. Furthermore, it evaluates current clinical insights regarding 
diagnostic and treatment strategies and addresses scientific gaps yet to be bridged.
PART I: DIAGNOSTIC MANAGAMENT OF ACUTE PE
Many clinical decision rules to estimate the pretest probability of the individual patient for 
having PE have been proposed. The most widely used one, the Wells rule, includes the subjec-
tive judgment of the clinician and as a result, this rule has average reproducibility. Chapter 2 
describes a study on the clinical validity and performance of the recently developed and more 
objective revised Geneva score in a patient cohort in whom the Wells rule was initially utilized 
for clinical practice. In 300 consecutive patients with suspected PE, the predictive accuracy 
of both scores was compared by the area under the receiver operating characteristic curves 
(AUC of ROC). These AUCs were not different for both rules: 0.72 (95% confidence interval [CI] 
0.65–0.80) and 0.67 (95% CI 0.59–0.76) respectively. Furthermore, after three months of follow-
up, no patient classified into the low or intermediate clinical probability category by the revised 
Geneva score and a normal D-dimer result was subsequently diagnosed with acute venous 
thromboembolism (VTE). In chapter 3, we simplified the revised Geneva score by attributing 1 
point to each item of the original clinical decision rule, as an alternative for the original different 
weights of the individual items. These different weights might be more difficult to remember 
and could lead to miscalculations in an acute setting. This simplification of the revised Geneva 
rule did not result in decreased AUC of the ROC analyses in 1049 patients with suspected PE: 
0.75 (95% CI 0.71-0.78) for the original and 0.74 (95% CI 0.70-0.77) for the simplified rule. Further 
analysis indicated that during a three months follow-up period, no patient with a combination 
of either a low or intermediate clinical probability, or a “PE unlikely” assessment with the simpli-
fied score and a normal D-dimer test result was diagnosed with symptomatic VTE. These study 
results suggest that the performances of the simplified and original revised Geneva score are 
equivalent to that of the Wells rule. Furthermore, it was safe to rule out acute PE by a combina-
tion of a “low”, “intermediate” or “unlikely” probability assessment by the simplified or original 
revised Geneva score, in combination with a normal highly sensitive D-dimer test result.
A negative computed tomography pulmonary angiography (CTPA) result alone is considered to 
be a controversial criterion for the safe exclusion of PE in a high risk population, since the nega-







probability for having PE. Chapter 4 is a meta-analysis to determine the safety of ruling out PE 
by a normal CTPA in a specific group of patients with a strict indication for CTPA, i.e. likely or high 
clinical probability for PE, an elevated D-dimer concentration, or both. The pooled NPV after 
three months was 98.8% (95% CI 98.2-99.2) based on a normal CTPA as a sole test and 98.9% 
(95% CI 98.0-99.4) based on normal CTPA followed by negative compression ultrasonography 
of the legs. In addition, risk of fatal PE did not differ between both diagnostic strategies (0.6% 
vs. 0.5%). Since these test characteristics compare favorably with those of normal conventional 
pulmonary angiography, we conclude that a normal CTPA alone can safely exclude PE in all 
patients in whom CTPA is required to rule out this disease.
PART II: SHORT TERM CLINICAL OUTCOME AFTER PE
The ability of accurately predicting adverse clinical outcome in hemodynamic stable patients 
with acute PE is of great importance for the therapeutic management of these patients. In 
chapter 5, the potential role of brain-type natriuretic peptides (BNP) in the differentiation 
of patients suffering from acute PE at risk for adverse clinical outcome is evaluated. A meta-
analysis of all previous studies on this subject revealed that patients with elevated levels of BNP 
or NT-pro-BNP were at higher risk of complicated in-hospital course (odds ratio [OR] 6.8, 95% CI 
4.4-10) and 30-day mortality (OR 7.6, 95% CI 3.4-17).
In a prospective study, the clinical utility of NT-pro-BNP for predicting adverse outcome after 
PE was further studied by comparing that to the utility of other biomarkers and right ventricular 
enlargement assessed on static CTPA images (chapter 6). We included 113 consecutive normo-
tensive patients with CT pulmonary angiography (CTPA) proven PE. All predictors under study 
were associated with adverse outcome in patients with PE, with ORs of 3.7 (95% CI 0.74-19) for 
right/left ventricular ratio >1 on axial CTPA view, 9.0 (95% CI 1.1-79) for right/left ventricular 
ratio >1 on 4-chamber CTPA view, 3.5 (95% CI 0.86-15) for D-dimer >3000 pg/mL FEU, 6.3 (95% 
CI 1.3-31) for Troponin-T >0.09 ng/mL and 31 (95% CI 3.6-257) for NT-pro-BNP >600 pg/mL. 
The NPV of NT-pro-BNP was highest (99%). Importantly, 72% of patients had a NT-pro-BNP 
≤600 pg/mL; 4-chamber RV/LV-ratio <1 had equally excellent NPV (98%), but less patients were 
categorized as having low risk for complications (43%). We concluded that NT-pro-BNP had the 
highest discriminative power and clinical utility as predictor of adverse events after PE in our 
study population. This conclusion could point towards using NT-pro-BNP as stratification tool 
for identifying patients for outpatient treatment.
The positive predictive value (PPV) of NT-pro-BNP or the other predictors was not sufficient 
to justify more invasive treatment measures in normotensive patients with PE. We hypothesized 
that CT-measured right ventricular ejection fraction would be a more specific predictor for 
adverse outcome, and therefore involve a higher PPV. In the identical patients who are described 
in chapter 6, the right ventricular ejection fraction was assessed by electrocardiography 
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(ECG)-synchronized multi-detector row CTPA (chapter 7). RV dysfunction was defined as RV 
ejection fraction below 47%, which was present in 45% of the patients. In addition, the AUC 
of its ROC analysis proved to be higher than simple, right/left ventricular ratio assessment. RV 
dysfunction was identified in 90% of the patients with adverse events (OR 36, 95% CI 2.2-590). 
In spite of this OR and high NPV (98%), this technique was not able to identify patients with 
such high risk for adverse events, that patients with RV ejection fraction below 47% are likely to 
benefit from more invasive treatment measures (positive predictive value 18%). Furthermore, 
the NPV of the ECG-synchronized ventricular measurements was comparable to those of the 
simple CTPA measurements. Importantly, ECG-synchronized cardiac CT involves increased 
radiation and contrast dose which should be considered before this technique is considered for 
integration in routine clinical care.
PART III: LONG TERM CLINICAL COURSE AFTER PE
In chapter 8, we discuss the results of a cohort screening study for chronic thromboembolic 
pulmonary hypertension (CTEPH) in an unselected series of 866 consecutive patients diagnosed 
with acute PE. All patients who were not previously diagnosed with pulmonary hypertension 
(PH) and had survived until study inclusion, were invited for transthoracic echocardiography. 
Patients with echocardiographic suspicion of PH underwent complete work-up for CTEPH, 
including ventilation-perfusion lung scan and right heart catheterization. For the patients who 
had died, the cause of death was extracted from autopsy reports or verified with the general 
practitioner. The presence of CTEPH in patients who were unable to visit our hospital for echo-
cardiography was assumed not present in case of absence of unexplained clinical symptoms 
of this disease. After an average follow-up of 34 months, PH was diagnosed in 19 patients by 
routine clinical care and in 10 by our screening program; 4 patients had CTEPH, who were all 
diagnosed by routine clinical care. The cumulative incidence of CTEPH after all cause acute PE 
was 0.57% (95% CI 0.02-1.2%) and after unprovoked PE 1.5% (95% CI 0.08-3.1%). Because of this 
low incidence and the very low yield of the echocardiography based screening program, wide 
scale implementation of prolonged follow-up including echocardiography of all patients with 
PE to detect CTEPH seems not warranted.
Dyspnea is one of the key clinical symptoms of CTEPH. Although we found CTEPH to be a rare 
complication after acute PE, persistent dyspnea is reported by one third of patients at 3.6 ±1.7 
years after the PE. This subjectively reported dyspnea is significantly correlated to decreased 
exercise performance. Therefore, the possibility of CTEPH is frequently considered. In chapter 
9, we study several non-invasive clinical tests for ruling out CTEPH in symptomatic patients with 
a history of PE. ECG criteria of right ventricular overload were more frequent in patients with 







Also, clotting factor FVIII activity and levels of NT-pro-BNP, growth differentiation factor-15, 
C-reactive protein and urate were higher in the patients with CTEPH, in contrast to D-dimer 
levels. A diagnostic model including ECG criteria and NT-pro-BNP levels had a sensitivity of 94% 
(95% CI 86-98), a specificity of 65% (95% CI 56-72) and an AUC of the ROC analysis of 0.80 (0.74-
0.85) for the presence of CTEPH in dyspnoeic patients. Adding other or additional biomarkers to 
ECG and NT-pro-BNP assessment resulted in a decrease of predictive value of the model. Even 
with unrealistically high disease prevalences up to 10%, the negative predictive value of our 
final model proved very high (>99%). We concluded that additional diagnostic tests to rule out 
CTEPH in dyspnoeic patients after acute PE are not necessary in absence of ECG criteria of right 
ventricular overload and a normal NT-pro-BNP level.
Chapter 10 extends the findings presented in chapters 8 and 9 by evaluating determinants 
and alternative causes of chronic dyspnea after acute PE. After multivariate analysis, cardio-
pulmonary comorbidity (OR 12; 95% CI 6.5-20), advanced age (OR 1.02 per year; 95% CI 1.01-
1.03), higher BMI (OR 1.06 per kg/m2; 95% CI 1.01-1.1) and a smoking history (OR 1.6; 95% CI 
1.02-2.6) were identified as independent predictors of chronic dyspnea after PE. An alternative 
diagnosis reasonably explaining the dyspnea could be established in all patients. The clinical 
consequence of our study is that chronic dyspnea in the clinical course of acute PE is mainly 
caused by pre-existing comorbid conditions and alarming direct complications of PE such as 
CTEPH are very rare.
In chapter 11, the association between venous thromboembolism and arterial cardiovascular 
disease is assessed by comparing the cumulative incidence of serious cardiovascular events 
(defined as clinically adjudicated acute myocardial infarction, stroke or transient ischemic 
attack, claudication, unstable angina, carotid endarterectomy, coronary artery bypass graft, 
peripheral arterial bypass or angioplasty) in patients with unprovoked PE to that of patients 
with provoked PE and a control population of patients in whom PE was suspected but ruled 
out. After a median follow-up period of 4.2 years, the adjusted hazard ratio (HR) for arterial 
cardiovascular events was not different between patients with all cause PE and control patients 
(1.4, 95% CI 0.83-2.3), but increased for patients with unprovoked PE versus patients with 
provoked PE as well as control patients without PE (HR 2.2; 95% CI 1.1-4.5 and 2.6; 95% CI 1.4-
4.9 respectively). This observation underlines the hypothesis of a shared but yet unidentified 
mechanism causing events in both venous and arterial systems.
In addition to arterial cardiovascular events and CTEPH, further adverse clinical events which 
are associated with acute PE and have a major impact on the long term prognosis of patients 
with PE include mortality, newly diagnosed malignancies and recurrent VTE. In chapter 12, we 
explore the risk of suffering from any of these conditions in the first years after the diagnosis 
of PE. Patients with unprovoked PE had lower overall risks for mortality than patients with 
provoked PE (adjusted HR 0.59, 95% CI 0.43-0.82), but higher risk for non-malignancy related 
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mortality (adjusted HR 1.8, 95% CI 1.3-2.5), recurrent VTE (adjusted HR 2.1, 95% CI 1.3-3.1), 
cancer (adjusted HR 4.4, 95% CI 2.0-10), cardiovascular events (adjusted HR 2.6, 95% CI 1.5-3.8) 
and CTEPH (cumulative incidence 1.5% vs 0%). The risk for the combined endpoint did not 
differ between both groups (adjusted HR 0.98, 95% CI 0.82-1.1). A control cohort consisting of 
patients without PE had similar risks for malignancy and cardiovascular events compared to 
patients with provoked PE, but significantly lower risks for the remaining outcomes and the 
combined outcome in patients with provoked as well as with unprovoked PE. Importantly, the 
fraction of both patients with provoked as well as with unprovoked PE without events after 1 
year was only 70%, and decreased to fewer than 60% after 2 years and fewer than 50% after 4 
years, whereas this latter was 84% for the control patients without PE.
In chapter 13, we validate a disease specific quality of life instrument for patients after acute PE. 
The recently developed Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire and the 
Short-Form 36 were distributed twice among 90 PE survivors, with a mean period of 38 months 
after diagnosis. Internal consistency of the questionnaire was adequate with a Cronbach’s α 
statistic ranging from 0.62 to 0.94. The test-retest reliability was good as well (intra-class correla-
tion coefficients 0.78-0.94). Furthermore, good correlations between the PEmb-QoL question-
naire and the SF-36 questionnaire supported convergent validity between the 2 instruments. 
Multivariate analysis identified age, obesity, cardiopulmonary comorbidity, centrally located PE 
and a family history of venous thromboembolism to be independent determinants for disease-
specific QoL. The PEmb-QoL questionnaire was shown to be a reliable instrument to specifically 
assess QoL following PE, which is helpful in the identification of patients with decreased QoL 
after surviving PE.
FUTURE PERSPECTIVES
Although the diagnostic management of suspected PE remains a challenge in clinical practice, 
physicians can fall back on a simple, non-invasive and well validated diagnostic algorithm 
consisting of a clinical decision rule, D-dimer tests and CTPA. This algorithm has been shown to 
be widely available and safe. Nonetheless, further studies are necessary to validate this -or an 
alternative- algorithm for recurrent PE, determine which of many clinical decision rules has the 
highest clinical efficacy and to address the increasing concern of radiation exposure by CTPA, 
especially in women of child bearing potential.
Risk stratification of normotensive patients with established PE can be based on high levels 
of biomarkers or measurements of right ventricular volume or function. Current evidence 
suggests that patients with a very low risk on adverse events can be treated on an outpatient 
basis, thereby saving costs and increasing patient satisfaction. However, the safety of home 







determined. On the other hand, with respect to identifying patients with very high risk who 
might benefit from thrombolytic therapy, evidence is scarce and inconsistent. Up till now, no 
stratification tool that can be easily integrated in routine clinical care and identifies a small 
patient group with particular high risk for complications, has been validated. Such a tool should 
be sought for in future trials.
Finally, although we have demonstrated that the risk of CTEPH after acute PE is very low, 
other very serious conditions occur frequent in the clinical course of acute PE. Especially those 
conditions that might be prevented, i.e. arterial cardiovascular events and recurrent PE, deserve 
a great deal of attention in the coming years. More accurate individualized assessment of the 
risk for recurrent PE followed by prolonged anticoagulant treatment for those patients with 
high recurrence risk, and individualized or population based proper preventive treatment 
measures to prevent arterial cardiovascular disease are likely to improve the patients’ prognosis 
after acute PE. In addition, it would be very interesting to use the PEmb-QoL to measure the 
QoL in a larger cohort of patients and moreover, establish the effect of cardiopulmonary reha-





Dit proefschrift beschrijft studies naar het valideren en vereenvoudigen van de huidige diag-
nostische strategieën bij patiënten met een klinische verdenking op een acute longembolie, 
en naar methoden om de klinische prognose na een longembolie op korte en langere termijn 
beter te kunnen voorspellen. Hoofdstuk 1 is een algemene inleiding in de pathofysiologie en 
klinische presentatie van acute longembolieën. Daarnaast worden de diagnostiek- en behan-
delingsstrategieën uit de dagelijkse praktijk en nog onopgeloste wetenschappelijk vragen 
hieromtrent besproken.
DEEL I: DIAGNOSTIEK NAAR ACUTE LONGEMBOLIEËN
In de literatuur zijn de afgelopen jaren verschillende klinische beslisregels gesuggereerd en 
gevalideerd. De best gevalideerde en daardoor meest gebruikte regel is de zogenaamde “Wells 
rule”. Het gebruik van de Wells rule blijft echter ter discussie aangezien deze zwaar leunt op de 
subjectieve beoordeling van de arts over de waarschijnlijkheid van de diagnose longembolie 
vergeleken met de waarschijnlijkheid van een alternatieve diagnose. Hoofdstuk 2 beschrijft 
een studie waarin de klinische validiteit en effectiviteit van de recent samengestelde en meer 
objectieve “revised Geneva score” wordt onderzocht in 300 patiënten die verdacht werden 
van het hebben van een longembolie. Hiertoe werd de voorspellende waarde van de revised 
Geneva score vergeleken met die van de Wells rule door middel van de oppervlakten onder de 
“receiver operating characteristic” (ROC) curves van beide regels. Deze bleken niet significant 
te verschillen: 0.72 (95% betrouwbaarheid interval [BI] 0.65–0.80) voor de Wells rule en 0.67 
(95% BI 0.59–0.76) voor de revised Geneva score. Verder bleek dat bij geen van de patiënten die 
onbehandeld zouden blijven op basis van een lage of intermediaire revised Geneva score en 
een normale D-dimeer uitslag, in de eerste daarop volgende 3 maanden een veneuze trombo-
embolie (VTE) zou zijn gediagnosticeerd. In aansluiting hierop evalueren we in hoofdstuk 
3 de “vereenvoudigde revised Geneva score”, waarbij we slechts 1 punt toekennen aan alle 
onderdelen van de score, in tegenstelling tot de uiteenlopende gewichten per item die voor 
de originele regel berekend waren. Deze vereenvoudigde regel is makkelijker te onthouden. 
Daarbovenop zou het verschillend aantal punten per onderdeel kunnen leiden tot verwarring 
bij het uitrekenen en interpreteren van de score in acute situaties. In 1049 patiënten met een 
verdenking op een longembolie bleek de oppervlakte onder ROC curve niet anders voor de 
vereenvoudigde dan voor de originele regel: 0.74 (95% BI 0.70-0.77) en 0.75 (95% BI 0.71-
0.78). Ook in dit grote cohort bleek het veilig om antistollingsbehandeling te onthouden aan 
patiënten met een door middel van de vereenvoudigde revised Geneva rule berekende lage, 
intermediaire (3-delige indeling van de regel) of onwaarschijnlijke (2-delige indeling van de 
regel) voorafkans op een longembolie en een normale D-dimeer concentratie in het bloed. 
Deze resultaten suggereren dat de gesimplificeerde en originele revised Geneva scores, net als 







De meest gebruikte diagnostische test om longembolieën aan te tonen is de spiraal CT-scan. 
Verschillende deskundigen hebben gesuggereerd dat bij een patiënt met een hoge voorafkans 
op een longembolie, een negatieve uitslag van de spiraal CT-scan mogelijk niet afdoende is om 
een longembolie ook daadwerkelijk veilig uit te kunnen sluiten. Dit fenomeen wordt verklaard 
door de afhankelijkheid van de negatief voorspellende waarde (NVW) van een test voor de 
prevalentie van de betreffende ziekte in een zekere populatie. Deze NVW neemt namelijk af als 
de ziekte vaker voorkomt in de onderzochte patiënten groep. In hoofdstuk 4 onderzoeken we 
de NVW van de spiraal CT-scan voor acute longembolieën door het uitvoeren van een meta-
analyse van studies die op basis van een CT-scan uitslag de aanwezigheid van longembolieën 
uitsloten in alle patiënten bij wie volgens de huidige richtlijnen het maken van een CT-scan 
noodzakelijk is, namelijk bij patiënten met een hoge of waarschijnlijke voorafkans op een long-
embolie en/of een verhoogde D-dimeer plasma concentratie. De NVW van de CT-scan alleen 
was 98.8% (95% BI 98.2-99.2), en na een combinatie van de CT-scan gevolgd door compressie 
echografie van de benen om een diep veneuze trombose op te sporen 98.9% (95% BI 98.0-
99.4). Het risico op een dodelijke longembolie 3 maanden na een negatieve CT-scan was erg 
laag (0.6%) en toevoegen van been echografie leverde geen significante additionele verlaging 
van dit risico op (0.5%). Omdat het risico op een al dat niet fatale longembolie na een negatieve 
CT-scan veilig laag bleek en goed overeenkwam met dat risico na een negatieve conventionele 
pulmonalis angiografie, welke nog steeds gezien wordt als gouden standaard voor de diagnose 
longembolie, concluderen wij dat een negatieve CT-scan uitslag afdoende is om een longem-
bolie uit te sluiten in alle patiënten die hiervoor in aanmerking komen.
DEEL II: HET KORTE TERMIJN KLINISCH BELOOP VAN EEN LONGEMBOLIE
Het schatten van het risico op ernstige klinische complicaties door een longembolie bij patiën-
ten die hemodynamisch stabiel zijn, is van het grootste belang voor het instellen van het juiste 
therapeutische beleid. Hoofdstuk 5 betreft een meta-analyse naar de potentiële rol van brain-
type natriuretic peptides (BNP) voor risicostratificatie van patiënten met een longembolie. Wij 
vonden een verhoogde Odds Ratio (OR) van verhoogde BNP of NT-pro-BNP bloedspiegels voor 
complicaties tijdens de ziekenhuisopname (6.8, 95% BI 4.4-10) en mortaliteit binnen 30 dagen 
na diagnose (7.6, 95% BI 3.4-17).
In hoofdstuk 6 vergelijken wij de voorspellende waarde en potentiële klinische toepas-
baarheid van NT-pro-BNP voor het stratificeren van hemodynamisch stabiele longembolie 
patiënten met andere biomarkers van hartfalen of embolus grootte, en de met een standaard 
CT-techniek gemeten rechter ventrikel omvang. Al deze voorspellers waren sterk geassocieerd 
met ons studie eindpunt, dat bestond uit overlijden binnen 6 weken, reanimatie na adem- of 
hartstilstand, noodzaak tot behandelen met trombolytica of inotropica, of opname op de 
intensive care afdeling voor mechanische beademing. De gecorrigeerde OR voor een hoge 
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NT-pro-BNP spiegel (>600 pg/mL) was 31 (95% BI 3.6-257), en deze was 3.7 (95% BI 0.74-19) 
voor een vergrote rechts/links ventriculaire omvang ratio op axiale CT coupes (> 1.0), 9.0 (95% 
BI 1.1-79) voor een vergrote rechts/links ventriculaire omvang ratio op geanguleerde 4-kamer 
CT coupes (>1.0), 3.5 (95% BI 0.86-15) voor een hoge D-dimeer concentratie (>3000 pg/mL FEU) 
en tenslotte 6.3 (95% BI 1.3-31) voor verhoogde Troponine-T spiegels (>0.09 ng/mL). De NVW 
van NT-pro-BNP was het hoogst van alle bestudeerde voorspellers (99%). Waarden onder dit 
afkappunt kwamen voor bij 72% van de patiënten. De NVW van de rechts/links ventriculaire 
omvang ratio op geanguleerde 4-kamer CT coupes was ook erg hoog (98%), maar een normale 
verhouding kon bij veel minder patiënten vastgesteld worden (43%). Hieruit concluderen wij 
dat NT-pro-BNP waarschijnlijk de nuttigste test is om hemodynamisch stabiele patiënten met 
een longembolie te categoriseren naar hun risicoprofiel.
De positief voorspellende waarde (PVW) van NT-pro-BNP evenals van de andere bestu-
deerde voorspellers was niet toereikend voor het overwegen van meer invasieve behandeling 
van patiënten met een hoge test uitslag. Wij hypothetiseerden dat de CT gemeten rechter 
ventrikel ejectiefractie een veel specifiekere voorspeller zou kunnen zijn voor complicaties, 
gezien het feit dat dit een directe afspiegeling is van de systolische rechter ventrikel functie. 
In dezelfde patiënten groep die werd beschreven in hoofdstuk 6 werd door middel van ECG-
gesynchroniseerde CT-scan opnamen de rechter ventrikel ejectiefractie gemeten (hoofdstuk 
7). Wij definieerden een ejectiefractie lager dan 47% als passend bij rechterventrikel dysfunc-
tie. Dit kwam voor bij 45% van alle patiënten en in 90% van de patiënten die één van onze 
klinische eindpunten bereikten. OR voor dit eindpunt was 36 (95% BI 2.2-590) en de NWV 
98%. Desondanks was de PVW niet hoog genoeg (18%) om meer invasieve behandeling te 
rechtvaardigen. Verder bleek de NPV van de ECG-gesynchroniseerde opnamen van het hart 
gelijkwaardig aan die van de standaard opnamen. Een belangrijk bijkomend nadeel van de 
ECG-gesynchroniseerde techniek is de hogere dosering straling en contrast vloeistof waar de 
patiënten aan blootgesteld worden. Om deze redenen lijkt de ECG-gesynchroniseerde hart 
scan van patiënten verdacht van een longembolie weinig toegevoegde klinische waarde te 
hebben.
DEEL III: LANGE TERMIJN PROGNOSE NA EEN LONGEMBOLIE
In hoofdstuk 8 worden de resultaten van een screening studie naar chronische trombo-embo-
lische pulmonale hypertensie (CTEPH) besproken. Wij brachten 866 opeenvolgende patiënten 
met een acute longembolie nauwkeurig in kaart. Alle patiënten die nog in leven waren bij de 
start van ons onderzoek en die nog niet waren gediagnosticeerd met pulmonale hypertensie 
werden verzocht terug te komen naar het LUMC voor echocardiografie. Alle patiënten bij wie 
een echografische verdenking op een longembolie bestond ondergingen een gestandaar-







hartkatheterisatie. Van patiënten die overleden waren achterhaalden wij de doodsoorzaak. 
De kans op de aanwezigheid van CTEPH in de patiënten die niet naar ons ziekenhuis konden 
of wilden komen, werd geschat aan de hand van hun klachtenpatroon. Na een gemiddelde 
vervolg duur van 34 maanden na diagnose van de longembolie was pulmonale hypertensie 
vastgesteld in 19 patiënten door standaard klinische zorg voordat onze studie van start ging, en 
in 10 patiënten door ons screening programma. CTEPH was gediagnosticeerd in 4 van hen door 
standaard klinische zorg, maar in geen van de patiënten door ons screening programma. De 
cumulatieve incidentie van CTEPH was 0.57% (95% BI 0.02-1.2%) in de totale studie populatie 
en 1.5% (95% BI 0.08-3.1%) in de patiënten die een longembolie doormaakten zonder duidelijk 
aanwijsbare oorzaak, de zogenaamde idiopatische longembolie. Daar de incidentie van CTEPH 
relatief laag was en ons screening programma geen extra patiënten opleverde bovenop de 
standaard klinische zorg, achten wij het niet nuttig alle patiënten na het doormaken van een 
longembolie te screenen op CTEPH met behulp van echocardiografie.
Kortademigheid is het meest voorkomende klinische symptoom van CTEPH. Hoewel we in 
hoofdstuk 8 concludeerden dat CTEPH een zeldzame complicatie van longembolieën is, bleken 
klachten van kortademigheid wel frequent voor te komen (één derde van de patiënten, 3.6 jaar 
na diagnose). Deze subjectieve klachten zijn significant gecorreleerd aan objectief gemeten 
inspanningstolerantie. Bijgevolg hiervan wordt de diagnose CTEPH regelmatig overwogen, 
welke slechts bevestigd kan worden na hartkatheterisatie. In hoofdstuk 9 wordt een studie 
naar de waarde van verschillende niet-invasieve testen voor het uitsluiten van CTEPH in symp-
tomatische patiënten na een longembolie gepresenteerd. ECG afwijkingen passend bij rechter 
ventrikel overbelasting werden vaker aangetoond in patiënten met CTEPH dan in symptomati-
sche patiënten die een longembolie hadden doorgemaakt, maar bij wie pulmonale hypertensie 
werd uitgesloten. Ook objectiveerden wij hogere stolling factor VIII activiteit en bloedspiegels 
van NT-pro-BNP, groei differentiatie factor-15, CRP en urinezuur in patiënten met CTEPH. 
D-dimeer bloedspiegels waren in tegenstelling hiermee vergelijkbaar tussen de twee groepen. 
Een diagnostisch model bestaande uit ECG beoordeling en NT-pro-BNP bepaling leverde een 
sensitiviteit voor CTEPH op van 94% (95% BI 86-98), een specificiteit van 65% (95% BI 56-72) en 
een oppervlakte onder de ROC curve van 0.80 (0.74-0.85). Het toevoegen van andere testen 
aan dit model leidde tot verslechtering van deze test karakteristieken. Zelfs als de incidentie 
van CTEPH in een willekeurig geteste populatie erg hoog zou zijn (tot 10%), bleef de NPV van 
ons uiteindelijke model zeer adequaat (>99%). Deze resultaten suggereren dat in het geval van 
klachten van kortademigheid in patiënten die een longembolie doorgemaakt hebben bij een 
normale ECG beoordeling en NT-pro-BNP spiegel, de kans op de diagnose CTEPH zeer gering is.
Hoofdstuk 10 vult de bevindingen van hoofdstuk 8 en 9 aan en beschrijft een evaluatie van de 
determinanten en alternatieve diagnoses van chronische kortademigheid na een longembolie. 
Na multivariate logistische regressie bleken cardiale en pulmonale comorbiditeit (OR 12, 95% 
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BI 6.5-20), hogere leeftijd (OR 1.02 per jaar, 95% BI 1.01-1.03), hogere BMI (OR 1.06 per kg/m2, 
95% BI 1.01-1.1) en roken (OR 1.6, 95% BI 1.02-2.6) onafhankelijke voorspellers van chronische 
kortademigheid na longembolieën te zijn. Verder werd bij alle patiënten met chronische 
kortademigheid een alternatieve diagnose gesteld die de kortademigheid kon verklaren. Het 
klinische belang van deze observatie is dat hoewel kortademigheid na een longembolie fre-
quent voorkomt, deze voornamelijk kan worden verklaard door reeds aanwezige morbiditeit 
en dat ernstige complicaties als CTEPH hier slechts zeer incidenteel aan ten grondslag liggen.
In hoofdstuk 11 wordt de associatie tussen veneuze trombose en arteriële cardiovasculaire 
ziekten besproken. Hiertoe werd het risico op arteriële cardiovasculaire ziekten voor patiënten 
met en zonder longembolie vergeleken. Na een mediane vervolgtijd van 4.2 jaar bleek de 
gecorrigeerde hazard ratio (HR) voor arteriële cardiovasculaire ziekten niet verhoogd te zijn 
voor patiënten met longembolie vergeleken met de controle patiënten zonder longembolie 
(1.4, 95% BI 0.83-2.3) maar wel voor patiënten met een idiopatische longembolie vergeleken 
met patiënten die een longembolie met duidelijke risicofactor hadden doorgemaakt (gecor-
rigeerde HR 2.2, 95% BI 1.1-4.5) evenals vergeleken met controle patiënten zonder longembolie 
(gecorrigeerde HR 2.6, 95% BI 1.4-4.9). Deze studie onderschrijft de associatie tussen arteriële 
cardiovasculaire aandoeningen en eerder doorgemaakte veneuze trombose, en ondersteunt 
de hypothese dat een nog onbekend mechanisme ten grondslag licht aan zowel veneuze 
trombose als arteriële cardiovasculaire aandoeningen.
Niet alleen CTEPH en arteriële cardiovasculaire aandoeningen, maar ook overlijden, nieuw 
gediagnosticeerde maligniteiten en recidief longembolieën komen relatief vaak voor na acute 
longembolieën en drukken hun stempel op de prognose van deze patiënten. Hoofdstuk 12 
behandelt het risico op het doormaken van één van deze 5 ernstige klinische complicaties in 
de eerste jaren nadat de diagnose longembolie gesteld was. Patiënten met een idiopatische 
longembolie bleken een lager risico te hebben op overlijden dan de patiënten die een duide-
lijke risicofactor voor hun longembolie hadden (gecorrigeerde HR 0.59, 95% BI 0.43-0.82). Aan 
de andere kant hadden deze eerste patiënten een hoger risico op niet-maligniteit gerelateerd 
overlijden (gecorrigeerde HR 1.8, 95% BI 1.3-2.5), recidief VTE (gecorrigeerde HR 2.1, 95% BI 
1.3-3.1), nieuw gediagnosticeerde maligniteit (gecorrigeerde HR 4.4, 95% BI 2.0-10), arteriële 
cardiovasculaire aandoeningen (gecorrigeerde HR 2.6, 95% BI 1.5-3.8) en CTEPH (cumulatieve 
incidentie 1.5% versus 0%). Het risico op het gecombineerde eindpunt verschilde niet tussen de 
2 groepen (gecorrigeerde HR 0.98, 95% BI 0.82-1.1). Een controle groep zonder longembolieën 
had een vergelijkbaar risico op een nieuw gediagnosticeerde maligniteit of een arteriële car-
diovasculaire aandoening als patiënten na een longembolie met duidelijke risicofactor, maar 
een duidelijk lager risico op alle overige uitkomsten in patiënten met en zonder een duidelijke 
risicofactor voor hun longembolie. Uiteindelijk bleek de proportie van beide patiënten groepen 







70% te zijn. Deze proportie daalde naar 60% na 2 jaar en verder naar 50% na 4 jaar, terwijl dat 
laatste 84% was voor de controle patiënten.
In hoofdstuk 13 wordt tenslotte de recent ontworpen ziekte-specifieke vragenlijst voor 
kwaliteit van leven na een longembolie, de PEmb-QoL, geëvalueerd. Een grote groep van 90 
patiënten vulde gemiddeld 38 maanden nadat een longembolie aangetoond en behandeld 
was de Short-Form 36 en de PEmb-QoL in. De psychometrische kenmerken van de PEmb-
QoL bleken van een hoog niveau te zijn, blijkens de goede interne consistentie, test-hertest 
betrouwbaarheid en logische correlaties met de uitkomsten van de Short-Form 36. Verder 
werd aangetoond dat leeftijd, overgewicht, cardiopulmonale comorbiditeit, centraal gelegen 
longembolieën en meerdere familieleden die trombose hebben doorgemaakt, significante en 
onafhankelijke voorspellers van kwaliteit van leven zijn. Wij concludeerden dat de PEmb-QoL 
een betrouwbare en klinisch toepasbare vragenlijst is om de ziekte-specifieke kwaliteit van 
leven na een longembolie te meten.
TOEKOMSTPERSPECTIEF
Hoewel diagnostiek naar longembolieën altijd een uitdaging zal blijven, kunnen artsen terug 
vallen op een simpel, niet-invasief en goed gevalideerd diagnostisch algoritme bestaande uit 
een klinische beslisregel, D-dimeer testen en spiraal CT-scans. Niettemin zijn verdere studies 
noodzakelijk om te evalueren welke van de vele bestaande klinische beslisregels de hoogste 
efficiëntie bewerkstelligt, hoe de diagnostiek naar recidief longembolieën zou moeten verlo-
pen en hoe vooral voor vrouwen in de fertiele leeftijd het hoofd geboden kan worden aan de 
toenemende zorg voor stralingbelasting door CT-scans.
Wat betreft risicostratificatie van hemodynamisch stabiele patiënten met een longembolie 
is er thans genoeg bewijs dat deze gebaseerd kan worden op waarden van verschillende bio-
markers en metingen aan het rechter ventrikel volume of zijn functie. Echter, er is nauwelijks 
tot geen bewijs dat alternatieve therapeutische interventies gebaseerd op deze voorspellers 
beter, veiliger of kosten effectiever zijn dan de huidige standaardbehandeling. Het lijkt zeker 
de moeite waard en veilig om patiënten met een laag risico thuis te behandelen, wat zou kun-
nen leiden tot lagere kosten en hogere patiënt tevredenheid. De waarde van het meer invasief 
behandelen van patiënten met een hoog risico staat minder vast, maar ook deze strategie heeft 
potentiële voordelen. Het is daarom van het grootste belang dat er op korte termijn studies 
worden uitgevoerd om beide alternatieve interventies ten opzichte van een standaard zieken-
huisopname te toetsen.
Tenslotte laten onze resultaten zien dat schrikbarend veel patiënten in de eerste jaren na 
een longembolie ernstige complicaties ondervinden. Een aantal van deze zou potentieel 
Nederlandse samenvatting 183
voorkomen kunnen worden. Dit betreft voornamelijk recidief longembolieën en arteriële 
cardiovasculaire aandoeningen. Toekomstige studies zullen moeten aantonen of een meer 
accurate risico-inschatting voor, en daarmee samenhangende adequate behandeling van deze 
belangrijke complicaties kunnen leiden tot een verbetering van de prognose van patiënten 
met een longembolie. Evenzo is het effect van actieve revalidatie of andere interventies op 
leefstijl of ziektegedrag van longemboliepatiënten op de kwaliteit van leven een mogelijk 
onderwerp van toekomstig onderzoek.
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